Page last updated: 2024-10-31

minoxidil and Alopecia

minoxidil has been researched along with Alopecia in 643 studies

Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.

Alopecia: Absence of hair from areas where it is normally present.

Research Excerpts

ExcerptRelevanceReference
"Cetirizine, a widely used agent for allergic disorders, has recently been topically used for treating androgenetic alopecia (AGA)."10.60Topical cetirizine for treating androgenetic alopecia: A systematic review. ( Chen, X; Xiang, H; Yang, M, 2022)
"PRP is effective in the treatment of moderate grades of androgenetic alopecia in men, although perhaps not different from minoxidil."9.69Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. ( Balasundaram, M; Kumari, R; Ramassamy, S, 2023)
"Platelet-rich plasma (PRP) has been increasingly accepted as a potential therapy in the treatment of androgenetic alopecia (AGA), However, there remains a dearth of data on the effectiveness of PRP prepared by automatic blood cell separator with a combination of topical minoxidil for the treatment of AGA."9.69Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. ( Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023)
"The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)."9.51Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia. ( Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022)
"Topical hydroalcoholic solution of flutamide plus minoxidil may be promising treatment for the androgenetic alopecia."9.51Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. ( Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022)
"Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy."9.51Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022)
"Treatment of androgenetic alopecia (AGA) with concurrent electrodynamic microneedling and 5% minoxidil may further stimulate hair growth."9.51Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. ( Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022)
"Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking."9.51Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022)
"Topical minoxidil 5% are effective in androgenetic alopecia (AGA)."9.41A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021)
" In the present study, the efficacy and safety of twice daily application of topical cetirizine 1% versus minoxidil 5% solutions for 16 weeks were compared in male androgenetic alopecia (AGA)."9.41Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. ( Firooz, A; Guishard, A; Hossein Mostafa, D; Nasrollahi, SA; Niknam, S; Samadi, A, 2021)
" Combining fractional Er:Glass laser therapy with topical minoxidil may yield therapeutic benefits for patients with androgenetic alopecia (AGA)."9.30A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019)
"Compared with topical minoxidil monotherapy, JetPeel-assisted topical minoxidil is more effective during the treatment of androgenetic alopecia."9.27The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. ( Bao, L; Gong, L; Li, Y; Tian, T, 2018)
"The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men."9.27A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. ( Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018)
"A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia."9.24An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. ( Anandan, S; Chitallia, J; Dhurat, R; Jayaraaman, AM; Klenk, A; Madhukara, J; May, TW; Vaidya, P, 2017)
"5% minoxidil solution is approved for the treatment of male androgenetic alopecia (AGA)."9.24A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. ( Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017)
"There are knowledge gaps regarding the relative efficacy of 3 commonly used drugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-α reductase inhibitors dutasteride and finasteride."9.22Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. ( Bamimore, MA; Gupta, AK; Talukder, M; Venkataraman, M, 2022)
"The objective of this article is to discuss various conditions in alopecia where oral minoxidil has found its role."9.22Comprehensive review of oral minoxidil in alopecia. ( Modha, JD; Pathania, YS, 2022)
"Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia (AGA) for 12 months."9.22Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. ( Blume-Peytavi, U; Canfield, D; Hillmann, K; Kanti, V; Kottner, J; Stroux, A, 2016)
"5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking."9.20A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. ( Blume-Peytavi, U; Canfield, D; Garcia Bartels, N; Hillmann, K; Kottner, J; Stroux, A, 2015)
"The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles."9.17Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. ( Adam, AN; Gado, AM; Mohammed, HR; Sakr, FM, 2013)
"We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia."9.15A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Canfield, D; Dietz, E; Garcia Bartels, N; Hillmann, K, 2011)
"Our study confirms the data of the literature and the evidence coming from years of clinical experience, that twice a day topical application of 5% minoxidil solution, Carexidil ®, is effective in the treatment of male and female androgenetic alopecia, with evident efficacy already after 6 months."9.15[Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study]. ( Alessandrini, A; Fiorucci, MC; Guarrera, M; Lorenzi, S; Piraccini, B; Starace, M, 2011)
"Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase."9.14Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. ( Arano, O; Katsuoka, K; Nishikawa, T; Tsuboi, R; Yamada, H, 2009)
"To evaluate the efficacy of fulvestrant solution in stimulating hair growth in men and postmenopausal women with androgenetic alopecia in two randomized, phase II, minoxidil- and/or vehicle-controlled studies."9.13Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. ( Gassmueller, J; Hoffmann, R; Webster, A, 2008)
"To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA)."9.12A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. ( Bergfeld, W; Hordinsky, M; Kohut, B; Miller, J; Olsen, EA; Wanser, R; Whiting, D; Zhang, P, 2007)
"Minoxidil solution stimulates hair growth in androgenetic alopecia."9.12Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? ( Mapar, MA; Omidian, M, 2007)
"Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA)."9.10A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. ( Dunlap, FE; Funicella, T; Koperski, JA; Olsen, EA; Swinehart, JM; Trancik, RJ; Tschen, EH, 2002)
"To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia."9.10Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002)
" Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata."9.08A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996)
"The aim of our study was to determine if ketoconazole (KCZ) which is active against the scalp microflora and shows some intrinsic anti-inflammatory activity might improve alopecia."9.08Ketoconazole shampoo: effect of long-term use in androgenic alopecia. ( Cauwenbergh, G; De Doncker, P; Piérard, GE; Piérard-Franchimont, C, 1998)
"Topical diphenylcyclopropenone (DPCP) and minoxidil have been used in the treatment of alopecia areata with variable results."9.07Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. ( Abbott, F; Ho, V; Shapiro, J; Tan, J; Tron, V, 1993)
" The purpose of this study was to evaluate a 2% topical minoxidil solution (Rogaine/Regaine, The Upjohn Co, Kalamazoo, Mich) for the treatment of female androgenetic alopecia."9.07Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. ( DeVillez, RL; Jacobs, JP; Szpunar, CA; Warner, ML, 1994)
"A 32-week, double-blind, placebo-controlled trial was conducted in 10 European centers to assess the efficacy and safety of 2% topical minoxidil solution for the treatment of androgenetic alopecia in women."9.07Use of topical minoxidil therapy for androgenetic alopecia in women. ( Jacobs, JP; Szpunar, CA; Warner, ML, 1993)
"A 48-week open label trial was conducted in five Middle-Eastern countries (Lebanon, Egypt, Saudi Arabia, Jordan, and the United Arab Emirates) to determine the safety and efficacy of 2% minoxidil in the treatment of early androgenic alopecia and to compare the response with Western countries."9.07Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. ( Karam, P, 1993)
"The safety and efficacy of minoxidil 2% for the treatment of female androgenetic alopecia was assessed in a 32-week double-blind placebo-controlled trial."9.07Treatment of female androgenetic alopecia with minoxidil 2%. ( Jacobson, C; Whiting, DA, 1992)
"Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil."9.06Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. ( Amara, IA; DeLong, ER; Olsen, EA; Weiner, MS, 1990)
"Seventy-two adult male patients were entered into a double-blind, placebo-controlled investigation using 2% to 3% topical minoxidil solution for androgenetic alopecia."9.06Topical minoxidil therapy for androgenetic alopecia. A 30-month study. ( Koperski, JA; Orenberg, EK; Wilkinson, DI, 1987)
"Of 149 subjects with androgenetic alopecia, 102 completed 1 year of a double-blind, randomized study comparing 2% minoxidil and 3% minoxidil solutions for safety and efficacy."9.06Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. ( Duncan, SH; Rietschel, RL, 1987)
"A double-blind 12-month trial was conducted to evaluate the safety and efficacy of topical minoxidil in patients with androgenetic alopecia."9.06Androgenetic alopecia: treatment results with topical minoxidil. ( Roberts, JL, 1987)
"Topical 5% minoxidil solution was used to treat 47 patients with severe alopecia areata."9.06Topical minoxidil dose-response effect in alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1986)
"The combination of finasteride and topical minoxidil has been used for treating patients with androgenetic alopecia (AGA)."9.05The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020)
"Topical minoxidil has been used for almost 40 years to treat alopecia."9.05Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020)
"Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia."9.01Off-Label Use of Topical Minoxidil in Alopecia: A Review. ( Choi, JN; Colavincenzo, M; Stoehr, JR; Vanderweil, S, 2019)
"Introduction: Topical minoxidil is the first-line therapy for treating both male and female androgenetic alopecia."9.01The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review ( Choi, FD; Juhasz, ML; Mesinkovska, NA; Sung, CT, 2019)
"Hypertrichosis has been reported more frequently in females than in males who use minoxidil topical solution (MTS) for the treatment of androgenetic alopecia (AGA)."8.82Hypertrichosis in females applying minoxidil topical solution and in normal controls. ( Dawber, RP; Rundegren, J, 2003)
"While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions."8.31Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023)
"To determine the causative gene mutation in a family with monilethrix and observe the therapeutic effect of 5% topical minoxidil."8.31Gene detection in a family with monilethrix and treatment with 5% topical minoxidil. ( Du, P; Fu, Z; Shen, Q; Wang, J, 2023)
"Non-adherence to topical minoxidil in alopecia patients is a barrier to efficacy."8.31Topical Minoxidil Adherence in Patients With Alopecia. ( De Souza, B; Eginli, A; Harris, T; Larrondo, J; McMichael, A; Senthilnathan, A, 2023)
"The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)."8.31Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023)
"To investigate the mechanism of minoxidil in treating androgenetic alopecia (AGA)."8.31New Target for Minoxidil in the Treatment of Androgenetic Alopecia. ( Shen, Y; Song, X; Sun, J; Xie, B; Zhang, H; Zhang, L; Zhu, Y, 2023)
" Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L."8.02Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. ( Antonelli, R; Barbarat, P; Buffat, L; Cheniti, A; de Bernard, S; Kanoun-Copy, L; Mahe, YF; Planard-Luong, L; Tacheau, C, 2021)
"The efficacy of minoxidil (MXD) ethanolic solutions (1%-5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions."7.96The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. ( Cutrignelli, A; Denora, N; Fontana, S; Franco, M; la Forgia, F; Laquintana, V; Lopedota, AA; Maqoud, F; Mele, A; Passantino, G; Scala, R; Tinelli, A; Tricarico, D; Zizzo, N, 2020)
"Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia."7.96Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. ( Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020)
"We report three cases of severe hypertrichosis in healthy infants, who did not present any type of endocrinological pathology and whose parents used topical minoxidil for the treatment of their baldness."7.96Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. ( Arcangeli, F; Delgado Rubio, A; García Del Monte, J; Lotti, T; Rica Echevarría, I, 2020)
"Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA)."7.96Efficacy and safety of oral minoxidil in female androgenetic alopecia. ( Annunziata, MC; Cantelli, M; Fabbrocini, G; Nappa, P; Patrì, A; Vastarella, M, 2020)
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects."7.91Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019)
"Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA)."7.88Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. ( Dhurat, R; Goldust, M; Goren, A; Kovacevic, M; Lotti, T; Lukinovic Skudar, V; McCoy, J; Shapiro, J; Sharma, A; Sinclair, R; Situm, M, 2018)
"Topical use of minoxidil is only one of the very few treatment options for alopecia."7.81Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells. ( Aljuffali, IA; Chang, SH; Fang, JY; Pan, TL; Sung, CT, 2015)
"We describe the case of a young man who developed syncope after using a high strength formulation of topical minoxidil as a hair growth restorer."7.81A hairy fall: syncope resulting from topical application of minoxidil. ( Dubrey, SW; Edwards, CM; VanGriethuysen, J, 2015)
"Although minoxidil (MX) is a drug known to stimulate hair growth, the treatment of androgenic alopecia could be improved by delivery strategies that would favor drug accumulation into the hair follicles."7.79Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia. ( Delgado-Charro, MB; Gelfuso, GM; Gratieri, T; Guy, RH; Vianna Lopez, RF, 2013)
"To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment."7.78Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012)
"Topical 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) solution has been widely used for the treatment of androgenetic alopecia for over 15 years now and the substance is currently approved for this indication in 2% and 5% formulation."7.73Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. ( Allam, JP; Bieber, T; Hagemann, T; Novak, N; Schlütter-Böhmer, B, 2005)
"We report a 24-year-old woman with androgenetic alopecia who became sensitized to topical minoxidil following use of an extemporaneous preparation of minoxidil 4% with retinoic acid in a propylene glycol base."7.71Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. ( Mallari, RS; Sinclair, RD; Tate, B, 2002)
"After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia."7.71Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. ( Cohen, DE; Friedman, ES; Friedman, PM; Washenik, K, 2002)
" Topical minoxidil is a proven therapy for androgenic alopecia and female senile alopecia."7.71Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients. ( Eremia, S; Li, CY; Umar, SH, 2002)
"As an extension to these observations, we chose to test the efficacy of minoxidil, a drug known to be a hypertrichotic agent, in preventing chemotherapy-induced alopecia in the newborn rat animal model."7.69Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. ( Hussein, AM, 1995)
"Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical minoxidil."7.69Diffuse hypertrichosis during treatment with 5% topical minoxidil. ( Misciali, C; Peluso, AM; Tosti, A; Vincenzi, C, 1997)
"Topical application of minoxidil has been reported to be effective in the treatment of androgenic alopecia."7.67Topical minoxidil for male pattern alopecia in two sets of twins. ( Kuruvilla, S; Roenigk, HH, 1987)
"A 1% minoxidil lotion was used to treat 670 male patients affected by androgenetic alopecia."7.67Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. ( Tosti, A, 1986)
"A male volunteer with frontal alopecia was treated simultaneously with 20 mg cyproterone acetate and 5 mg minoxidil topically (daily)."7.66Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate. ( Vermorken, AJ, 1983)
"Cetirizine is an antihistamine that may be effective in hair loss treatment."7.30Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023)
" However, the efficacy of PRPF combined with minoxidil treatment remains unknown."7.30Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial. ( Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023)
"Minoxidil is a common therapeutic option for AGA patients because of its availability."7.30A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia. ( Asim, M; Ouellette, S; Rao, B; Shah, A; Shah, R; Sharif, S, 2023)
" Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects."7.11Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022)
"Female pattern hair loss (FPHL) is a hereditary form of hair loss in women and the most common patterned progressive hair loss in female patients with androgenetic alopecia (AGA)."7.01A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Nikkhah, F; Nobari, NN; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2023)
" No scarring nor serious adverse events were reported in any of the studies."7.01Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. ( Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023)
"Minoxidil 2% and 5% have been FDA approved for treatment of this condition."7.01Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. ( Alarawi, A; Bessar, H; Ghonemy, S, 2021)
"Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined."7.01Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial. ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021)
"Androgenetic alopecia (AGA) is a hair loss disorder that frequently affects the male population."7.01Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial. ( Contin, LA; de Brito, FF; Donati, A; Ferrara, F; Kakizaki, P; Machado, CJ, 2021)
"Androgenic alopecia (AGA) is a common hair loss disorder."6.94A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. ( Arthurs, JR; Bruce, AJ; Bruce, CJ; Desmond, CM; Diehl, NN; Douglass, EJ; Heckman, MG; Pincelli, TP; Shapiro, SA, 2020)
" Although successful encapsulation of MIN has been observed in these nanocarriers, there is still scarce data regarding their loading in a final dosage form."6.82Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. ( Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022)
"Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss."6.73Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Ellwanger, U; Garcia Bartels, N; Hoffmann, R; Krisp, A; Kunte, C, 2007)
"Minoxidil (Loxon) was topically applied twice a day massaging the solution into the scalp over 6-12 months."6.70[Effect of minoxidil on hair growth in androgenic alopecia in women]. ( Brzezińska-Wcisło, L, 2002)
"Sixty-four healthy men with early male pattern baldness completed a 6-month, double-blind, placebo-controlled study in which the efficacy of 2% minoxidil gel and solution formulations was compared."6.66Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia. ( Piepkorn, MW; Weidner, M, 1988)
"Fifty-eight men with Hamilton scale type III vertex or type IV male pattern baldness were studied to determine the dose-response activity of low concentrations of topical minoxidil in promoting hair growth."6.66Dose-response study of topical minoxidil in male pattern alopecia. ( Jondreau, L; Kassimir, JJ; Reed, ML; Shupack, JL; Thirumoorthy, T, 1987)
"Frontotemporal hair loss did not respond to treatment and in fact progressed in severity, despite the twice-daily applications of minoxidil."6.66Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. ( DeVillez, RL, 1987)
"Minoxidil, 1."6.66Topical minoxidil therapy in hereditary androgenetic alopecia. ( De Villez, RL, 1985)
"Cetirizine, a widely used agent for allergic disorders, has recently been topically used for treating androgenetic alopecia (AGA)."6.60Topical cetirizine for treating androgenetic alopecia: A systematic review. ( Chen, X; Xiang, H; Yang, M, 2022)
"Male pattern hair loss (androgenetic alopecia) is a common problem."6.37Topical minoxidil in the treatment of male pattern alopecia. ( Baden, HP; Kvedar, JC, 1987)
"Topical minoxidil (Rogaine) has recently been approved by the Food and Drug Administration for treatment of androgenetic alopecia."6.16Topical minoxidil: review of efficacy and safety. ( Katz, HI, 1989)
"The most prevalent kind of hair loss is androgenic alopecia (AGA), which is characterized by hair follicle miniaturization and microenvironment dysfunction."5.91Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia. ( Guan, Y; Liu, M; Qiang, W; Ruan, R; Sun, H; Yan, A; Yu, Q; Zhu, H; Zhu, X, 2023)
"Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA."5.72Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. ( Alencar-Silva, T; Carvalho, JL; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Oliveira, PM; Pires, FQ, 2022)
" Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use."5.72Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model. ( An, BS; Jeong, JS; Kim, DS; Kim, MJ; Kim, SY; Lee, S; Seong, KY; Yang, SY, 2022)
"Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders."5.72Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022)
"PRP is effective in the treatment of moderate grades of androgenetic alopecia in men, although perhaps not different from minoxidil."5.69Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. ( Balasundaram, M; Kumari, R; Ramassamy, S, 2023)
"Platelet-rich plasma (PRP) has been increasingly accepted as a potential therapy in the treatment of androgenetic alopecia (AGA), However, there remains a dearth of data on the effectiveness of PRP prepared by automatic blood cell separator with a combination of topical minoxidil for the treatment of AGA."5.69Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia. ( Long, B; Wei, W; Zhang, C; Zhang, S; Zhang, Y, 2023)
"The goal was to explore the efficacy and side effects of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male patients with early stage of androgenetic alopecia (AGA)."5.51Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia. ( Liu, C; Wu, W; Zhang, Y; Zhao, H, 2022)
"Topical hydroalcoholic solution of flutamide plus minoxidil may be promising treatment for the androgenetic alopecia."5.51Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. ( Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022)
"Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy."5.51Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022)
"To observe the efficacy of unilateral subcutaneous injection of botulinum toxin A combined with finasteride and minoxidil in the treatment of androgenic alopecia."5.51A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia. ( Gao, S; Jia, Z; Li, K; Tian, K; Wu, L; Xu, W, 2022)
"Treatment of androgenetic alopecia (AGA) with concurrent electrodynamic microneedling and 5% minoxidil may further stimulate hair growth."5.51Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. ( Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022)
"Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking."5.51Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022)
"In a small cohort of androgenetic alopecia men, adding the SULT1A1 adjuvant to their daily minoxidil treatment regimen improved hair regrowth."5.51SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. ( Daruwalla, S; Dhurat, R; Goren, A; Kovacevic, M; McCoy, J; Pai, S; Shapiro, J; Sinclair, R; Vano-Galvan, S, 2022)
"Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50."5.51Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( Andy, G; Aseem, S; John, M; Maja, K; Michael, K; Mirna, S; Rachita, D; Zeljana, B, 2019)
"Minoxidil has been approved for the treatment of hair loss, however its mechanism of action is still not fully clarified."5.46An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. ( Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017)
"Tofacitinib-treated mice exhibited more hair regrowth than either minoxidil-treated or control mice did between day 7 and 21 (P < 0."5.46Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. ( Deenonpoe, R; Meephansan, J; Ponnikorn, S; Suchonwanit, P; Thummakriengkrai, J; Yingmema, W, 2017)
"Treatment with dutasteride 0."5.46Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. ( Cranwell, WC; Sinclair, R, 2017)
" The safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the botanical hair solution for 12 weeks in 54 subjects was evaluated in a multicenter, single-arm, open-label study."5.43Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( McMichael, A; Meckfessel, MH; Pham, H; von Grote, E, 2016)
" The safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with a novel botanical hair solution was evaluated in a 12-week, multicenter, single-arm, open label study in 56 subjects with mild to moderate AGA."5.43Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( Keaney, TC; Meckfessel, MH; Pham, H; von Grote, E, 2016)
" Currently, there are 3 Food and Drug Administration-approved nonsurgical androgenetic alopecia treatments: minoxidil, finasteride, and low-light laser therapy."5.41Noninvasive Hair Rejuvenation. ( Sand, J; Walen, S, 2023)
"Finasteride and minoxidil are medicaments commonly prescribed for treating benign prostatic hyperplasia (BPA), hypertension, and/or androgenetic alopecia (AGA)."5.41Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence. ( Da Matta, SLP; Da Silva, J; Gonçalves, RV; Lozi, AA; Santana, FFV, 2023)
"Topical minoxidil 5% are effective in androgenetic alopecia (AGA)."5.41A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021)
" In the present study, the efficacy and safety of twice daily application of topical cetirizine 1% versus minoxidil 5% solutions for 16 weeks were compared in male androgenetic alopecia (AGA)."5.41Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. ( Firooz, A; Guishard, A; Hossein Mostafa, D; Nasrollahi, SA; Niknam, S; Samadi, A, 2021)
"Tretinoin is a mitogen by itself and also enhances the absorption of minoxidil which acts by enlarging the miniaturized hair follicles."5.35Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. ( Dhurat, RS; Jerajani, HR; Melkote, S; Palav, A, 2009)
"A 45-year-old Japanese man with paroxysmal atrial fibrillation (AF) developed acute anteroseptal myocardial infarction (MI)."5.31A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness. ( Fujiwara, C; Morikaw, S; Ohno, R; Satoh, H; Terada, H; Uehara, A, 2000)
" Combining fractional Er:Glass laser therapy with topical minoxidil may yield therapeutic benefits for patients with androgenetic alopecia (AGA)."5.30A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019)
"One patient had no hair loss in either the treatment or control area."5.28The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. ( Baden, H; Frederickson, H; Gajewski, W; Goldstein, A; Goodman, A; Granai, CO, 1991)
"Compared with topical minoxidil monotherapy, JetPeel-assisted topical minoxidil is more effective during the treatment of androgenetic alopecia."5.27The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. ( Bao, L; Gong, L; Li, Y; Tian, T, 2018)
"The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men."5.27A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. ( Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018)
"A caffeine-based topical liquid should be considered as not inferior to minoxidil 5% solution in men with androgenetic alopecia."5.24An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. ( Anandan, S; Chitallia, J; Dhurat, R; Jayaraaman, AM; Klenk, A; Madhukara, J; May, TW; Vaidya, P, 2017)
"5% minoxidil solution is approved for the treatment of male androgenetic alopecia (AGA)."5.24A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. ( Suvanasuthi, S; Thanomkitti, K; Thuangtong, R, 2017)
"There are knowledge gaps regarding the relative efficacy of 3 commonly used drugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-α reductase inhibitors dutasteride and finasteride."5.22Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. ( Bamimore, MA; Gupta, AK; Talukder, M; Venkataraman, M, 2022)
"Oral finasteride is an FDA-approved treatment for androgenetic alopecia (AGA)."5.22Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? ( Gupta, AK; Talukder, M, 2022)
" Currently, the FDA-approved drugs for the treatment of androgenetic alopecia (AGA) are minoxidil and finasteride and immunosuppressives are therapeutic options for alopecia areata (AA), but the objective adverse effects and high cost of these treatments reduce patient compliance and thus the effectiveness of the drugs."5.22Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds. ( Dou, J; Xu, X; Zhang, X; Zhang, Z, 2022)
"Minoxidil solution is used for the treatment of androgenetic alopecia (AGA)."5.22Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? ( Goldust, M; Kianfar, N; Patil, A; Rudnicka, L; Sinclair, R; Singh, S; Waśkiel-Burnat, A, 2022)
" Currently, there are 3 Food and Drug Administration-approved nonsurgical androgenetic alopecia treatments: minoxidil, finasteride, and low-light laser therapy."5.22Noninvasive Hair Rejuvenation. ( Sand, J; Walen, S, 2022)
"The objective of this article is to discuss various conditions in alopecia where oral minoxidil has found its role."5.22Comprehensive review of oral minoxidil in alopecia. ( Modha, JD; Pathania, YS, 2022)
"Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia (AGA) for 12 months."5.22Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. ( Blume-Peytavi, U; Canfield, D; Hillmann, K; Kanti, V; Kottner, J; Stroux, A, 2016)
"5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking."5.20A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. ( Blume-Peytavi, U; Canfield, D; Garcia Bartels, N; Hillmann, K; Kottner, J; Stroux, A, 2015)
"The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles."5.17Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. ( Adam, AN; Gado, AM; Mohammed, HR; Sakr, FM, 2013)
"The aim of this study was to evaluate the efficacy of 5% hexane extract of Curcuma aeruginosa, a botanically derived inhibitor of 5α-reductase and 5% minoxidil in the treatment of androgenetic alopecia."5.16Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study. ( Asawanonda, P; Ingkaninan, K; Jariyasethavong, V; Leelapornpisit, P; Pumthong, G; Suthipinittharm, P; Triwongwaranat, D; Varothai, S; Waranuch, N, 2012)
"Topical minoxidil and oral finasteride have been used to treat men with androgenetic alopecia (AGA)."5.16Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. ( Tanglertsampan, C, 2012)
"We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia."5.15A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Canfield, D; Dietz, E; Garcia Bartels, N; Hillmann, K, 2011)
"Our study confirms the data of the literature and the evidence coming from years of clinical experience, that twice a day topical application of 5% minoxidil solution, Carexidil ®, is effective in the treatment of male and female androgenetic alopecia, with evident efficacy already after 6 months."5.15[Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study]. ( Alessandrini, A; Fiorucci, MC; Guarrera, M; Lorenzi, S; Piraccini, B; Starace, M, 2011)
"Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase."5.14Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. ( Arano, O; Katsuoka, K; Nishikawa, T; Tsuboi, R; Yamada, H, 2009)
"To evaluate the efficacy of fulvestrant solution in stimulating hair growth in men and postmenopausal women with androgenetic alopecia in two randomized, phase II, minoxidil- and/or vehicle-controlled studies."5.13Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. ( Gassmueller, J; Hoffmann, R; Webster, A, 2008)
"To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA)."5.12A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. ( Bergfeld, W; Hordinsky, M; Kohut, B; Miller, J; Olsen, EA; Wanser, R; Whiting, D; Zhang, P, 2007)
"5% topical minoxidil solution has been widely used to stimulate new hair growth and help stop hair loss in men with androgenetic alopecia (AGA)."5.12Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. ( Eun, HC; Kim, KH; Kwon, OS; Lee, SH; Shin, HS; Won, CH, 2007)
"Minoxidil solution stimulates hair growth in androgenetic alopecia."5.12Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice? ( Mapar, MA; Omidian, M, 2007)
"To pical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in men with androgenetic alopecia and women with female pattern hair loss."5.11A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. ( Ditre, CM; Dunlap, F; Kantor, I; Lucky, AW; Pandya, AG; Piacquadio, DJ; Savin, RC; Tharp, MD, 2004)
"Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA)."5.10A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. ( Dunlap, FE; Funicella, T; Koperski, JA; Olsen, EA; Swinehart, JM; Trancik, RJ; Tschen, EH, 2002)
"To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia."5.10Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002)
" Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata."5.08A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996)
"The aim of our study was to determine if ketoconazole (KCZ) which is active against the scalp microflora and shows some intrinsic anti-inflammatory activity might improve alopecia."5.08Ketoconazole shampoo: effect of long-term use in androgenic alopecia. ( Cauwenbergh, G; De Doncker, P; Piérard, GE; Piérard-Franchimont, C, 1998)
"Topical diphenylcyclopropenone (DPCP) and minoxidil have been used in the treatment of alopecia areata with variable results."5.07Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. ( Abbott, F; Ho, V; Shapiro, J; Tan, J; Tron, V, 1993)
" The purpose of this study was to evaluate a 2% topical minoxidil solution (Rogaine/Regaine, The Upjohn Co, Kalamazoo, Mich) for the treatment of female androgenetic alopecia."5.07Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. ( DeVillez, RL; Jacobs, JP; Szpunar, CA; Warner, ML, 1994)
"A 32-week, double-blind, placebo-controlled trial was conducted in 10 European centers to assess the efficacy and safety of 2% topical minoxidil solution for the treatment of androgenetic alopecia in women."5.07Use of topical minoxidil therapy for androgenetic alopecia in women. ( Jacobs, JP; Szpunar, CA; Warner, ML, 1993)
"A 48-week open label trial was conducted in five Middle-Eastern countries (Lebanon, Egypt, Saudi Arabia, Jordan, and the United Arab Emirates) to determine the safety and efficacy of 2% minoxidil in the treatment of early androgenic alopecia and to compare the response with Western countries."5.07Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. ( Karam, P, 1993)
"The safety and efficacy of minoxidil 2% for the treatment of female androgenetic alopecia was assessed in a 32-week double-blind placebo-controlled trial."5.07Treatment of female androgenetic alopecia with minoxidil 2%. ( Jacobson, C; Whiting, DA, 1992)
"Psychologic characteristics were studied in a sample of 168 men with alopecia androgenetica who participated in a clinical trial on the efficacy of minoxidil gel."5.07Psychologic characteristics of men with alopecia androgenetica and their modification. ( Dutree-Meulenberg, RO; Passchier, J; Stolz, E; van der Donk, J; Verhage, F, 1991)
"One hundred and sixty nine men with early male pattern baldness (androgenic alopecia) were treated in a random, double-blind fashion with either 2% minoxidil solution or placebo vehicle for 24 weeks, one ml applied twice daily."5.06Australian trial of topical minoxidil and placebo in early male pattern baldness. ( Connors, TJ; Cooke, DE; De Launey, WE; Downie, M; Eggleston, AS; Knudsen, RG; Shumack, S, 1990)
"The paper reports the results of local treatment using minoxidil 2% in a watery solution at a dose of 2 ml/day in 50 patients affected by androgenetic alopecia."5.06[Efficacy and cardiovascular tolerability of minotricon in the treatment of seborrheic alopecia]. ( Pinelli, S; Rigoni, C; Scarabelli, G; Terenzio, C; Toffolo, P, 1990)
"Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil."5.06Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. ( Amara, IA; DeLong, ER; Olsen, EA; Weiner, MS, 1990)
"Cutaneous blood flow was measured by Laser Doppler Flowmetry after topical application of minoxidil lotion, in 9 healthy males with androgenetic alopecia, and other volunteers."5.06Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study. ( Bezemer, PD; Bruynzeel, DP; de Boer, EM; Nieboer, C, 1988)
"Consultations, motives, experience, and attitudes were explored in 201 men with alopecia androgenetica who had two years before shown interest in hair treatment using minoxidil."5.06Why men with hair loss go to the doctor. ( Dutrée-Meulenberg, RO; Passchier, J; Rijpma, SE; Stolz, E; Verhage, F, 1989)
"Seventy-two adult male patients were entered into a double-blind, placebo-controlled investigation using 2% to 3% topical minoxidil solution for androgenetic alopecia."5.06Topical minoxidil therapy for androgenetic alopecia. A 30-month study. ( Koperski, JA; Orenberg, EK; Wilkinson, DI, 1987)
"Of 149 subjects with androgenetic alopecia, 102 completed 1 year of a double-blind, randomized study comparing 2% minoxidil and 3% minoxidil solutions for safety and efficacy."5.06Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. ( Duncan, SH; Rietschel, RL, 1987)
"A double-blind 12-month trial was conducted to evaluate the safety and efficacy of topical minoxidil in patients with androgenetic alopecia."5.06Androgenetic alopecia: treatment results with topical minoxidil. ( Roberts, JL, 1987)
"5% minoxidil has been tested for the promotion of hair growth in 56 subjects with androgenetic alopecia."5.06Topical tretinoin for hair growth promotion. ( Bazzano, GS; Galen, W; Terezakis, N, 1986)
"Topical 5% minoxidil solution was used to treat 47 patients with severe alopecia areata."5.06Topical minoxidil dose-response effect in alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1986)
"The combination of finasteride and topical minoxidil has been used for treating patients with androgenetic alopecia (AGA)."5.05The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( Chen, B; Chen, L; Wang, H; Wang, L; Zhang, J, 2020)
"Topical minoxidil has been used for almost 40 years to treat alopecia."5.05Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020)
"low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and other types of hair loss."5.05Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. ( Fernandez-Nieto, D; Jaen-Olasolo, P; Jimenez-Cauhe, J; Moreno-Arrones, OM; Ortega-Quijano, D; Rodrigues-Barata, R; Saceda-Corralo, D; Vaño-Galvan, S, 2020)
"Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia."5.01Off-Label Use of Topical Minoxidil in Alopecia: A Review. ( Choi, JN; Colavincenzo, M; Stoehr, JR; Vanderweil, S, 2019)
"Introduction: Topical minoxidil is the first-line therapy for treating both male and female androgenetic alopecia."5.01The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review ( Choi, FD; Juhasz, ML; Mesinkovska, NA; Sung, CT, 2019)
"This meta-analysis strongly suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growth in men with androgenetic alopecia and that minoxidil is effective in women with androgenetic alopecia."4.95The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. ( Adil, A; Godwin, M, 2017)
" However, a recent Cochrane systematic review concludes that the only drug proven to improve alopecia by randomized controlled studies using rigorous criteria is minoxidil."4.91An update on the treatment of female alopecia and the introduction of a potential novel therapy. ( Check, JH; Cohen, R, 2015)
"Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials."4.86Male androgenetic alopecia. ( Rathnayake, D; Sinclair, R, 2010)
"Hypertrichosis has been reported more frequently in females than in males who use minoxidil topical solution (MTS) for the treatment of androgenetic alopecia (AGA)."4.82Hypertrichosis in females applying minoxidil topical solution and in normal controls. ( Dawber, RP; Rundegren, J, 2003)
" Minoxidil and Finasteride were recently introduced for the treatment of androgenetic alopecia in Japan, and TGF-beta1 is the next target for innovative treatment."4.82[Pathomechanism of androgenetic alopecia and new treatment]. ( Itami, S, 2004)
"The management of androgenetic alopecia (AGA) has been materially altered by the availability of the 5 alpha-reductase type 2 inhibitor, finasteride."4.81Management of male pattern hair loss. ( Sinclair, RD, 2001)
"While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions."4.31Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023)
"Topical minoxidil has been used for many years to treat adult alopecia, and there is growing evidence supporting the off-label use of low-dose oral minoxidil (LDOM)."4.31Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review. ( John, JM; Sinclair, RD, 2023)
"To determine the causative gene mutation in a family with monilethrix and observe the therapeutic effect of 5% topical minoxidil."4.31Gene detection in a family with monilethrix and treatment with 5% topical minoxidil. ( Du, P; Fu, Z; Shen, Q; Wang, J, 2023)
"Minoxidil has been used as an effective and cost-efficient topical treatment for androgenic alopecia."4.31Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging. ( Elnawawy, T; Makhlouf, A, 2023)
"Non-adherence to topical minoxidil in alopecia patients is a barrier to efficacy."4.31Topical Minoxidil Adherence in Patients With Alopecia. ( De Souza, B; Eginli, A; Harris, T; Larrondo, J; McMichael, A; Senthilnathan, A, 2023)
"The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)."4.31Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023)
"This study evaluated the topical effect of Lepidium sativum lyophilized seed extract (LSLE) towards Sustanon-induced alopecia in male adult Wistar albino rats in vivo, compared to minoxidil topical reference standard drug (MRD)."4.31The medicinal activity of lyophilized aqueous seed extract of Lepidium sativum L. in an androgenic alopecia model. ( Albalawi, MA; Bakeer, RM; El Hadi, SA; El-Desoky, AH; Elhawary, SS; Hafez, AM; Hassan, OF; Mahgoub, S; Mokhtar, FA; Sedky, NK, 2023)
"Recent studies are promising for the intradermal delivery of dutasteride and minoxidil in the treatment of androgenetic alopecia."4.31Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects. ( Alhanshali, L; Buontempo, M; Lo Sicco, K; Majerson, D; Shapiro, J, 2023)
"To investigate the mechanism of minoxidil in treating androgenetic alopecia (AGA)."4.31New Target for Minoxidil in the Treatment of Androgenetic Alopecia. ( Shen, Y; Song, X; Sun, J; Xie, B; Zhang, H; Zhang, L; Zhu, Y, 2023)
" Since scalp inflammation was recognized as a potential physiological obstacle to the efficacy of the reference hair regrowth drug Minoxidil in vivo and since perifollicular inflammation is the hallmark of about 50%-70% follicular units in androgenetic alopecia, we decided to investigate whether the anti-inflammatory activity of LLLT/GentleWaves® device were assigned to L'Oréal by Light BioScience L."4.02Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. ( Antonelli, R; Barbarat, P; Buffat, L; Cheniti, A; de Bernard, S; Kanoun-Copy, L; Mahe, YF; Planard-Luong, L; Tacheau, C, 2021)
"The efficacy of minoxidil (MXD) ethanolic solutions (1%-5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions."3.96The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. ( Cutrignelli, A; Denora, N; Fontana, S; Franco, M; la Forgia, F; Laquintana, V; Lopedota, AA; Maqoud, F; Mele, A; Passantino, G; Scala, R; Tinelli, A; Tricarico, D; Zizzo, N, 2020)
"Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia."3.96Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. ( Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020)
"We report three cases of severe hypertrichosis in healthy infants, who did not present any type of endocrinological pathology and whose parents used topical minoxidil for the treatment of their baldness."3.96Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. ( Arcangeli, F; Delgado Rubio, A; García Del Monte, J; Lotti, T; Rica Echevarría, I, 2020)
"Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA)."3.96Efficacy and safety of oral minoxidil in female androgenetic alopecia. ( Annunziata, MC; Cantelli, M; Fabbrocini, G; Nappa, P; Patrì, A; Vastarella, M, 2020)
"In spite of several modalities for androgenic alopecia therapy used such as topical minoxidil solution or oral finasteride; it still has a great challenge."3.96Evaluation of the effect of autologous platelet-rich plasma on androgenic alopecia. ( Makki, M; Salah, I; Younes, AH, 2020)
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects."3.91Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019)
"The aim of this study was to prepared minoxidil-encapsulated PLLGA nanoparticles and accumulate minoxidil in hair follicles utilizing its drug delivery properties for effective treatment of male and female androgenetic alopecia."3.88Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication. ( Hida, Y; Makino, K; Takeuchi, I, 2018)
"The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed."3.88Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. ( Chan, D; Dusza, S; Fornier, M; Freites-Martinez, A; Gajria, D; Goldfarb, S; Lacouture, ME; Modi, S; Shapiro, J, 2018)
"Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA)."3.88Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. ( Dhurat, R; Goldust, M; Goren, A; Kovacevic, M; Lotti, T; Lukinovic Skudar, V; McCoy, J; Shapiro, J; Sharma, A; Sinclair, R; Situm, M, 2018)
"Minoxidil is widely used for treatment of androgenic alopecia."3.85Preparation and in vivo evaluation of lecithin-based microparticles for topical delivery of minoxidil. ( Choi, HC; Han, K; Kim, DW; Lee, HJ; Lee, YB; Na, MJ; Oh, DW; Park, CW; Yuk, DY, 2017)
"Minoxidil (Mx) is a conventional drug for treating androgenetic alopecia, preventing hair loss, and promoting hair growth."3.83Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhance Hair Growth. ( Chen, HK; Liao, AH; Lin, YC; Lu, YJ; Sytwu, HK; Wang, CH, 2016)
"Topical use of minoxidil is only one of the very few treatment options for alopecia."3.81Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells. ( Aljuffali, IA; Chang, SH; Fang, JY; Pan, TL; Sung, CT, 2015)
"We describe the case of a young man who developed syncope after using a high strength formulation of topical minoxidil as a hair growth restorer."3.81A hairy fall: syncope resulting from topical application of minoxidil. ( Dubrey, SW; Edwards, CM; VanGriethuysen, J, 2015)
"For therapy, the following medications are used: topical minoxidil solution for AGA of men and women; systemic finasteride 1 mg for men with AGA; topical diphencyprone immunotherapy for alopecia areata; systemic antimycotic agents for tinea capitis; antibiotics such as clindamycin and rifampicin for folliculitis decalvans; systemic corticosteroids and isotretinoin for folliculitis et perifolliculitis capitis abscedens et suffodiens; topical corticosteroids for lichen planus and Kossard's frontal fibrosing alopecia."3.81[Drug treatment of alopecia]. ( Wolff, H, 2015)
"Although minoxidil (MX) is a drug known to stimulate hair growth, the treatment of androgenic alopecia could be improved by delivery strategies that would favor drug accumulation into the hair follicles."3.79Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia. ( Delgado-Charro, MB; Gelfuso, GM; Gratieri, T; Guy, RH; Vianna Lopez, RF, 2013)
"Minoxidil is one of the drugs approved for the treatment of androgenetic alopecia."3.78Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness. ( Cacciamani, A; Colletti, M; Mezzana, P; Pasquini, P; Scarinci, F, 2012)
" VPA induced ALP in human dermal papilla cells by up-regulating the Wnt/β-catenin pathway, whereas minoxidil (MNX), a drug commonly used to treat alopecia, did not significantly affect the Wnt/β-catenin pathway."3.78Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. ( Choi, KY; Kim, HJ; Kim, HY; Lee, SH; Min, do S; Park, PJ; Park, WS; Shin, SH; Yoon, J; Zahoor, M, 2012)
"To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment."3.78Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012)
" Topical minoxidil treatment promotes hair growth in men with androgenetic alopecia, suggesting that minoxidil may prolong the actively growing phase of the anagen hair cycle."3.77Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. ( Kang, BM; Kim, JC; Kim, MK; Kwack, MH; Sung, YK, 2011)
"Minoxidil (2,4-diamino-6-(piperidin-1'-yl)pyrimidine N(3)-oxide; CASRN 38304-91-5) is a bioactive molecule with several nitrosatable groups widely used as an antihypertensive and antialopecia agent."3.77Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil. ( Arenas-Valgañón, J; Calle, E; Casado, J; González-Jiménez, M, 2011)
"Minoxidil has generated new interest in hair-loss research."3.76Topical minoxidil therapy for hair regrowth. ( Fiedler-Weiss, VC; Rumsfield, JA; West, DP, 1987)
"Minoxidil enhances hair growth by prolonging the anagen phase and induces new hair growth in androgenetic alopecia (AGA), whereas retinol significantly improves scalp skin condition and promotes hair growth."3.74The additive effects of minoxidil and retinol on human hair growth in vitro. ( Chang, IY; Cho, KH; Eun, HC; Kang, YJ; Kim, KH; Kwon, OS; Lee, SH; Pyo, HK; Yoo, HG, 2007)
"A 53-year-old woman with clinical evidence of female pattern hair loss and histological evidence of androgenetic alopecia was initially treated with the oral antiandrogen spironolactone 200 mg daily."3.74Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. ( Hoedemaker, C; Sinclair, R; van Egmond, S, 2007)
"Topical 2,4-diamino-6-piperidinopyrimidine-3-oxide (minoxidil) solution has been widely used for the treatment of androgenetic alopecia for over 15 years now and the substance is currently approved for this indication in 2% and 5% formulation."3.73Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. ( Allam, JP; Bieber, T; Hagemann, T; Novak, N; Schlütter-Böhmer, B, 2005)
"Minoxidil has been widely used to treat androgenetic alopecia, but little is known about its pharmacological activity or about the identity of its target cells in hair follicles."3.72Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. ( Cho, KH; Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS, 2004)
"We report a 24-year-old woman with androgenetic alopecia who became sensitized to topical minoxidil following use of an extemporaneous preparation of minoxidil 4% with retinoic acid in a propylene glycol base."3.71Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. ( Mallari, RS; Sinclair, RD; Tate, B, 2002)
"After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia."3.71Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. ( Cohen, DE; Friedman, ES; Friedman, PM; Washenik, K, 2002)
" Topical minoxidil is a proven therapy for androgenic alopecia and female senile alopecia."3.71Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients. ( Eremia, S; Li, CY; Umar, SH, 2002)
"As an extension to these observations, we chose to test the efficacy of minoxidil, a drug known to be a hypertrichotic agent, in preventing chemotherapy-induced alopecia in the newborn rat animal model."3.69Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. ( Hussein, AM, 1995)
"Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical minoxidil."3.69Diffuse hypertrichosis during treatment with 5% topical minoxidil. ( Misciali, C; Peluso, AM; Tosti, A; Vincenzi, C, 1997)
"A 2% solution of topical minoxidil was applied on the recipient bald scalp of 16 patients aged 25 to 52 years with Hamilton classifications of androgenetic alopecia from III to VI."3.67Topical minoxidil used before and after hair transplantation. ( Bouhanna, P, 1989)
"Twelve patients, aged 21 to 60 years, with varying Hamilton classifications of androgenetic alopecia (male pattern baldness) were treated with a 3% solution of topical minoxidil."3.67Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. ( Kassimir, JJ, 1987)
"Topical application of minoxidil has been reported to be effective in the treatment of androgenic alopecia."3.67Topical minoxidil for male pattern alopecia in two sets of twins. ( Kuruvilla, S; Roenigk, HH, 1987)
"A 1% minoxidil lotion was used to treat 670 male patients affected by androgenetic alopecia."3.67Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. ( Tosti, A, 1986)
"A male volunteer with frontal alopecia was treated simultaneously with 20 mg cyproterone acetate and 5 mg minoxidil topically (daily)."3.66Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate. ( Vermorken, AJ, 1983)
"Cetirizine is an antihistamine that may be effective in hair loss treatment."3.30Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. ( Abbassi, MM; Bassiouny, EA; El-Samanoudy, SI; Farid, SF; Nada, HR, 2023)
" However, the efficacy of PRPF combined with minoxidil treatment remains unknown."3.30Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial. ( Chen, J; Dai, D; Guan, Q; Hu, Z; Le, D; Liu, S; Liu, W; Miao, Y; Qu, Q; Wu, S, 2023)
"Minoxidil is a common therapeutic option for AGA patients because of its availability."3.30A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia. ( Asim, M; Ouellette, S; Rao, B; Shah, A; Shah, R; Sharif, S, 2023)
"To evaluate the efficacy and safety of 2% minoxidil combined with microneedling in the treatment of female pattern hair loss."3.11Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population. ( Hu, R; Sheng, Y; Wang, W; Yang, Q; Zeng, Y; Zhang, Y; Zhao, J, 2022)
" Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects."3.11Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022)
"(2), Minoxidil (5%) treated group (3), Methylsulfonylmethane (10%) treated group (4), Methylsulfonylmethane plus Minoxidil treated group."3.11EVALUATION OF THE EFFECT OF TOPICALLY APPLIED METHYLSULFONYLMETHANE AND THEIR COMBINATION WITH MINOXIDIL SOLUTION FOR IMPROVEMENT OF HAIR GROWTH IN MALE MICE. ( Gany, SN; Hadi, NR; Hummadi, AA, 2022)
" Second-line options include daily oral minoxidil dosed at 1."3.01Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. ( Dommasch, ED; Gao, JL; Peebles, JK; Streed, CG; Thompson, J, 2023)
"Alopecia is the most common and difficult-to-treat hair disorder."3.01Advances in microneedles research based on promoting hair regrowth. ( Chen, G; Fu, Q; Jia, L; Li, N; Zhou, D; Zhou, Y, 2023)
"Pediatric androgenetic alopecia is an underrecognized disorder."3.01Pediatric androgenetic alopecia: an updated review. ( Gomes, TF; Soares, RO, 2023)
"Female pattern hair loss (FPHL) is a hereditary form of hair loss in women and the most common patterned progressive hair loss in female patients with androgenetic alopecia (AGA)."3.01A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Nikkhah, F; Nobari, NN; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2023)
"Hair loss or alopecia is a common dermatological condition affecting up to 2% of the world population."3.01Natural Compounds Used for Treating Hair Loss. ( Beley, N; Bjørklund, G; Fedorovska, M; Gasmi, A; Komisarenko, A; Lenchyk, L; Lysiuk, R; Muhammad, A; Mujawdiya, PK; Noor, S; Piscopo, S; Shanaida, M; Strus, O, 2023)
"Patterned hair loss is a common type of non-scarring alopecia, characterized by miniaturization of hair follicles."3.01Combination therapy in female pattern hair loss. ( Deoghare, S; Sadick, NS, 2023)
"Alopecia is a treatable benign disease, however, approximately 15-30% of women and 50% of men suffer from alopecia, which greatly affects patient's self-esteem and quality of life."3.01Dissolving microneedles for alopecia treatment. ( Chen, J; Li, Y; Lv, Y; Miao, X; Xiang, H; Xu, S; Xue, X; Zhang, W, 2023)
"Novel medical and procedural options for androgenetic alopecia have arrived."3.01Medical and procedural treatment of androgenetic alopecia - Where are we? ( Arruda, S; Farah, RS; Fruechte, S; Hordinsky, MK; Ly, NY; Sadick, N, 2023)
" No scarring nor serious adverse events were reported in any of the studies."3.01Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. ( Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023)
"Minoxidil 2% and 5% have been FDA approved for treatment of this condition."3.01Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. ( Alarawi, A; Bessar, H; Ghonemy, S, 2021)
"Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined."3.01Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial. ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021)
"Androgenetic alopecia (AGA) is a hair loss disorder that frequently affects the male population."3.01Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial. ( Contin, LA; de Brito, FF; Donati, A; Ferrara, F; Kakizaki, P; Machado, CJ, 2021)
"Androgenic alopecia (AGA) is a common hair loss disorder."2.94A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. ( Arthurs, JR; Bruce, AJ; Bruce, CJ; Desmond, CM; Diehl, NN; Douglass, EJ; Heckman, MG; Pincelli, TP; Shapiro, SA, 2020)
"Drug trials for male-pattern hair loss (MPHL) did not investigate hair cycling."2.94Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol. ( Van Neste, D, 2020)
"The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL."2.90Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. ( Iamsumang, W; Rojhirunsakool, S; Suchonwanit, P, 2019)
"Female pattern hair loss (FPHL) is the most common form of hair loss in women."2.84Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: A randomized controlled study. ( Abdel Hay, RM; Allam, RS; El Naggar, R; Esmat, SM; Gawdat, HI; Hegazy, RA; Moneib, H, 2017)
"Bicalutamide has no diuretic effect."2.82Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. ( Acioly, P; Barcaui, CB; Carvalho, RM; Donda, ALV; Frattini, SC; Machado, CJ; Melo, DF; Ramos, PM; Santos, LDN, 2022)
"Individuals with hair loss experience a substantial mental burden, which potentially hinders their social life."2.82Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management. ( Fujita, T; Matsudo, K; Ohyama, M, 2022)
" Although successful encapsulation of MIN has been observed in these nanocarriers, there is still scarce data regarding their loading in a final dosage form."2.82Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. ( Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022)
"Various treatments exist for androgenetic alopecia (AGA); we determined the relative efficacies of non-surgical AGA monotherapies separately for men and women."2.82Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. ( Bamimore, MA; Foley, KA; Gupta, AK, 2022)
"This study confirmed that minoxidil 5% topical foam is a safe and effective treatment for MPHL."2.82Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction. ( Firooz, A; Halavati, N; Hasanzadeh, H; Nasrollahi, SA; Saberi, M, 2016)
"Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss."2.73Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. ( Blume-Peytavi, U; Ellwanger, U; Garcia Bartels, N; Hoffmann, R; Krisp, A; Kunte, C, 2007)
"The scheme of hair loss treatment, by means of preparations affecting pathogenetical mechanisms of diffuse hair loss development is offered."2.73[Effectiveness of the treatment plan for androgenetic alopecia]. ( Tsiskarishvili, NV; Tsiskarishvili, TsI, 2007)
"To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients."2.72Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. ( Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021)
"We identified 7 articles discussing androgenetic alopecia in patients aged younger than 18."2.72Pediatric androgenetic alopecia: A review. ( Burroway, B; Griggs, J; Tosti, A, 2021)
"Oral minoxidil was found to be an effective and well-tolerated treatment alternative for healthy patients having difficulty with topical formulations."2.72Oral minoxidil treatment for hair loss: A review of efficacy and safety. ( Randolph, M; Tosti, A, 2021)
" The main side effect was pain due to PRP injection, which disappeared after ending the treatment and only one article reported more serious side effects."2.72Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2021)
"Alopecia areata is the third most common cause of dermatology consultations in children but the treatment of paediatric alopecia areata remains challenging."2.72Therapeutic management in paediatric alopecia areata: A systematic review. ( Kołodziejak, M; Olszewska, M; Rakowska, A; Rudnicka, L; Sikora, M; Stochmal, A; Waśkiel-Burnat, A, 2021)
"Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies."2.72Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. ( Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021)
"Significant androgenetic hair loss occurs in men older than 50 years, and in women it occurs in many who are perimenopausal, menopausal, and postmenopausal."2.72Combination Approaches for Combatting Hair Loss. ( Rose, PT, 2021)
"Thus, in patients with cancer, alopecia can be iatrogenic (chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy, surgery) or directly the consequence of the disease itself (malnutrition, scalp metastases, paraneoplastic syndromes)."2.72[Alopecia and cancers: From basics to clinical practice]. ( Baussard, L; Fiteni, F; Guichard, A; Le Vigouroux, S; Quesada, S, 2021)
" The conventional topical dosage forms available in the market falls short in effectively managing alopecia."2.72Potential of nanoparticulate based delivery systems for effective management of alopecia. ( Handa, M; Kesharwani, P; Mishra, P; Shukla, R; Singh, V; Ujjwal, RR, 2021)
"Our understanding of the aetiology of androgenetic alopecia (AGA) has substantially increased in recent years."2.70Comparative efficacy of various treatment regimens for androgenetic alopecia in men. ( Khandpur, S; Reddy, BS; Suman, M, 2002)
"Minoxidil (Loxon) was topically applied twice a day massaging the solution into the scalp over 6-12 months."2.70[Effect of minoxidil on hair growth in androgenic alopecia in women]. ( Brzezińska-Wcisło, L, 2002)
" Cumulative urinary excretion profiles within steady-state, 12-h dosing intervals were well described by straight lines for all treatments, indicating that systemic minoxidil elimination was rate controlled by constant, zero-order percutaneous drug absorption."2.67Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. ( Ferry, JJ; Shepard, JH; Szpunar, GJ, 1990)
"Female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women."2.66Female Androgenetic Alopecia: An Update on Diagnosis and Management. ( Alessandrini, A; Orlando, G; Piraccini, BM; Starace, M, 2020)
"Minoxidil is a strong arterial vasodilator, first introduced as an antihypertensive medication."2.66Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far? ( de La-Rocque, M; de Oliveira, DS; Lemes, LR; Melo, DF; Ramos, PM; Zompero, C, 2020)
"Androgenic alopecia is a common and unpleasant problem that directly influences the self-confidence and individual life quality."2.66Herbal Medicines For Treatment of Androgenic Alopecia. ( Asnaashari, S; Javadzadeh, Y, 2020)
"Forty-seven men with male pattern baldness were treated in a double-blind clinical trial with topical 2% minoxidil or placebo."2.66Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. ( Cotterill, PC; James, KC; Kingsley, P; Rushton, DH; Unger, WP, 1989)
"Nine healthy men with type IVa or Va male pattern baldness completed a 4-month single-blinded controlled pilot study designed to assess the effect of ultraviolet light (UVL) on topical minoxidil-induced hair growth."2.66Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness. ( Delong, ER; Murray, JC; Olsen, EA; Pestana, A, 1987)
"Ten men with male pattern baldness who had been treated with 2% or 3% minoxidil for at least 4 months were evaluated for any changes in scalp hair growth on and off drug."2.66Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. ( Olsen, EA; Weiner, MS, 1987)
"Sixty-four healthy men with early male pattern baldness completed a 6-month, double-blind, placebo-controlled study in which the efficacy of 2% minoxidil gel and solution formulations was compared."2.66Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia. ( Piepkorn, MW; Weidner, M, 1988)
"Fifty-eight men with Hamilton scale type III vertex or type IV male pattern baldness were studied to determine the dose-response activity of low concentrations of topical minoxidil in promoting hair growth."2.66Dose-response study of topical minoxidil in male pattern alopecia. ( Jondreau, L; Kassimir, JJ; Reed, ML; Shupack, JL; Thirumoorthy, T, 1987)
"Forty-one men with male pattern baldness completed 132 study weeks (2 years 9 months) with topical minoxidil and had follow-up 1-inch target-area vertex scalp hair counts."2.66Long-term follow-up of men with male pattern baldness treated with topical minoxidil. ( DeLong, ER; Olsen, EA; Weiner, MS, 1987)
"Frontotemporal hair loss did not respond to treatment and in fact progressed in severity, despite the twice-daily applications of minoxidil."2.66Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. ( DeVillez, RL, 1987)
"Eighty-nine healthy men with male pattern baldness completed a 6-month double-blind, placebo-controlled study of 0."2.66Dose-response study of topical minoxidil in male pattern baldness. ( DeLong, ER; Olsen, EA; Weiner, MS, 1986)
"Minoxidil, 1."2.66Topical minoxidil therapy in hereditary androgenetic alopecia. ( De Villez, RL, 1985)
"No subject had a net hair loss in the target area during the study."2.66Topical minoxidil in early male pattern baldness. ( Delong, ER; Olsen, EA; Pinnell, SR; Weiner, MS, 1985)
"Three of five patients with androgenic alopecia using 5% minoxidil for 12 months noted hair regrowth, ranging from minimally observable hair to an appreciable restoration of larger, pigmented, terminal hair in one patient."2.65Topical minoxidil for hair regrowth. ( Case, P; Ellis, CN; Headington, JT; Kang, S; Swanson, NA; Vanderveen, EE; Voorhees, JJ, 1984)
"Its physiopathology comprises a genetic predisposition affording an exacerbated response of the hair follicles cells to androgens aggravated by scalp inflammation and extrinsic factors."2.61Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. ( Beck, R; da Silva, C; Katzer, T; Leite Junior, A, 2019)
"Alopecia is mostly reversible, but permanent damage can occur depending on the type, overall length, and dose of oncological treatment and other factors."2.61Alopecia and Hair Damage Induced by Oncological Therapy. ( Jedličková, H; Malečková, A; Vojtíšek, R; Vokurka, S, 2019)
"(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia."2.61Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019)
"minoxidil 5% was high; minoxidil 5% vs."2.58Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. ( Dotzert, MS; Gupta, AK; Mays, RR; Piguet, V; Shear, NH; Versteeg, SG, 2018)
"

INTRODUCTION: Hair loss is a common complaint seen in dermatology clinics."

2.55Hair Loss Myths. ( DiMarco, G; McMichael, A, 2017)
"Female pattern hair loss (FPHL), or androgenic alopecia, is the most common type of hair loss affecting women."2.53Interventions for female pattern hair loss. ( Fedorowicz, Z; Schoones, J; van Zuuren, EJ, 2016)
"The use of the medical term androgenetic alopecia reflects current knowledge about the important role of androgens and genetic factors in its etiology."2.53Multi-therapies in androgenetic alopecia: review and clinical experiences. ( Anzalone, A; Carlesimo, M; Caro, G; Fortuna, MC; Garelli, V; Pranteda, G; Rossi, A, 2016)
"Excessive daily hair loss (effluvium) may be physiological, as in the postpartum state, or pathological, due for example to thyroid disturbances, drug effects, iron deficiency, or syphilis."2.53The Diagnosis and Treatment of Hair and Scalp Diseases. ( Blume-Peytavi, U; Fischer, TW; Wolff, H, 2016)
"Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence."2.53Androgenetic Alopecia: An Update of Treatment Options. ( Blanco, A; Kelly, Y; Tosti, A, 2016)
"Common types of nonscarring hair loss, including female pattern hair loss and telogen effluvium, may be diagnosed and managed by the obstetrician/gynecologist."2.52Hair loss in women. ( Bechtel, MA; Harfmann, KL, 2015)
"Male baldness is the most common diagnosis in men that present with hair loss."2.52Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management. ( Torres, F, 2015)
"Female pattern hair loss, or female pattern androgenetic alopecia, is a nonscarring alopecia with a multi-factorial etiology that mostly affects postmenopausal women and is characterized by a reduction in hair density over the crown and frontal scalp."2.52Female pattern hair loss. ( Ioannides, D; Lazaridou, E, 2015)
"To fully understand hair loss during childhood, a basic comprehension of normal hair growth is necessary."2.52Hair loss in children. ( Alves, R; Grimalt, R, 2015)
"It is characterized by progressive hair loss, especially of scalp hair, and has distinctive patterns of loss in women versus men, but in both genders the central scalp is most severely affected."2.50Androgenetic alopecia: an evidence-based treatment update. ( Bergfeld, WF; Varothai, S, 2014)
"Some degree of hair loss is accepted as a normal part of the aging process, in line with the observation that more than 50% of men will develop androgenetic alopecia by the age of 50 years."2.49Hair restoration approaches for early onset male androgenetic alopecia. ( Basra, MK; Bhatti, HA; Patel, GK, 2013)
"Because androgenetic alopecia is progressive in nature, stabilization of the process using medical therapy is an important adjunct to any surgical hair-restoration plan."2.49Nonsurgical therapy for hair loss. ( Nusbaum, AG; Nusbaum, BP; Rose, PT, 2013)
"Female pattern hair loss (FPHL) is the most common cause of alopecia in women."2.49Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. ( Atanaskova Mesinkovska, N; Bergfeld, WF, 2013)
"The exact pathogenesis of androgenetic alopecia is not well understood."2.49Pattern hair loss in men: diagnosis and medical treatment. ( Banka, N; Bunagan, MJ; Shapiro, J, 2013)
"Minoxidil is a potassium channel opener, causing hyperpolarization of cell membranes and it is also a vasodilator, it is speculated that, by widening blood vessels and opening potassium channels, it allows more oxygen, blood and nutrients to the follicle."2.48Minoxidil use in dermatology, side effects and recent patents. ( Calvieri, S; Cantisani, C; Iorio, A; Melis, L; Rossi, A; Scali, E, 2012)
"Female pattern hair loss, or androgenic alopecia, is the most common type of hair loss affecting women."2.48Interventions for female pattern hair loss. ( Andriolo, RB; Carter, B; Fedorowicz, Z; Schoones, J; van Zuuren, EJ, 2012)
"Female pattern hair loss (FPHL) or androgenic alopecia is the most common type of hair loss affecting women with reduced hair density and can have a serious psychological impact."2.48Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. ( Carter, B; Fedorowicz, Z; van Zuuren, EJ, 2012)
"In men it produces male pattern hair loss with bitemporal recession and vertex baldness."2.47Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. ( Dawson, TL; Patel, M; Perez, A; Rufaut, NW; Sinclair, R; Yazdabadi, A; Yip, L, 2011)
"Traditional methods of treating hair loss have included minoxidil, finasteride, and surgical transplantation."2.46Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. ( Ghanaat, M, 2010)
"Fortunately, chemotherapy-induced hair loss is mostly reversible, and appropriate hair and scalp care and temporarily wearing a wig may be the most effective coping strategy."2.46Chemotherapy-induced alopecia. ( Trüeb, RM, 2010)
"Dutasteride has been shown to be more effective than finasteride in the treatment of AGA but is not yet a recommended therapy."2.45Androgens and hair loss. ( Alsantali, A; Shapiro, J, 2009)
"Focal hair loss can be further broken down into scarring and nonscarring."2.45Diagnosing and treating hair loss. ( Mounsey, AL; Reed, SW, 2009)
"Flutamide was found to be more effective than spironolactone or cyproterone in one study."2.44A review of hormonal therapy for female pattern (androgenic) alopecia. ( Scheinfeld, N, 2008)
"Male and female pattern hair loss affects a large percentage of the population, and patients frequently present for treatment of this to their dermatologist."2.44Medical treatments for male and female pattern hair loss. ( Avram, MR; Rogers, NE, 2008)
"Female pattern hair loss is the commonest cause of hair loss in women and prevalence increases with advancing age."2.44Female pattern hair loss: current treatment concepts. ( Dinh, QQ; Sinclair, R, 2007)
"Frontal scalp DPCs from androgenetic alopecia (AGA) are the target cells of androgen action."2.44[Hair follicle regeneration]. ( Itami, S, 2008)
"Androgenetic alopecia In men, or male pattern baldness, is recognized increasingly as a physically and psychologically harmful medical condition that can be managed effectively by generalist clinicians."2.43Psychological effect, pathophysiology, and management of androgenetic alopecia in men. ( Haber, R; Parsley, WM; Stenn, K; Stough, D; Vogel, JE; Washenik, K; Whiting, DA, 2005)
"In advanced cases, men may develop baldness with remaining hair exclusively in the temporal and occipital regions."2.42[Androgenetic alopecia. Current aspects of a common phenotype]. ( Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S, 2003)
"Minoxidil may also cause prolongation of anagen and increases hair follicle size."2.42Minoxidil: mechanisms of action on hair growth. ( Messenger, AG; Rundegren, J, 2004)
"Hair loss is a common complaint in the outpatient setting."2.42Hair loss remedies--separating fact from fiction. ( Bandaranayake, I; Mirmirani, P, 2004)
"Pharmacologic management of pattern hair loss is an active area of research, and clinicians should be aware of new data and treatment modalities."2.42Pharmacologic management of pattern hair loss. ( Haber, RS, 2004)
"Female pattern hair loss is a common condition characterized by a diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline."2.41Female pattern hair loss. ( Birch, MP; Lalla, SC; Messenger, AG, 2002)
"Knowledge of the pathogenesis of androgenetic alopecia has increased markedly in recent years."2.41Androgenetic alopecia: pathogenesis and potential for therapy. ( Ellis, JA; Harrap, SB; Sinclair, R, 2002)
"Male pattern baldness, or androgenetic alopecia (AGA) in men, occurs with varying severity and age of onset."2.41Male pattern baldness. ( Chamberlain, M; Hogan, DJ, 2000)
"Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction."2.41Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. ( Meidan, VM; Touitou, E, 2001)
"Common baldness or androgenetic alopecia is a normal physiological process of hair loss in genetically predisposed individuals."2.40Understanding and managing common baldness. ( Sinclair, RD; Tran, D, 1999)
" Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years."2.40Management of androgenetic alopecia. ( Camacho-Martinez, F; Dawber, R; Tosti, A, 1999)
"More importantly, androgenetic alopecia is typically experienced as a moderately stressful condition that diminishes body image satisfaction."2.40The psychosocial consequences of androgenetic alopecia: a review of the research literature. ( Cash, TF, 1999)
"The pattern of hair loss in women differs from that of classical male pattern alopecia, being more diffuse and with retention of the frontal hair line in most cases."2.39Female androgenetic alopecia: an update. ( Callan, AW; Montalto, J, 1995)
"Minoxidil has been studied extensively and has been shown to improve balding at the vertex of the scalp, particularly in young men who have only begun to lose hair."2.38Hair loss. What causes it and what can be done about it. ( Burke, KE, 1989)
"Male pattern hair loss (androgenetic alopecia) is a common problem."2.37Topical minoxidil in the treatment of male pattern alopecia. ( Baden, HP; Kvedar, JC, 1987)
"Male androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition."1.91What's New in Therapy for Male Androgenetic Alopecia? ( Domínguez-Santas, M; Grimalt, R; Saceda-Corralo, D; Vañó-Galván, S, 2023)
"Minoxidil was radiolabeled with technetium (99mTc) with an efficiency of 99."1.91In Vitro and In Vivo Scalp Retention and Penetration of 99mTc-Minoxidil Solution. ( Arora, G; Chandra, N; Jain, GK; Kesharwani, P; Mishra, A, 2023)
" The few and widely used monotherapies approved by the US Food and Drug Administration, such as minoxidil or finasteride, are not efficacious in all people and cause adverse events that prevent patient compliance."1.91Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia. ( Abidi, Z; Arruda, S; Rapaport, J; Sadgrove, NJ; Sadick, N; Swearingen, A, 2023)
"The most common causes of hair loss are androgenetic alopecia (AGA) and telogen effluvium (TE)."1.91Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia. ( Bruni, F; Caro, G; Cedirian, S; Fortuna, M; Piraccini, BM; Quadrelli, F; Rossi, A; Starace, M, 2023)
"Many people suffer from hair loss and abnormal skin pigmentation, highlighting the need for simple assays to support drug discovery research."1.91Sensitive Quantitative In Vivo Assay for Evaluating the Effects of Biomolecules on Hair Growth and Coloring Using Direct Microinjections into Mouse Whisker Follicles. ( Gao, L; Liao, XH; Song, H; Tan, XY; Wang, YG; Yuan, VL; Zhang, HL, 2023)
"The most prevalent kind of hair loss is androgenic alopecia (AGA), which is characterized by hair follicle miniaturization and microenvironment dysfunction."1.91Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia. ( Guan, Y; Liu, M; Qiang, W; Ruan, R; Sun, H; Yan, A; Yu, Q; Zhu, H; Zhu, X, 2023)
"Alopecia is a common cutaneous adverse event reported with CK4/6i therapy."1.91Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. ( Cathcart-Rake, E; Cherian, M; Dulmage, B; Gatti-Mays, M; Loprinzi, CL; Lustberg, M; Minta, A; Park, C; Ramaswamy, B; Rose, L; Ruddy, KJ; Sardesai, S; Stover, D; Sudheendra, P; Trovato, S; Wesolowski, R; Williams, N, 2023)
"Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA."1.72Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. ( Alencar-Silva, T; Carvalho, JL; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Oliveira, PM; Pires, FQ, 2022)
" Minoxidil (MXD) is commonly used topically to treat alopecia, but its low absorption rate limits widespread use."1.72Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model. ( An, BS; Jeong, JS; Kim, DS; Kim, MJ; Kim, SY; Lee, S; Seong, KY; Yang, SY, 2022)
" In animal tests, compared with topical administration of minoxidil, the drug-free microneedle patches can more significantly promote hair regeneration within 7 days with lower dosing frequency."1.72A Drug-Free, Hair Follicle Cycling Regulatable, Separable, Antibacterial Microneedle Patch for Hair Regeneration Therapy. ( Chen, X; Kong, M; Li, H; Qin, D; Qiu, K; Shi, Y; Yu, M; Zhang, W; Zhao, J, 2022)
"Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders."1.72Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022)
"Hair loss, specifically androgenetic alopecia (AGA), is a common outpatient dermatology complaint."1.72A Survey of Patient Attitudes Towards Topical Minoxidil in the Treatment of Hair Loss. ( Friedman, A; Gonzalez-Lopez, A; Murphy, E; Nelson, K; Nussbaum, D; Qureshi, A; Schwartz, J, 2022)
"Androgenic alopecia is a genetically determined and leads to a progressive hair loss of the vertex, affecting both men and women."1.62[A new treatment for androgenetic alopecia : platelet-rich plasma injections]. ( Castronovo, C; Kaux, JF; Moreau, T; Nikkels, AF; Paquet, P, 2021)
"The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects."1.62Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. ( Bhoyrul, B; Hermosa-Gelbard, A; Jaén-Olasolo, P; Jerjen, R; Jimenez-Cauhe, J; John, JM; Koh, WL; Lo-Sicco, K; Moreno-Arrones, ÓM; Piraccini, BM; Pirmez, R; Poa, JE; Rodrigues-Barata, R; Rudnicka, L; Saceda-Corralo, D; Salas-Callo, CI; Shapiro, J; Sinclair, R; Starace, M; Tosti, A; Trindade de Carvalho, L; Vañó-Galván, S; Vincenzi, C; Waskiel-Burnat, A; Yin, L; Zamorano, JL, 2021)
"The clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans."1.56Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. ( Beal, K; Disa, JJ; Dusza, SW; Freites-Martinez, A; Freret, ME; Friedman, DN; Kukoyi, O; Lacouture, ME; Mechalakos, JG; Phillips, GS; Tinkle, CL; Trelles, S; Unger, RH; Wexler, LH; Wolden, SL, 2020)
"Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50."1.51Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( Andy, G; Aseem, S; John, M; Maja, K; Michael, K; Mirna, S; Rachita, D; Zeljana, B, 2019)
"Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = ."1.51Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. ( Chan, D; Cho, J; Cigler, T; Fabbrocini, G; Freites-Martinez, A; Gajria, D; Goldfarb, S; Lacouture, ME; Modi, S; Norton, L; Paus, R; Shapiro, J; Sibaud, V; Tosti, A, 2019)
"Androgenetic alopecia is the most common hair loss disorder, affecting both men and women."1.48Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. ( Blume-Peytavi, U; Blumeyer, A; Del Marmol, V; Dobos, G; Finner, A; Kanti, V; Messenger, A; Nast, A; Piraccini, BM; Reygagne, P; Tosti, A; Trakatelli, M, 2018)
"Mean hair loss severity at baseline was Sinclair 2."1.48Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. ( Sinclair, RD, 2018)
"Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty."1.48Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. ( Amoh, Y; Inui, S; Itami, S; Ito, T; Kono, T; Kurata, S; Manabe, M; Nakamura, M; Narusawa, H; Ohyama, M; Osada, SI; Saito, N; Sato, A; Shimomura, Y; Tsuboi, R; Ueki, R; Yamazaki, M, 2018)
"Female pattern hair loss (FPHL) is a commonly encountered clinical presentation in primary care."1.48Female pattern hair loss. ( Chan, L; Cook, DK, 2018)
"Overall, 40."1.48Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. ( Chitalia, J; Dhurat, R; Goren, A; Kovacevic, M; Lotti, T; McCoy, J; Naccarato, T; Situm, M, 2018)
"Minoxidil has been approved for the treatment of hair loss, however its mechanism of action is still not fully clarified."1.46An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia. ( Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017)
"Tofacitinib-treated mice exhibited more hair regrowth than either minoxidil-treated or control mice did between day 7 and 21 (P < 0."1.46Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. ( Deenonpoe, R; Meephansan, J; Ponnikorn, S; Suchonwanit, P; Thummakriengkrai, J; Yingmema, W, 2017)
"Treatment with dutasteride 0."1.46Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. ( Cranwell, WC; Sinclair, R, 2017)
"Traction alopecia is characterized by localized hair loss related to persistent excessive traction."1.43Bitemporal hair loss related to traction alopecia. ( Muñoz Moreno-Arrones, O; Vañó-Galván, S, 2016)
" The safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the botanical hair solution for 12 weeks in 54 subjects was evaluated in a multicenter, single-arm, open-label study."1.43Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( McMichael, A; Meckfessel, MH; Pham, H; von Grote, E, 2016)
" The safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with a novel botanical hair solution was evaluated in a 12-week, multicenter, single-arm, open label study in 56 subjects with mild to moderate AGA."1.43Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( Keaney, TC; Meckfessel, MH; Pham, H; von Grote, E, 2016)
" However, little is known about the differences in adverse effects between these two drugs."1.43Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. ( Li, Q; Wu, M; Yu, Q, 2016)
"Female pattern hair loss is a common but difficult to manage condition."1.37Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. ( Sinclair, R; Yazdabadi, A, 2011)
"Adolescent androgenic alopecia is pattern hair loss occurring in boys and girls younger than 18 years, whereas early-onset androgenic alopecia refers to pattern hair loss before 35 years of age."1.37Adolescent androgenic alopecia. ( McDonough, PH; Schwartz, RA, 2011)
"While androgenetic alopecia (AGA) is the most common form of hair loss in adults, little is known about its prevalence, clinical features and response to treatments in the paediatric population."1.36Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. ( Cantatore-Francis, J; Gonzalez, ME; Orlow, SJ, 2010)
"Spironolactone is a synthetic steroid structurally related to aldosterone."1.36Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. ( Rathnayake, D; Sinclair, R, 2010)
"Tretinoin is a mitogen by itself and also enhances the absorption of minoxidil which acts by enlarging the miniaturized hair follicles."1.35Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin. ( Dhurat, RS; Jerajani, HR; Melkote, S; Palav, A, 2009)
"Three of these women were premenopausal."1.33Frontal fibrosing alopecia: a survey in 16 patients. ( Camacho Martínez, F; Moreno-Ramírez, D, 2005)
"Regression of male androgenetic alopecia from Hamilton type V to type III can be achieved by combining drugs with hair grafts."1.32Androgenetic alopecia: combining medical and surgical treatments. ( Bouhanna, P, 2003)
"Patients seeking advice for hair loss are not necessarily bald."1.31[TrichoScan. A new instrument for digital hair analysis]. ( Hoffmann, R, 2002)
"A 45-year-old Japanese man with paroxysmal atrial fibrillation (AF) developed acute anteroseptal myocardial infarction (MI)."1.31A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness. ( Fujiwara, C; Morikaw, S; Ohno, R; Satoh, H; Terada, H; Uehara, A, 2000)
"Respondents rated their hair loss on a 5-point, textual scale that ranged from 'no hair loss' to 'bald areas'."1.31[Status of scalp hair and therapy of alopecia in men in Switzerland]. ( de Viragh, PA; Trüeb, RM, 2001)
"Especially for young men progressive hair loss can be distressing."1.31[Androgenetic alopecia in the man]. ( Bader, U; Trüeb, RM, 2002)
"Diffuse hair loss in women was formerly classified as an entity of its own."1.31[Diffuse hair loss in women]. ( Trüeb, RM, 2002)
"Although androgenetic alopecia (common baldness) is the most frequently occurring type of hair loss, hair loss can result from a variety of local and systemic conditions."1.29Alopecia: diagnosis and management. ( Nielson, TA; Reichel, M, 1995)
"Male pattern baldness is a common affliction affecting up to half the adult male population."1.29Male pattern baldness. ( Duplechain, G; White, JA, 1994)
"Both minoxidil-SEPA treatments produced significantly greater cumulative hair weight over the entire 16-week study compared to either of the Rogaine TS treatments."1.29The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque. ( Brunden, MN; Diani, AR; Shull, KL; Zaya, MJ, 1995)
"Minoxidil is a potent vasodilator useful in treating severe hypertension."1.28Topical treatment with minoxidil 2% and smoking intolerance. ( Ingber, A; Trattner, A, 1992)
"One patient had no hair loss in either the treatment or control area."1.28The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. ( Baden, H; Frederickson, H; Gajewski, W; Goldstein, A; Goodman, A; Granai, CO, 1991)
" However, the safety of no systemic adverse effect and the potential of inhibiting progressive shedding of hair were valuable as a topical drug."1.28Safety and efficacy of 2% topical minoxidil in the management of male pattern baldness in Chinese. ( Chan, HL; Chen, MJ; Chen, SY; Kuan, YZ; Wang, CN, 1990)
"The data demonstrate that hair loss in the AGA mouse is androgen dependent and that this mutant strain can serve as a suitable model for the screening of compounds, such as antiandrogens and vasodilators, which may influence the balding process."1.28Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness. ( Malloy, V; Matias, JR; Orentreich, N, 1989)
"The cause of male pattern baldness remains unknown."1.27Unravelling the pathophysiology of male pattern baldness. ( Herring, BD, 1985)

Research

Studies (643)

TimeframeStudies, this research(%)All Research%
pre-1990103 (16.02)18.7374
1990's80 (12.44)18.2507
2000's97 (15.09)29.6817
2010's147 (22.86)24.3611
2020's216 (33.59)2.80

Authors

AuthorsStudies
Li, JJ1
Mitchell, LH1
Dow, RL1
Vahabi-Amlashi, S1
Layegh, P1
Kiafar, B1
Hoseininezhad, M1
Abbaspour, M1
Khaniki, SH1
Forouzanfar, M1
Sabeti, V1
Yin, L2
Svigos, K1
Gutierrez, D1
Peterson, E1
Lo Sicco, K2
Shapiro, J18
Trüeb, RM10
Caballero-Uribe, N1
Gupta, AK8
Quinlan, EM1
Venkataraman, M2
Bamimore, MA4
Moussa, A3
Kazmi, A2
Bokhari, L4
Sinclair, RD13
Nestor, MS1
Ablon, G1
Gade, A1
Han, H1
Fischer, DL1
Gao, JL1
Streed, CG1
Thompson, J1
Dommasch, ED1
Peebles, JK1
Melo, DF4
Saceda-Corralo, D13
Tosti, A20
Weffort, F1
Carla Jorge, M1
de Barros, CC1
de Melo Carvalho, R1
Starace, M8
Gilhar, A2
Keren, A2
Ullmann, Y1
Wu, J2
Paus, R4
Hassan, GFR1
Sadoma, MET1
Elbatsh, MM1
Ibrahim, ZA1
Elsebay, SAG1
Nada, HF1
Sultan, NSS1
El-Waseef, DAEA1
Carvalho, RM1
Santos, LDN1
Ramos, PM8
Machado, CJ2
Acioly, P1
Frattini, SC1
Barcaui, CB1
Donda, ALV1
Liu, C1
Zhao, H2
Zhang, Y4
Wu, W2
Subedi, L1
Pandey, P1
Shim, JH1
Kim, KT1
Cho, SS1
Koo, KT1
Kim, BJ3
Park, JW1
Talukder, M5
Korbi, M1
Said El Mabrouk, R1
Abdelaali, M1
Youssef, M1
Belhadjali, H1
Zili, J1
Nascimento E Silva, M1
Silva, MR1
Nascimento E Silva, R1
Barbosa Raposo, NR1
Huang, KP1
Senna, MM2
Oliveira, PM1
Alencar-Silva, T1
Pires, FQ1
Cunha-Filho, M1
Gratieri, T2
Carvalho, JL1
Gelfuso, GM2
Faghihi, G3
Iraji, F4
Siadat, AH1
Saber, M1
Jelvan, M1
Hoseyni, MS1
Kim, MJ2
Seong, KY1
Kim, DS1
Jeong, JS1
Kim, SY1
Lee, S1
Yang, SY1
An, BS1
Feaster, B1
Onamusi, T1
Cooley, JE1
McMichael, AJ2
Villarreal-Villarreal, CD1
Boland-Rodriguez, E1
Rodríguez-León, S1
Le Voti, F1
Vano-Galvan, S19
Luu, NC1
Rezende, HD1
Mao, Y1
Xu, Z1
Song, J1
Xie, Y1
Mei, X1
Shi, W1
Feryel, A1
Mouna, K1
Nesrine, BS1
Hichem, B1
Jameleddine, Z1
de Nicolas-Ruanes, B1
Moreno-Arrones, OM8
Hermosa-Gelbard, A6
Rodrigues-Barata, R6
Gil-Redondo, R2
Garcia-Mouronte, E1
Dou, J1
Zhang, Z1
Xu, X1
Zhang, X2
Mir-Bonafé, JF1
Mir-Bonafé, M1
Rozas-Muñoz, E1
Mir-Bonafé, JM1
Nilforoushzadeh, MA2
Heidari-Kharaji, M2
Torkamaniha, E1
Sadeghi, S1
Seirafianpour, F1
Yekaninejad, MS1
Behrangi, E4
Roohaninasab, M3
Amini, Z1
Goodarzi, A4
Sanabria, BD1
Palmegiani, E1
Seron, AF1
Perdomo, YC1
Miot, HA5
Müller Ramos, P3
Ohyama, M2
Matsudo, K1
Fujita, T1
Klein, EJ1
Karim, M1
Sicco, KL1
Sánchez-Meza, E1
Ocampo-Candiani, J3
Gómez-Flores, M1
Herz-Ruelas, ME1
Ocampo-Garza, J1
Orizaga-Y-Quiroga, TL1
Martínez-Moreno, A1
Ocampo-Garza, SS4
Tian, K1
Gao, S1
Jia, Z1
Xu, W1
Li, K2
Wu, L1
Vastarella, M3
Martora, F1
Ocampo-Garza, S1
Patri, A2
Battista, T1
Nappa, P2
Fabbrocini, G6
Cantelli, M3
Toma, DM1
Atallah, RB1
Eldahshan, RM1
John, JM3
Sinclair, R23
Shi, Y1
Zhao, J2
Li, H1
Yu, M1
Zhang, W3
Qin, D1
Qiu, K1
Chen, X2
Kong, M1
Jia, L2
Xiong, J1
Guo, R1
Li, Y5
Jiang, H1
Singh, S1
Patil, A1
Kianfar, N1
Waśkiel-Burnat, A3
Rudnicka, L3
Goldust, M5
Williams, G1
Sand, J2
Walen, S2
Yuan, A3
Gu, Y3
Bian, Q3
Wang, R3
Xu, Y2
Ma, X3
Zhou, Y3
Gao, J3
Jimenez-Cauhe, J8
Pindado-Ortega, C2
de Dios Berna-Rico, E1
Ortega-Quijano, D5
Fernandez-Nieto, D6
Gallo, G1
Burzi, L1
Torrelli, F1
Quaglino, P1
Ribero, S1
Xiang, H2
Yang, M1
Abdurrahman, S1
Ruslin, R1
Hasanah, AN1
Mustarichie, R1
Ifaya, M1
Ammar, AM1
Elshahid, AR1
Abdel-Dayem, HA1
Mohamed, AA1
Elsaie, ML3
Modha, JD1
Pathania, YS2
Hu, D1
Yang, S1
Shome, D2
Tandel, H1
Kumar, V2
Kapoor, R2
Domínguez-Santas, M1
Grimalt, R5
Arora, G1
Mishra, A1
Chandra, N1
Kesharwani, P2
Jain, GK1
Sheng, Y1
Zeng, Y2
Hu, R1
Wang, W2
Yang, Q2
Nussbaum, D1
Murphy, E1
Nelson, K1
Gonzalez-Lopez, A1
Qureshi, A1
Schwartz, J1
Friedman, A1
Young, PC1
Mahajan, C1
Ghassemi, M3
Yazdanian, N1
Jafari, M1
Zhang, C3
Yu, Y1
Shi, S1
Liang, M1
Yang, D1
Sui, N1
Yu, WW1
Wang, L2
Zhu, Z1
Saleem, K1
Siddiqui, B1
Ur Rehman, A1
Taqi, MM1
Ahmed, N1
Haddad, N1
Arruda, S3
Sadick, N3
Shen, Q3
Fu, Z3
Du, P3
Wang, J4
Kang, J2
Lee, JW4
Kwon, O2
Zhong, T1
Zhang, S2
Li, L1
Hu, W1
Qin, C1
Navarro-Triviño, FJ1
Pegalajar-García, MD2
Gil-Villalba, A2
Ruiz-Villaverde, R1
Zhou, D1
Chen, G3
Fu, Q1
Li, N1
Bassiouny, EA1
El-Samanoudy, SI1
Abbassi, MM1
Nada, HR1
Farid, SF1
Hummadi, AA1
Gany, SN1
Hadi, NR1
Clarysse, KLJ1
Gomes, TF1
Soares, RO1
Alsalhi, W2
Nguyen, B1
Morrison, BW1
Gwillim, EC1
Makhlouf, A1
Elnawawy, T1
Balasundaram, M1
Kumari, R1
Ramassamy, S1
Awad, A1
Chim, I1
Sharma, P1
Bhoyrul, B5
Senthilnathan, A1
Larrondo, J1
De Souza, B1
Harris, T1
Eginli, A2
McMichael, A3
Nobari, NN1
Sadeghzadeh-Bazargan, A2
Nikkhah, F1
Lee, YY1
Sung, YK2
Hong, D1
Jung, KE1
Seo, YJ2
Lee, Y2
Yin, M1
Liu, HQ1
Wang, C1
Chen, C2
Li, W1
Elshall, AA1
Ghoneim, AM1
Abd-Elmonsif, NM1
Osman, R1
Shaker, DS1
Gasmi, A1
Mujawdiya, PK1
Beley, N1
Shanaida, M1
Lysiuk, R1
Lenchyk, L1
Noor, S1
Muhammad, A1
Strus, O1
Piscopo, S1
Komisarenko, A1
Fedorovska, M1
Bjørklund, G1
Goodwin Cartwright, BM1
Wang, M1
Rodriguez, P1
Stewart, S1
Worsham, CM1
Stucky, N1
Jena, AB1
Devjani, S1
Ezemma, O1
Kelley, KJ1
Stratton, E1
Senna, M1
Albalawi, MA1
Hafez, AM1
Elhawary, SS1
Sedky, NK1
Hassan, OF1
Bakeer, RM1
El Hadi, SA1
El-Desoky, AH1
Mahgoub, S1
Mokhtar, FA1
Milan, E1
Alessandrini, A4
Bruni, F2
Piraccini, BM10
Wu, S1
Liu, S1
Chen, J2
Dai, D1
Liu, W1
Le, D1
Guan, Q1
Miao, Y4
Hu, Z3
Qu, Q3
Rapaport, J1
Sadgrove, NJ1
Swearingen, A1
Abidi, Z1
Deoghare, S1
Sadick, NS1
de la Torre-Gomar, FJ1
Alhanshali, L1
Buontempo, M1
Majerson, D1
Cedirian, S1
Quadrelli, F1
Caro, G2
Fortuna, M1
Rossi, A4
Minta, A2
Park, C2
Rose, L2
Trovato, S2
Dulmage, B2
Gao, L1
Zhang, HL1
Tan, XY1
Wang, YG1
Song, H1
Yuan, VL1
Liao, XH1
Li, P1
Sun, Y1
Nie, L1
Shavandi, A1
Yunusov, KE1
Hua, Y1
Jiang, G1
Wei, W1
Long, B1
Xu, S1
Xue, X1
Lv, Y1
Miao, X1
Polla Ravi, S1
Wang, T2
Mokhtari, F2
Zavare, Z1
Ly, NY1
Fruechte, S1
Hordinsky, MK2
Farah, RS1
Wang, Q1
Yang, K1
Lin, J2
Liu, Q1
Zhu, Y2
Li, Z1
Ni, C1
Legiawati, L1
Suseno, LS1
Sitohang, IBS1
Yusharyahya, SN1
Pawitan, JA1
Liem, IK1
Kurniawati, T1
Ardelia, A1
Paramastri, K1
Shen, Y1
Zhang, L1
Sun, J1
Xie, B1
Zhang, H2
Song, X1
Abdi, P1
Awad, C1
Anthony, MR1
Farkouh, C1
Kenny, B1
Maibach, HI2
Ogunyemi, B1
Asim, M1
Shah, R1
Sharif, S1
Ouellette, S1
Shah, A1
Rao, B1
Santana, FFV1
Lozi, AA1
Gonçalves, RV1
Da Silva, J1
Da Matta, SLP1
Yan, A1
Ruan, R1
Zhu, X1
Qiang, W1
Guan, Y1
Yu, Q2
Sun, H1
Liu, M1
Zhu, H1
Hu, L1
Luo, F1
Ibraheim, MK1
Elsensohn, A1
Hauschild, C1
Hilliard, A1
Dao, H1
Mirmirani, P5
Young, PA1
Vanderweil, SG1
Vanchinathan, V1
Click, JW1
McCleskey, PE1
Ramaswamy, B1
Stover, D1
Gatti-Mays, M1
Cherian, M1
Williams, N1
Sudheendra, P1
Wesolowski, R1
Sardesai, S1
Lustberg, M1
Loprinzi, CL1
Ruddy, KJ1
Cathcart-Rake, E1
Katzer, T1
Leite Junior, A1
Beck, R1
da Silva, C1
Ghonemy, S1
Alarawi, A1
Bessar, H1
Dowd, M1
Antonov, N1
Garzon, M1
Lauren, C1
Griggs, J1
Burroway, B1
Goren, A12
Kasprzak, M1
Wambier, CG1
Craiglow, BG2
King, BA1
Pirmez, R2
Salas-Callo, CI2
Bruce, AJ1
Pincelli, TP1
Heckman, MG1
Desmond, CM1
Arthurs, JR1
Diehl, NN1
Douglass, EJ1
Bruce, CJ1
Shapiro, SA1
Jedličková, H1
Vokurka, S1
Vojtíšek, R1
Malečková, A1
Orlando, G1
Ismail, FF1
Kochar, P1
Nayak, K1
Thakkar, S1
Polaka, S1
Khunt, D1
Misra, M1
Li, A1
Meng, X1
Xing, X1
Tan, H1
Liu, J1
Li, C1
Lyakhovitsky, A1
Warshavsky, K1
Ben Mordechai, Y1
Pavlotsky, F1
Barzilai, A1
Van Neste, D3
Alalola, A1
Randolph, M2
Gwillim, E1
Yi, Y1
Qiu, J1
Jia, J1
Djakaya, GDN1
Li, X1
Fu, J2
Chen, Y1
Chen, Q1
York, K1
Meah, N2
Marks, DH1
Sfouq Aleanizy, F1
Yahya Alqahtani, F1
Alkahtani, HM1
Alquadeib, B1
Eltayeb, EK1
Aldarwesh, A1
Abdelhady, HG1
Alsarra, IA1
Galadari, H1
Shivakumar, S1
Lotti, T5
Wollina, U1
Rokni, GR1
Grabbe, S1
Nilforooshzadeh, MA1
Lotfi, E1
Zolghadr, S1
Mansouri, P1
Chen, L1
Zhang, J1
Wang, H1
Chen, B1
Foley, KA1
Therianou, A1
Vincenzi, C4
Trindade de Carvalho, L3
Kerkemeyer, KL1
Gentile, P1
Garcovich, S1
Tai, T1
Kochhar, A1
Maqoud, F2
Zizzo, N1
Mele, A1
Denora, N3
Passantino, G1
Scala, R1
Cutrignelli, A3
Tinelli, A1
Laquintana, V3
la Forgia, F2
Fontana, S2
Franco, M3
Lopedota, AA1
Tricarico, D2
Ferial Ismail, F1
Bao, L2
Zong, H1
Fang, S1
Zheng, L1
McCoy, J7
Wambier, C2
Yang, G1
Gu, Z1
Chrétien, B1
Sassier, M1
Alexandre, J1
Lelong-Boulouard, V1
Dolladille, C1
Fedrizzi, S1
Fan, Z1
Jha, AK1
Sonthalia, S1
Zeeshan, MD1
Vinay, K1
Behbahani, S1
Ward, B1
Montovano, M1
Wilson, BN1
Ravikumar, V1
Karanfilian, K1
Paskhover, B1
Fujita, J1
Venkatesh, R1
Pereira, A1
Jain, K1
Yadav, NK1
Sharma, AN1
Michelle, L1
Juhasz, M2
Atanaskova Mesinkovska, N2
Sohng, C1
Lee, EH1
Woo, SK1
Kim, JY1
Park, KD1
Lee, SJ1
Lee, WJ1
Gohad, P1
Lemes, LR1
de Oliveira, DS1
de La-Rocque, M1
Zompero, C1
Barbareschi, M2
Vescovi, V1
Milani, M1
Abdallah, MAE1
Shareef, R1
Soltan, MY1
Nagarajan, H1
Rai, R1
Huerth, K1
Kindred, C1
Phillips, GS1
Freret, ME1
Friedman, DN1
Trelles, S1
Kukoyi, O1
Freites-Martinez, A3
Unger, RH1
Disa, JJ1
Wexler, LH1
Tinkle, CL1
Mechalakos, JG1
Dusza, SW1
Beal, K1
Wolden, SL1
Lacouture, ME3
Jaen-Olasolo, P4
Gozali, MM1
Kurniawati, Y1
Zulkarnain, SD1
Rica Echevarría, I1
García Del Monte, J1
Delgado Rubio, A1
Arcangeli, F1
Kovacevic, M5
Situm, M4
Annunziata, MC1
Cinelli, E1
Villani, A2
Nabavinejad, S1
Fatemi Naeini, F1
Pakhomova, EE1
Smirnova, IO1
Makki, M1
Younes, AH1
Salah, I1
Liu, Y1
Jiang, LL1
Liu, F1
Fan, ZX1
Guo, Z1
Hu, ZQ1
Guillon-Rolf, R1
Boutboul, S1
Borderie, V1
Dincer, D1
Tanacan, E1
Kose Ozkan, C1
Beach, RA3
McDonald, KA2
Muylaert Barrett, B1
Masoud, F1
Alamdari, HA1
Asnaashari, S2
Shokri, J1
Javadzadeh, Y2
Martínez-Pizarro, S1
Yu, CQ1
Guo, ME1
Li, XK1
Chen, HD1
Li, YH2
Xu, XG2
Sanabria, B1
Vanzela, TN1
Uzel, BPC1
Takano, GHS1
Chartuni, JCN1
Cesetti, MV1
Gavioli, CFB1
Lemes, AM1
Costa, IMC1
Abdel-Raouf, H1
Aly, UF1
Medhat, W1
Ahmed, SS1
Abdel-Aziz, RTA1
Bukowiecki, J1
Pförringer, D1
Thor, D1
Duscher, D1
Brett, E1
Olamiju, B1
Barrett, BM1
Abdel-Qadir, H1
Zaky, MS1
Abo Khodeir, H1
Ahmed, HA1
Najar Nobari, N1
Heymann, WR1
Moreau, T1
Castronovo, C1
Kaux, JF1
Nikkels, AF1
Paquet, P1
Ibrahim, IM1
Hasan, MS1
Elsabaa, KI1
Kołodziejak, M1
Sikora, M1
Stochmal, A1
Rakowska, A1
Olszewska, M1
Koh, WL1
Poa, JE1
Jerjen, R1
Lo-Sicco, K1
Zamorano, JL1
Ruggiero, A1
Mercuri, SR1
Paolino, G1
Di Nicola, MR1
Vollono, L1
Dong, X1
Jin, X1
Doshi, K1
Patel, G1
Vadera, S1
Hossein Mostafa, D1
Samadi, A1
Niknam, S1
Nasrollahi, SA2
Guishard, A1
Firooz, A2
Mahe, YF1
Cheniti, A1
Tacheau, C1
Antonelli, R1
Planard-Luong, L1
de Bernard, S1
Buffat, L1
Barbarat, P1
Kanoun-Copy, L1
Ferrara, F1
Kakizaki, P1
de Brito, FF1
Contin, LA1
Donati, A1
Rose, PT3
Dhurat, R5
Daruwalla, S1
Pai, S1
Lobon, K1
Pinczewski, J1
Xia, F1
Wu, H1
Huang, L1
Huang, Q1
Rao, Y1
Ling, D1
Li, F1
Quesada, S1
Guichard, A1
Le Vigouroux, S1
Baussard, L1
Fiteni, F1
Mishra, P1
Handa, M1
Ujjwal, RR1
Singh, V1
Shukla, R1
Jones, LN1
Muñoz Moreno-Arrones, O1
Qiu, L1
Yi, C1
Xue, P1
Yu, Z1
Su, Y1
Guo, S1
Chen, YF2
Chen, LH1
Yeh, YM1
Wu, PY1
Chang, LY1
Chang, JY1
Shen, MR1
Adil, A1
Godwin, M1
Dothard, E1
Bagayoko, CW1
Huang, K1
Daniel, A1
Esmat, SM1
Hegazy, RA1
Gawdat, HI1
Abdel Hay, RM1
Allam, RS1
El Naggar, R1
Moneib, H1
Alves, R2
Wehner, MR1
Nead, KT1
Lipoff, JB1
Stamatas, GN1
Pappas, A1
McCormick, TS1
Cooper, KD1
Consolo, M2
Schastnaya, J1
Ozerov, IV1
Aliper, A1
Zhavoronkov, A1
DiMarco, G1
Rodrigues, M1
Antunes, I1
Magalhães, S1
Pereira, N1
Lee, HJ1
Oh, DW1
Na, MJ1
Kim, DW1
Yuk, DY1
Choi, HC1
Lee, YB1
Han, K1
Park, CW1
Abdelmaksoud, A1
Meephansan, J1
Thummakriengkrai, J1
Ponnikorn, S1
Yingmema, W1
Deenonpoe, R1
Suchonwanit, P4
Chitallia, J1
May, TW1
Jayaraaman, AM1
Madhukara, J1
Anandan, S1
Vaidya, P1
Klenk, A1
Gong, L1
Tian, T2
Kanti, V2
Messenger, A1
Dobos, G1
Reygagne, P3
Finner, A1
Blumeyer, A1
Trakatelli, M1
Del Marmol, V1
Nast, A1
Blume-Peytavi, U6
Lopedota, A2
Lopalco, A2
Curci, A1
Mastrodonato, M1
Rubio-Gonzalez, B1
Fortman, J1
Mesinkovska, NA2
Takeuchi, I1
Hida, Y1
Makino, K1
Chan, D2
Fornier, M1
Modi, S2
Gajria, D2
Dusza, S1
Goldfarb, S2
Zimmerman, B1
Ivars, M1
Cordoro, KM1
Mays, RR1
Dotzert, MS1
Versteeg, SG1
Shear, NH2
Piguet, V1
Manabe, M2
Tsuboi, R3
Itami, S5
Osada, SI1
Amoh, Y1
Ito, T1
Inui, S2
Ueki, R2
Kurata, S2
Kono, T2
Saito, N2
Sato, A1
Shimomura, Y1
Nakamura, M1
Narusawa, H1
Yamazaki, M2
Miguel-Gómez, L1
Rodrigues-Barata, AR1
Molina-Ruiz, A1
Martorell-Calatayud, A2
Fernández-Crehuet, P2
Barco, D1
Arias-Santiago, S2
Serrano-Falcón, C1
Camacho, FM1
Anitua, E1
Pino, A1
Jaén, P1
Navarro, MR1
Thuangtong, R1
Thanomkitti, K1
Suvanasuthi, S1
Yu, AJ1
Luo, YJ1
Bao, LL1
Li, ZX1
Dong, YX1
Srisuwanwattana, P1
Chalermroj, N1
Khunkhet, S2
Chan, L1
Cook, DK1
Naccarato, T2
Iamsumang, W1
Rojhirunsakool, S2
Sharma, A2
Lukinovic Skudar, V1
Andy, G1
John, M1
Mirna, S1
Rachita, D1
Michael, K1
Maja, K1
Aseem, S1
Zeljana, B1
Rahmatpour Rokni, G1
Sadr, S1
Mirabi, A1
Rezaee, E1
Chitalia, J1
Bater, K1
Rieder, E1
Stoehr, JR1
Choi, JN1
Colavincenzo, M1
Vanderweil, S1
Kinoshita-Ise, M1
Foster, FS1
Paik, SH1
Kim, HT1
Chang, SE1
Iorizzo, M2
Carmina, E1
Azziz, R1
Bergfeld, W3
Escobar-Morreale, HF1
Futterweit, W1
Huddleston, H1
Lobo, R1
Olsen, E1
Sung, CT2
Juhasz, ML1
Choi, FD1
Kozicka, K1
Łukasik, A1
Pastuszczak, M1
Wojas-Pelc, A1
Sibaud, V1
Cho, J1
Norton, L1
Cigler, T1
Cohen, PR1
Agrawal, S1
Tan, Y1
Hunter, N1
Sayed, K1
Hay, RA1
Allam, R1
Hussein, N1
de Mattos Barreto, T1
Plata, GT1
Araujo, LR1
Tortelly, VD1
Park, GH1
Kim, WI1
Yang, MY1
Lee, WK1
Kim, GW1
Kim, HS1
Ko, HC1
Kim, BS1
Kim, MB1
Delgado-Charro, MB1
Guy, RH2
Vianna Lopez, RF1
Lee, HE1
Chang, IK1
Im, M1
Lee, JH1
Sakr, FM1
Gado, AM1
Mohammed, HR1
Adam, AN1
Bhatti, HA1
Basra, MK1
Patel, GK1
Nusbaum, AG1
Nusbaum, BP1
Rajaee Harandi, M1
Askari, G1
Ryu, HJ1
Yoo, MG1
Son, SW1
Calvieri, S2
Gomes, MJ1
Martins, S1
Ferreira, D1
Segundo, MA1
Reis, S1
Selva, S1
Ragni, L1
Tongiani, S1
Chen, W1
Kigitsidou, E1
Prucha, H1
Ring, J1
Andres, C1
Gupta, R1
High, WA1
Butler, D1
Murase, JE2
Varothai, S2
Bergfeld, WF5
Oyetakin-White, P1
Baron, E1
Leahy, P1
Karnik, P1
Guerouaz, N1
Mohamed, AO1
Choi, JC1
Uyama, H1
Lee, CH1
Sung, MH1
Harfmann, KL1
Bechtel, MA1
Gargallo, V1
Gutierrez, C1
Vanaclocha, F1
Guerra-Tapia, A1
Hillmann, K3
Garcia Bartels, N3
Kottner, J2
Stroux, A2
Canfield, D3
Kwon, TR1
Oh, CT1
Park, HM1
Han, HJ1
Ji, HJ1
Rossi, AM1
Aljuffali, IA1
Pan, TL1
Chang, SH1
Fang, JY1
Danesh, M1
Dubrey, SW1
VanGriethuysen, J1
Edwards, CM1
Goodier, M1
Hordinsky, M2
Torres, F1
Ioannides, D1
Lazaridou, E1
Wolff, H5
Check, JH1
Cohen, R1
Vary, JC1
Hugh Rushton, D1
Norris, MJ1
Pham, H2
von Grote, E2
Meckfessel, MH2
Keaney, TC1
Liao, AH1
Lu, YJ1
Lin, YC1
Chen, HK1
Sytwu, HK1
Wang, CH1
van Zuuren, EJ4
Fedorowicz, Z4
Schoones, J2
Cranwell, WC1
Anzalone, A1
Fortuna, MC1
Garelli, V1
Pranteda, G1
Carlesimo, M1
Fischer, TW1
Camacho-Martínez, FM1
Kelly, Y1
Blanco, A1
Hasanzadeh, H1
Halavati, N1
Saberi, M1
Wu, M1
Li, Q1
Avram, MR3
Rogers, NE2
Scheinfeld, N1
Melkote, S1
Dhurat, RS1
Palav, A1
Jerajani, HR1
Alsantali, A1
Mounsey, AL1
Reed, SW1
Arano, O1
Nishikawa, T1
Yamada, H1
Katsuoka, K2
Sisti, A1
Duque-Estrada, B1
Lam, SM1
Karamanovski, E1
Gonzalez, ME1
Cantatore-Francis, J1
Orlow, SJ1
Rastmanesh, R1
Rathnayake, D2
Ghanaat, M1
Jandali, S1
Low, DW1
Torgerson, R1
Kwack, MH1
Kang, BM1
Kim, MK1
Kim, JC1
Yazdabadi, A2
Dietz, E1
Pumthong, G1
Asawanonda, P1
Jariyasethavong, V1
Triwongwaranat, D1
Suthipinittharm, P1
Ingkaninan, K1
Leelapornpisit, P1
Waranuch, N1
González-Jiménez, M1
Arenas-Valgañón, J1
Calle, E1
Casado, J1
Mireles-Rocha, H1
Sánchez-Dueñas, LE1
Hernández-Torres, M1
Scarinci, F1
Mezzana, P1
Pasquini, P1
Colletti, M1
Cacciamani, A1
Guarneri, C1
Cannavò, SP1
McDonough, PH1
Schwartz, RA1
Patel, M1
Dawson, TL1
Yip, L1
Perez, A1
Rufaut, NW1
Choi, JW1
Na, SY1
Park, KC1
Youn, SW1
Huh, CH1
Park, MK1
Kim, MN1
Piraccini, B1
Guarrera, M1
Fiorucci, MC1
Lorenzi, S1
Bergstrom, KG1
Cantisani, C1
Melis, L1
Iorio, A1
Scali, E1
Lee, SH3
Yoon, J1
Shin, SH1
Zahoor, M1
Kim, HJ1
Park, PJ1
Park, WS1
Min, do S1
Kim, HY1
Choi, KY1
Kluger, N1
Jacot, W1
Frouin, E1
Rigau, V1
Poujol, S1
Dereure, O1
Guillot, B1
Romieu, G1
Bessis, D1
Carter, B2
Andriolo, RB1
McElwee, KJ1
Shapiro, JS1
Jang, WS1
Yoo, KH1
Han, TY1
Seo, SJ1
Hong, CK1
Adenuga, P1
Summers, P1
Banka, N1
Bunagan, MJ1
Lim, C1
Lee, JY1
Im, KR1
Yoon, KS1
Song, JM1
Tanglertsampan, C1
Birch, MP1
Lalla, SC1
Messenger, AG4
Olsen, EA11
Dunlap, FE1
Funicella, T1
Koperski, JA2
Swinehart, JM1
Tschen, EH1
Trancik, RJ2
Khandpur, S1
Suman, M1
Reddy, BS1
Foote, SI1
Cole, JP1
Gandelman, M1
Haber, R2
Knudsen, R2
Leavitt, MT1
Leonard, RT1
Puig, CJ1
Vogel, JE2
Ziering, CL1
Mallari, RS1
Tate, B1
Hoffmann, R4
Brzezińska-Wcisło, L1
Price, VH7
Dawber, RP1
Rundegren, J2
Springer, K1
Brown, M1
Stulberg, DL1
Robb-Nicholson, C1
Berger, RS1
Fu, JL1
Smiles, KA1
Turner, CB1
Schnell, BM1
Werchowski, KM1
Lammers, KM1
Hanneken, S1
Ritzmann, S1
Nöthen, MM1
Kruse, R1
Saraswat, A1
Kumar, B1
Ellis, JA1
Harrap, SB1
Bouhanna, P4
Arck, PC1
Handjiski, B1
Peters, EM1
Hagen, E1
Klapp, BF1
Bandaranayake, I1
Han, JH1
Kwon, OS3
Chung, JH1
Cho, KH2
Eun, HC3
Kim, KH3
Lucky, AW1
Piacquadio, DJ1
Ditre, CM1
Dunlap, F1
Kantor, I1
Pandya, AG1
Savin, RC3
Tharp, MD1
Haber, RS1
Arca, E1
Açikgöz, G1
Taştan, HB1
Köse, O1
Kurumlu, Z1
Roberts, JL2
Stough, D2
Washenik, K3
Whiting, DA4
Bienová, M1
Kucerová, R1
Fiurásková, M1
Hajdúch, M1
Koláŕ, Z1
Hagemann, T1
Schlütter-Böhmer, B1
Allam, JP1
Bieber, T1
Novak, N1
Simon, HB1
Stenn, K1
Parsley, WM1
Luggen, AS1
Chen, CH1
Sheu, MT1
Wu, AB1
Lin, KP1
Ho, HO1
Moreno-Ramírez, D1
Camacho Martínez, F1
Kwong, RA1
Kossard, S1
Hannuksela, M2
Yoo, HG1
Chang, IY1
Pyo, HK1
Kang, YJ1
Hoedemaker, C1
van Egmond, S1
Epstein, JS1
Kunte, C3
Krisp, A1
Ellwanger, U1
Tsiskarishvili, NV1
Tsiskarishvili, TsI1
Otberg, N1
Finner, AM1
Whiting, D1
Miller, J1
Wanser, R1
Zhang, P1
Kohut, B1
Shin, HS1
Won, CH1
Mapar, MA1
Omidian, M1
Gassmueller, J1
Webster, A1
Dinh, QQ1
Vermorken, AJ1
Wester, RC2
Novak, E2
Vanderveen, EE1
Ellis, CN1
Kang, S1
Case, P1
Headington, JT3
Voorhees, JJ2
Swanson, NA1
King, CM1
Harrop, B1
Dave, VK1
Ingles, RM1
Kahn, T1
Seidman, M1
Westfried, M1
Maxey, R1
Rao, TK1
Friedman, EA1
Zappacosta, AR1
Walsh, DS1
Dunn, CL1
James, WD1
Vickers, MA1
Barton, CJ1
Hussein, AM1
Ebner, H1
Müller, E1
Callan, AW1
Montalto, J1
Shrank, AB1
Nielson, TA1
Reichel, M1
Roblin, X1
Blais, J1
Boisson, C1
Kalmouni, M1
André, F1
Rodriguez, R1
Machiavelli, M1
Leone, B1
Romero, A1
Cuevas, MA1
Langhi, M1
Romero Acuña, L1
Romero Acuña, J1
Amato, S1
Barbieri, M1
Tan, J1
Ho, V1
Abbott, F1
Tron, V1
Baral, J2
DeVillez, RL2
Jacobs, JP2
Szpunar, CA2
Warner, ML2
Duplechain, G1
White, JA1
Sasson, M1
Shupack, JL2
Stiller, MJ1
Karam, P1
Duvic, M2
Atton, AV1
Kohl, PK1
Bammel, A1
Stern, R1
Sterry, W1
Diani, AR1
Shull, KL1
Zaya, MJ1
Brunden, MN1
Rand, S2
Lemak, NA1
Valero, V1
Hymes, SR1
Farmer, KL1
Hortobagyi, GN1
Bandstra, BA1
Compton, LD1
Peluso, AM1
Misciali, C1
Piérard-Franchimont, C2
Piérard, GE2
Davies, K1
Zhong, WZ1
Sánchez-Motilla, JM1
Pont, V1
Nagore, E1
Rodríguez-Serna, M1
Sánchez, JL1
Aliaga, A1
De Doncker, P1
Cauwenbergh, G1
Esteve, E1
Aubin, F1
Dubertret, L1
Molitor, L1
Tran, D2
Sato, T1
Tadokoro, T1
Sonoda, T1
Asada, Y1
Takayasu, S1
Scow, DT1
Nolte, RS1
Shaughnessy, AF1
Camacho-Martinez, F1
Dawber, R3
Menefee, E2
Strauss, PC1
Sawaya, M1
Cash, TF1
Kurbel, S1
Kurbel, B1
Zanić-Matanić, D1
Tschöp, M1
Pflaum, CD1
Strasburger, CJ1
Gärtner, R1
Schopohl, J1
Barth, JH1
Dey, R1
Donald, TG1
Scheman, AJ1
West, DP4
Hordinksy, MK1
Osburn, AH1
West, LE1
Schwarer, AP1
Chow, CW1
Wasielewski, S1
Hogan, DJ1
Chamberlain, M1
Saiag, P1
Granel, F1
Satoh, H1
Morikaw, S1
Fujiwara, C1
Terada, H1
Uehara, A1
Ohno, R1
Meidan, VM1
Touitou, E1
Bierl, H1
Patel, JC1
Shirai, A2
Ikeda, J1
Kawashima, S1
Tamaoki, T2
Kamiya, T2
de Viragh, PA1
Tsunoda, H1
Paukstadt, W1
Sawaya, ME1
Friedman, ES1
Friedman, PM1
Cohen, DE1
Eremia, S1
Umar, SH1
Li, CY1
Vexiau, P1
Chaspoux, C1
Boudou, P1
Fiet, J1
Jouanique, C1
Hardy, N1
Trattner, A2
David, M1
Bader, U1
Kidwai, BJ1
George, M1
Jacobson, C1
Ingber, A1
Gandy, W1
Brenner, S1
Tamir, A1
Uno, H3
Takeshita, K1
Yamagishi, I1
Sugimoto, T1
Otomo, S1
Moriwaki, K1
Wilson, C1
Walkden, V1
Powell, S1
Shaw, S1
Wilkinson, J1
van der Donk, J1
Passchier, J2
Dutree-Meulenberg, RO3
Stolz, E4
Verhage, F2
Kiesewetter, F1
Langer, P1
Schell, H1
Lavrijsen, AP1
Vermeer, BJ1
O'Loughlin, S1
Granai, CO1
Frederickson, H1
Gajewski, W1
Goodman, A1
Goldstein, A1
Baden, H1
Connors, TJ1
Cooke, DE1
De Launey, WE1
Downie, M1
Knudsen, RG1
Shumack, S1
Eggleston, AS1
Rigoni, C2
Pinelli, S2
Toffolo, P1
Scarabelli, G1
Terenzio, C1
Weiner, MS5
Amara, IA1
DeLong, ER5
Fenske, NA1
Albers, SE1
Shiell, R1
Kuan, YZ1
Chen, SY1
Chen, MJ1
Wang, CN1
Chan, HL1
D'Ovidio, R1
Di Prima, T1
De Pasquale, R1
D'Ovidio, F1
London-Wong, DM1
Hart, LL1
Burnett, JW1
Jordan, WP1
Farmer, ER1
Uitto, JJ1
Ferry, JJ1
Shepard, JH1
Szpunar, GJ1
Anderson, C1
Berne, B1
Juhlin, L1
Skogh, M1
Strand, A1
Vahlquist, A1
de Boer, EM1
Bezemer, PD1
Bruynzeel, DP1
Nieboer, C2
Burton, JL1
Bardelli, A1
Rebora, A1
Katz, HI2
Burke, KE1
Grimalt, F1
Rijpma, SE1
Rushton, DH2
Unger, WP2
Cotterill, PC1
Kingsley, P1
James, KC2
Bardazzi, F2
Montagnani, A1
Dover, JS1
Arndt, KA2
de Groot, AC4
Nater, JP4
Blanchard, G1
Blanchard, B1
Matias, JR1
Malloy, V1
Orentreich, N1
Baran, R1
Stålhammar, J1
Neher, JO1
Herxheimer, A2
Mitchell, AD2
De Villez, R1
Jorizzo, JL1
Feldman, SR1
Degreef, H1
Hendrickx, I1
Dooms-Goossens, A1
van der Willigen, AH1
Geursen-Reitsma, AM1
van Joost, T2
Valsecchi, R1
Cainelli, T1
Zaun, H1
Mørk, C1
Braathen, LR1
Zlotogorski, A1
Seidenbaum, M1
Heyman, A1
Birnbaum, PS1
Leenen, FH1
Smith, DL1
Menni, S1
Pestana, A1
Murray, JC1
Rumsfield, JA2
Fiedler-Weiss, VC2
Orenberg, EK1
Wilkinson, DI1
Civatte, J1
Laux, B1
Simpson, NB1
Vickers, CF1
Kvedar, JC1
Baden, HP1
Epstein, E2
Alomar, A1
Smandia, JA1
Piepkorn, MW1
Weidner, M1
Rietschel, RL2
Robertson, DB1
Storer, JS1
Brzuskiewicz, J1
Floyd, H1
Rice, JC1
De Villez, RL2
Kassimir, JJ2
Thirumoorthy, T1
Reed, ML1
Jondreau, L1
Duncan, SH1
Hien, NT1
Prawer, SE1
Goldman, SJ1
Kreindler, TG1
Spindler, JR1
Clissold, SP1
Heel, RC1
Roenigk, HH2
Pepper, E1
Kuruvilla, S2
Cappas, A2
Brigham, P1
De Prost, Y1
van der Sluis, I1
de Koning Gans, HJ1
Devillez, R1
Morgan, JP1
Zappa, M1
Bunker, CB1
Dowd, PM1
Shi, YP1
Bazzano, GS1
Terezakis, N1
Galen, W1
Natow, AJ1
Stern, RS1
Bamford, JT1
Franz, TJ1
Pinnell, SR1
Feinstein, RP1
Buys, CM1
Weiss, VC1
Herring, BD1
Schlagel, C1
De Padova, MP1
Caponeri, GM1
Melino, M1
Veronesi, S1

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial[NCT05296863]Phase 337 participants (Actual)Interventional2021-10-11Completed
A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women[NCT03488108]Phase 1/Phase 220 participants (Actual)Interventional2017-01-23Completed
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia[NCT05456087]Phase 220 participants (Anticipated)Interventional2022-08-12Recruiting
International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922]Phase 3520 participants (Anticipated)Interventional2024-03-31Not yet recruiting
The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945]Phase 430 participants (Anticipated)Interventional2021-04-01Not yet recruiting
Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study[NCT03753113]Phase 324 participants (Actual)Interventional2018-11-28Completed
Randomised, Crossover Bioavailability Clinical Trial of Oral Minoxidil 1 MG, After Single and Multiple Dose Administration to Healthy Volunteers Under Fasting Conditions.[NCT06015516]Phase 114 participants (Anticipated)Interventional2024-02-29Not yet recruiting
the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial[NCT03388840]Phase 440 participants (Anticipated)Interventional2018-01-15Recruiting
Efficacy of Platelet-rich Plasma Versus Mesotherapy With Recombinant Growth Factors and Stem Cell Conditioned Media in Androgenetic Alopecia: A Retrospective Study.[NCT05129800]100 participants (Anticipated)Observational2021-12-31Not yet recruiting
Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata[NCT05600673]Phase 1/Phase 230 participants (Actual)Interventional2019-01-01Completed
Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis[NCT04191005]15 participants (Anticipated)Observational2020-01-07Recruiting
Role of Vitamin D in Androgenetic Alopecia[NCT03154528]90 participants (Anticipated)Observational2019-03-30Not yet recruiting
Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.[NCT02548689]10 participants (Actual)Observational2015-07-31Terminated (stopped due to Original lead investigator left Northwestern University)
A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients[NCT04678544]170 participants (Actual)Interventional2020-12-23Completed
Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement : A Randomized, Double-blind, Placebo-controlled Study[NCT02275832]Phase 448 participants (Actual)Interventional2014-11-30Completed
Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement : A Randomized, Double-blind, Placebo-controlled Study[NCT02283645]Phase 464 participants (Anticipated)Interventional2015-01-31Not yet recruiting
Assessment of the Role of the JAK-STAT Pathway in the Pathogenesis of Male Androgenetic Alopecia[NCT03694067]25 participants (Actual)Observational2018-10-15Completed
Minoxidil Response Testing in Males With Androgenetic Alopecia[NCT02198261]300 participants (Anticipated)Observational2014-07-31Completed
Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil[NCT02486848]0 participants (Actual)Interventional2016-06-30Withdrawn
Minoxidil Response Testing in Females With Female Pattern Hair Loss[NCT02206802]300 participants (Anticipated)Observational2014-07-31Completed
Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata[NCT05861401]100 participants (Anticipated)Interventional2023-04-30Recruiting
Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial[NCT02999737]Phase 440 participants (Actual)Interventional2016-11-30Active, not recruiting
Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil[NCT01309191]14 participants (Actual)Interventional2011-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adverse Event of Redness on Scalp

Total number of participants experiencing Redness on Scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment

InterventionParticipants (Count of Participants)
Platelet Rich Plasma0
Minoxidil Foam0

Adverse Event of Swelling on Scalp

Total number of participants experiencing swelling on scalp was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: after 12 weeks of treatment

InterventionParticipants (Count of Participants)
Platelet Rich Plasma0
Minoxidil Foam0

Change in Cumulative Thickness

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total sum of thickness of each hair was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma-3.5
Minoxidil Foam20.6

Change in Hair Count

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of hairs per 0.65 cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma7.7
Minoxidil Foam22.7

Change in Terminal Hair Density

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of Terminal hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma-0.7
Minoxidil Foam12.8

Change in Vellus Hair Density

Phototrichograms of all scalps performed using FotoFinder video-epiluminescence microscopy (FotoFinder Systems GmbH) in combination with TrichoScan digital image analysis (TRICHOLOG GmbH and DatInf mbH). The percent change in the total number of vellus hairs per cm2 was measured after both interventions, in each Arm/Group. (NCT03488108)
Timeframe: baseline, after 12 weeks of treatment

Interventionpercent change (Median)
Platelet Rich Plasma25.7
Minoxidil Foam18.6

Patients Self - Assessment Questionnaire

Self-administered hair growth questionnaire, consisting of 4 questions in the patient's language on treatment efficacy and three questions on satisfaction with appearance. For differences between self-assessment questionnaires. This questionnaire following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. Higher scores indicated a worse outcome. (NCT03753113)
Timeframe: through study completion

Interventionscore on a scale (Mean)
Treatment Group1.25
Control Group2.58

Adverse Events

Incidence of adverse events such as itching, redness, inflammation etc (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks

,
InterventionParticipants (Count of Participants)
scalp itchingscalp drynessheadache
Control Group422
Treatment Group100

Change in Hair Diameter

Change in hair diameter over time as compared to Baseline. Hair diameter measured via a digital micrometer. (NCT03753113)
Timeframe: baseline, 12, 24, and 36 weeks

,
Interventionmicrometer (Mean)
Week 12Week 24Week 36
Control Group51.5851.1750.58
Treatment Group57.4260.9262.67

Reviews

164 reviews available for minoxidil and Alopecia

ArticleYear
Microneedling for Hair Loss.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:1

    Topics: Alopecia; Hair; Humans; Minoxidil; Needles; Platelet-Rich Plasma; Treatment Outcome

2022
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:12

    Topics: Alopecia; Alopecia Areata; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Quality of L

2021
Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics.
    Journal of the American Academy of Dermatology, 2023, Volume: 89, Issue:4

    Topics: Alopecia; Dutasteride; Finasteride; Humans; Minoxidil; Transgender Persons; Treatment Outcome

2023
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:10

    Topics: Alopecia; Dermatologists; Female; Humans; Minoxidil; Quality of Life

2022
Natural products for male androgenetic alopecia.
    Dermatologic therapy, 2022, Volume: 35, Issue:4

    Topics: Alopecia; Biological Products; Finasteride; Humans; Male; Minoxidil; Treatment Outcome

2022
Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.
    JAMA dermatology, 2022, Mar-01, Volume: 158, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Bayes Theorem; Dutasteride; Finasteride; Humans; Male

2022
Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:5

    Topics: Administration, Topical; Alopecia; Clinical Trials, Phase III as Topic; Female; Finasteride; Hair; H

2022
Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds.
    Journal of ethnopharmacology, 2022, Aug-10, Volume: 294

    Topics: Alopecia; Alopecia Areata; China; Drugs, Chinese Herbal; Humans; Minoxidil; Plants, Medicinal; Signa

2022
The first study on combined carboxytherapy and minoxidil 20% in the treatment of Lichen planopilaris: A case series and literature review.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Alopecia; Humans; Lichen Planus; Minoxidil

2022
Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.
    The Journal of dermatology, 2022, Volume: 49, Issue:10

    Topics: Alopecia; Alopecia Areata; COVID-19; COVID-19 Drug Treatment; Humans; Minoxidil; SARS-CoV-2

2022
Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:11

    Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome

2022
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    The Journal of dermatological treatment, 2022, Volume: 33, Issue:7

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Hair; Humans; Male; Minoxidil

2022
Noninvasive Hair Rejuvenation.
    Facial plastic surgery clinics of North America, 2022, Volume: 30, Issue:3

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Rejuvenation; Treatment Outcome

2022
Topical cetirizine for treating androgenetic alopecia: A systematic review.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil; Treatment Outcome

2022
Comprehensive review of oral minoxidil in alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Female; Humans; Minoxidil; Treatment Outcome

2022
Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil.
    AAPS PharmSciTech, 2022, Nov-01, Volume: 23, Issue:8

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil; Nanoparticles; Particle Si

2022
Advances in microneedles research based on promoting hair regrowth.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 353

    Topics: Alopecia; Drug Delivery Systems; Finasteride; Hair; Humans; Minoxidil

2023
Pediatric androgenetic alopecia: an updated review.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023, Volume: 21, Issue:1

    Topics: Adolescent; Alopecia; Child; Female; Finasteride; Hair; Humans; Minoxidil; Treatment Outcome

2023
A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2023, Volume: 32, Issue:7

    Topics: Alopecia; Combined Modality Therapy; Female; Finasteride; Humans; Minoxidil; Postmenopause; Treatmen

2023
Natural Compounds Used for Treating Hair Loss.
    Current pharmaceutical design, 2023, Volume: 29, Issue:16

    Topics: Alopecia; Animals; Bees; Finasteride; Hair; Minoxidil; Plants, Medicinal; Quality of Life; United St

2023
Androgenetic Alopecia: Therapy Update.
    Drugs, 2023, Volume: 83, Issue:8

    Topics: Administration, Oral; Administration, Topical; Alopecia; Female; Finasteride; Humans; Male; Minoxidi

2023
Noninvasive Hair Rejuvenation.
    Clinics in plastic surgery, 2023, Volume: 50, Issue:3

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Rejuvenation; Treatment Outcome

2023
Combination therapy in female pattern hair loss.
    Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2023, May-19, Volume: 25, Issue:1-4

    Topics: Alopecia; Combined Modality Therapy; Female; Finasteride; Humans; Minoxidil; Spironolactone; Treatme

2023
Dissolving microneedles for alopecia treatment.
    Colloids and surfaces. B, Biointerfaces, 2023, Volume: 229

    Topics: Alopecia; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Quality of Life; Treatment Ou

2023
Systematic review of mesotherapy: a novel avenue for the treatment of hair loss.
    The Journal of dermatological treatment, 2023, Volume: 34, Issue:1

    Topics: Alopecia; Humans; Injections, Intradermal; Mesotherapy; Minoxidil; Treatment Outcome

2023
Medical and procedural treatment of androgenetic alopecia - Where are we?
    Journal of the American Academy of Dermatology, 2023, Volume: 89, Issue:2S

    Topics: Alopecia; Behavior Therapy; Dietary Supplements; Finasteride; Humans; Minoxidil

2023
Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis.
    Archives of dermatological research, 2023, Volume: 315, Issue:10

    Topics: Alopecia; Female; Hair; Humans; Male; Meta-Analysis as Topic; Minoxidil; Systematic Reviews as Topic

2023
Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence.
    Toxicology and applied pharmacology, 2023, 11-01, Volume: 478

    Topics: Administration, Oral; Adult; Alopecia; Animals; Finasteride; Humans; Male; Mice; Minoxidil; Prostati

2023
Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens.
    Dermatologic therapy, 2019, Volume: 32, Issue:5

    Topics: Adult; Alopecia; Androgen Antagonists; Finasteride; Genetic Predisposition to Disease; Hair; Humans;

2019
Pediatric androgenetic alopecia: A review.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:5

    Topics: Adolescent; Alopecia; Child; Finasteride; Humans; Incidence; Minoxidil; Retrospective Studies

2021
Alopecia and Hair Damage Induced by Oncological Therapy.
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2019,Fall, Volume: 32, Issue:5

    Topics: Alopecia; Antineoplastic Agents; Humans; Minoxidil; Neoplasms; Radiotherapy

2019
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:1

    Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid

2020
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:1

    Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid

2020
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:1

    Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid

2020
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:1

    Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid

2020
Novel drug delivery approaches for the management of hair loss.
    Expert opinion on drug delivery, 2020, Volume: 17, Issue:3

    Topics: Alopecia; Drug Delivery Systems; Humans; Minoxidil; Nanoparticles; Pharmaceutical Preparations

2020
A review of the treatment of male pattern hair loss
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:5

    Topics: Administration, Oral; Administration, Topical; Alopecia; Dry Needling; Finasteride; Hair; Humans; Lo

2020
Androgenetic Alopecia in Gender Minority Patients.
    Dermatologic clinics, 2020, Volume: 38, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Dermatologic Agents; Estrogens; Finasteride; Hair

2020
Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia.
    Lasers in medical science, 2020, Volume: 35, Issue:6

    Topics: Alopecia; Androgen Antagonists; Hair; Humans; Low-Level Light Therapy; Minoxidil; Platelet-Rich Plas

2020
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Aesthetic plastic surgery, 2020, Volume: 44, Issue:3

    Topics: Alopecia; Finasteride; Hair; Humans; Minoxidil; Photography; Treatment Outcome

2020
Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality.
    The Journal of dermatological treatment, 2022, Volume: 33, Issue:1

    Topics: Alopecia; Female; Finasteride; Humans; Male; Minoxidil; Network Meta-Analysis; Treatment Outcome

2022
Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil
    International journal of molecular sciences, 2020, Apr-13, Volume: 21, Issue:8

    Topics: Adult Stem Cells; Alopecia; Combined Modality Therapy; Finasteride; Humans; Minoxidil; Platelet-Rich

2020
Physiology and Medical Treatments for Alopecia.
    Facial plastic surgery clinics of North America, 2020, Volume: 28, Issue:2

    Topics: Alopecia; Dihydrotestosterone; Dutasteride; Finasteride; Hair Preparations; Humans; Low-Level Light

2020
Transdermal Drug Delivery for Hair Regrowth.
    Molecular pharmaceutics, 2021, 02-01, Volume: 18, Issue:2

    Topics: Acrylates; Administration, Cutaneous; Alopecia; Drug Carriers; Finasteride; Hair Follicle; Humans; J

2021
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis.
    Dermatologic therapy, 2020, Volume: 33, Issue:4

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Treatment Outcome

2020
Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.
    International journal of dermatology, 2020, Volume: 59, Issue:8

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Female; Humans; Hypertrichosis; Male; Minoxidil;

2020
Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Child; Hair; Humans; Minoxidil; Vasodilator Ag

2020
Oral minoxidil treatment for hair loss: A review of efficacy and safety.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:3

    Topics: Administration, Oral; Alopecia; Drug Administration Schedule; Humans; Medication Adherence; Minoxidi

2021
Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Alopecia; Humans; Hypertrichosis; Minoxidil; Treatment Outcome

2020
Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Alopecia; Finasteride; Hair; Humans; Low-Level Light Therapy; Minoxidil

2020
Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability.
    Dermatologic therapy, 2021, Volume: 34, Issue:2

    Topics: Alopecia; Alopecia Areata; Hair; Humans; Injections; Minoxidil; Platelet-Rich Plasma; Treatment Outc

2021
Therapeutic management in paediatric alopecia areata: A systematic review.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:6

    Topics: Adolescent; Alopecia; Alopecia Areata; Child; Humans; Janus Kinase Inhibitors; Leflunomide; Minoxidi

2021
Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021.
    JAMA, 2021, Mar-02, Volume: 325, Issue:9

    Topics: Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Humans; Male; Minoxidil; Primary Health

2021
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:7

    Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil; Monilethrix

2021
Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature.
    Medicina (Kaunas, Lithuania), 2021, Mar-25, Volume: 57, Issue:4

    Topics: Adult; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Platelet-Rich Plasma; Quality of Life

2021
Combination Approaches for Combatting Hair Loss.
    Dermatologic clinics, 2021, Volume: 39, Issue:3

    Topics: Alopecia; Child; Female; Finasteride; Humans; Male; Middle Aged; Minoxidil

2021
[Alopecia and cancers: From basics to clinical practice].
    Bulletin du cancer, 2021, Volume: 108, Issue:10

    Topics: Alopecia; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Hair; Hair Follicle; Humans;

2021
Potential of nanoparticulate based delivery systems for effective management of alopecia.
    Colloids and surfaces. B, Biointerfaces, 2021, Volume: 208

    Topics: Administration, Topical; Adult; Alopecia; Drug Delivery Systems; Hair; Humans; Minoxidil; Pharmaceut

2021
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:1

    Topics: Alopecia; Finasteride; Humans; Low-Level Light Therapy; Minoxidil; Randomized Controlled Trials as T

2017
Hair Loss Myths.
    Journal of drugs in dermatology : JDD, 2017, Jul-01, Volume: 16, Issue:7

    Topics: Administration, Topical; Alopecia; Biological Products; Dermatologists; Dietary Supplements; Humans;

2017
The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2018, Volume: 153, Issue:1

    Topics: Administration, Topical; Alopecia; Chemistry, Pharmaceutical; Female; Hair; Hair Follicle; Humans; M

2018
Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review.
    International journal of dermatology, 2018, Volume: 57, Issue:12

    Topics: Alopecia; Animals; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Cryotherapy; Hair Fo

2018
Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:12

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Humans; Low-Level Light Therapy; M

2018
Minoxidil in the treatment of androgenetic alopecia.
    Dermatologic therapy, 2018, Volume: 31, Issue:5

    Topics: Alopecia; Humans; Minoxidil; Vasodilator Agents

2018
Off-Label Use of Topical Minoxidil in Alopecia: A Review.
    American journal of clinical dermatology, 2019, Volume: 20, Issue:2

    Topics: Administration, Topical; Adult; Alopecia; Animals; Humans; Minoxidil; Off-Label Use; Treatment Outco

2019
Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment.
    American journal of clinical dermatology, 2019, Volume: 20, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Calcineurin Inhibitors; Chronic Dis

2019
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
    The Journal of clinical endocrinology and metabolism, 2019, 07-01, Volume: 104, Issue:7

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low-

2019
The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review
    Journal of drugs in dermatology : JDD, 2019, Feb-01, Volume: 18, Issue:2

    Topics: Administration, Topical; Alopecia; Female; Humans; Male; Minoxidil; Treatment Outcome; Vasodilator A

2019
Herbal Medicines For Treatment of Androgenic Alopecia.
    Alternative therapies in health and medicine, 2020, Volume: 26, Issue:4

    Topics: Alopecia; Finasteride; Herbal Medicine; Humans; Minoxidil; Phytotherapy; Plants, Medicinal; Scalp

2020
Hair restoration approaches for early onset male androgenetic alopecia.
    Journal of cosmetic dermatology, 2013, Volume: 12, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Azasteroids; Cosmetic Techniques; Drug Therapy, Combination;

2013
Nonsurgical therapy for hair loss.
    Facial plastic surgery clinics of North America, 2013, Volume: 21, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Azasteroids; Combined Modality Therapy; Dutasteride; Female;

2013
Androgenetic alopecia.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Biopsy; Comorbidity; Contraindications

2014
Treatment for alopecia.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Adrenal Cortex Hormones; Alopecia; Androgen Antagonists; Anti-Infectiv

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Androgenetic alopecia: an evidence-based treatment update.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:3

    Topics: Administration, Oral; Administration, Topical; Alopecia; Evidence-Based Medicine; Female; Finasterid

2014
Hair loss in women.
    Clinical obstetrics and gynecology, 2015, Volume: 58, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Finasteride; Flutamide; Hair;

2015
Men's aesthetic dermatology.
    Seminars in cutaneous medicine and surgery, 2014, Volume: 33, Issue:4

    Topics: Alopecia; Botulinum Toxins; Cosmetic Techniques; Dermal Fillers; Face; Female; Humans; Lipectomy; Ma

2014
Normal and aging hair biology and structure 'aging and hair'.
    Current problems in dermatology, 2015, Volume: 47

    Topics: 5-alpha Reductase Inhibitors; Aging; Alopecia; Finasteride; Hair; Hair Follicle; Humans; Melanocytes

2015
Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management.
    Current problems in dermatology, 2015, Volume: 47

    Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Dutasteride; Finasteride; Hair; H

2015
Female pattern hair loss.
    Current problems in dermatology, 2015, Volume: 47

    Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Androgen Antagonists; Androgen Re

2015
Hair loss in children.
    Current problems in dermatology, 2015, Volume: 47

    Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Child; Child, Preschool; Diagnosis, Differential

2015
An update on the treatment of female alopecia and the introduction of a potential novel therapy.
    Clinical and experimental obstetrics & gynecology, 2015, Volume: 42, Issue:4

    Topics: Alopecia; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Minoxidil; Randomize

2015
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
    The Medical clinics of North America, 2015, Volume: 99, Issue:6

    Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe

2015
Interventions for female pattern hair loss.
    The Cochrane database of systematic reviews, 2016, May-26, Issue:5

    Topics: Alopecia; Drug Administration Schedule; Female; Finasteride; Hair; Humans; Low-Level Light Therapy;

2016
Multi-therapies in androgenetic alopecia: review and clinical experiences.
    Dermatologic therapy, 2016, Volume: 29, Issue:6

    Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Administration, Oral; Alopecia; Finasteride

2016
The Diagnosis and Treatment of Hair and Scalp Diseases.
    Deutsches Arzteblatt international, 2016, May-27, Volume: 113, Issue:21

    Topics: Alopecia; Combined Modality Therapy; Dermatologic Agents; Diagnosis, Differential; Evidence-Based Me

2016
Androgenetic Alopecia: An Update of Treatment Options.
    Drugs, 2016, Volume: 76, Issue:14

    Topics: Alopecia; Androgen Antagonists; Animals; Female; Finasteride; Humans; Male; Minoxidil

2016
[Androgenetic alopecia: What's new in the last two years ?]
    Annales de dermatologie et de venereologie, 2016, Volume: 143, Issue:12S

    Topics: Alopecia; Early Diagnosis; Finasteride; France; Gene Expression Regulation; Genetic Association Stud

2016
Hair transplantation for men.
    Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2008, Volume: 10, Issue:3

    Topics: Alopecia; Cicatrix; Cosmetic Techniques; Finasteride; Hair; Hair Follicle; Humans; Low-Level Light T

2008
A review of hormonal therapy for female pattern (androgenic) alopecia.
    Dermatology online journal, 2008, Mar-15, Volume: 14, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Dermat

2008
Medical treatments for male and female pattern hair loss.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4

    Topics: Adult; Alopecia; Androgen Antagonists; Azasteroids; Drug Therapy, Combination; Dutasteride; Female;

2008
Chemotherapy-induced alopecia.
    Seminars in cutaneous medicine and surgery, 2009, Volume: 28, Issue:1

    Topics: Alopecia; Antineoplastic Agents; Cryotherapy; Hair Follicle; Humans; Minoxidil; Vasodilator Agents

2009
Androgens and hair loss.
    Current opinion in endocrinology, diabetes, and obesity, 2009, Volume: 16, Issue:3

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alop

2009
Diagnosing and treating hair loss.
    American family physician, 2009, Aug-15, Volume: 80, Issue:4

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Hair; Humans; M

2009
Hair loss in women.
    Minerva ginecologica, 2009, Volume: 61, Issue:5

    Topics: Alopecia; Biotin; Contraceptives, Oral, Hormonal; Female; Finasteride; Gonadal Steroid Hormones; Hai

2009
Hair restoration in the ethnic patient and review of hair transplant fundamentals.
    Facial plastic surgery clinics of North America, 2010, Volume: 18, Issue:1

    Topics: Alopecia; Enzyme Inhibitors; Esthetics; Ethnicity; Finasteride; Hair; Hair Follicle; Humans; Minoxid

2010
Male androgenetic alopecia.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:8

    Topics: Administration, Oral; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Azasteroids;

2010
Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism.
    Southern medical journal, 2010, Volume: 103, Issue:9

    Topics: Alopecia; Androgens; Dermatologic Agents; Drugs, Investigational; Female; Finasteride; Humans; Male;

2010
From surgery to pharmacology to gene therapy: the past, present, and future of hair restoration.
    Annals of plastic surgery, 2010, Volume: 65, Issue:4

    Topics: Alopecia; Female; Finasteride; Forecasting; Genetic Therapy; Hair; Hair Follicle; Humans; Male; Mino

2010
Chemotherapy-induced alopecia.
    Current opinion in supportive and palliative care, 2010, Volume: 4, Issue:4

    Topics: Alopecia; Antineoplastic Agents; Female; Hair Follicle; Humans; Male; Minoxidil; Neoplasms; Scalp; V

2010
Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.
    The British journal of dermatology, 2011, Volume: 165 Suppl 3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Cosmetic Techniques; Female; Finasteri

2011
Minoxidil use in dermatology, side effects and recent patents.
    Recent patents on inflammation & allergy drug discovery, 2012, Volume: 6, Issue:2

    Topics: Administration, Topical; Alopecia; Animals; Antihypertensive Agents; Female; Hair; Humans; Male; Min

2012
Interventions for female pattern hair loss.
    The Cochrane database of systematic reviews, 2012, May-16, Issue:5

    Topics: Alopecia; Drug Administration Schedule; Female; Hair; Humans; Minoxidil; Randomized Controlled Trial

2012
Promising therapies for treating and/or preventing androgenic alopecia.
    Skin therapy letter, 2012, Volume: 17, Issue:6

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Laser Therapy; Male; Minoxidil; Sex Factors

2012
Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review.
    The British journal of dermatology, 2012, Volume: 167, Issue:5

    Topics: Alopecia; Databases, Factual; Evidence-Based Medicine; Female; Hair; Humans; Laser Therapy; Minoxidi

2012
Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment.
    Dermatologic clinics, 2013, Volume: 31, Issue:1

    Topics: 14-alpha Demethylase Inhibitors; Alopecia; Androgen Antagonists; Female; Hair; Humans; Ketoconazole;

2013
Pattern hair loss in men: diagnosis and medical treatment.
    Dermatologic clinics, 2013, Volume: 31, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Azasteroids; Dutasteride; Female; Finasteride; Ge

2013
Female pattern hair loss.
    Clinical and experimental dermatology, 2002, Volume: 27, Issue:5

    Topics: Alopecia; Androgens; Female; Hair; Humans; Minoxidil

2002
The potential role of minoxidil in the hair transplantation setting.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2002, Volume: 28, Issue:10

    Topics: Administration, Oral; Administration, Topical; Alopecia; Combined Modality Therapy; Enzyme Inhibitor

2002
Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss.
    Journal of the American Academy of Dermatology, 2003, Volume: 48, Issue:2

    Topics: Alopecia; Female; Hair; Humans; Male; Minoxidil; Photography; Treatment Outcome

2003
Androgenetic alopecia in adolescents.
    Cutis, 2003, Volume: 71, Issue:2

    Topics: Adolescent; Alopecia; Humans; Incidence; Minoxidil; Self Concept; Vasodilator Agents

2003
Hypertrichosis in females applying minoxidil topical solution and in normal controls.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2003, Volume: 17, Issue:3

    Topics: Administration, Cutaneous; Adult; Alopecia; Dose-Response Relationship, Drug; Facial Dermatoses; Fem

2003
Common hair loss disorders.
    American family physician, 2003, Jul-01, Volume: 68, Issue:1

    Topics: Alopecia; Antifungal Agents; Diagnosis, Differential; Fluconazole; Humans; Hypotrichosis; Minoxidil;

2003
Androgenetic alopecia in women.
    The journal of investigative dermatology. Symposium proceedings, 2003, Volume: 8, Issue:1

    Topics: Alopecia; Clinical Laboratory Techniques; Controlled Clinical Trials as Topic; Diagnosis, Differenti

2003
[Androgenetic alopecia. Current aspects of a common phenotype].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:8

    Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Disease Progression; Enzyme Inhibitors; Female;

2003
Androgenetic alopecia: pathogenesis and potential for therapy.
    Expert reviews in molecular medicine, 2002, Nov-19, Volume: 4, Issue:22

    Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Dihydrotestosterone; Female; Finasteride; Genes

2002
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Minoxidil: mechanisms of action on hair growth.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Alopecia; Animals; Antihypertensive Agents; Cells, Cultured; Dose-Response Relationship, Drug; Hair;

2004
Hair loss remedies--separating fact from fiction.
    Cutis, 2004, Volume: 73, Issue:2

    Topics: Alopecia; Azasteroids; Dietary Supplements; Dutasteride; Enzyme Inhibitors; Female; Finasteride; Hum

2004
Pharmacologic management of pattern hair loss.
    Facial plastic surgery clinics of North America, 2004, Volume: 12, Issue:2

    Topics: Administration, Topical; Alopecia; Androgen Antagonists; Dose-Response Relationship, Drug; Drug Admi

2004
[Pathomechanism of androgenetic alopecia and new treatment].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2004, Volume: 41, Issue:6

    Topics: Alopecia; Androgens; Animals; Coculture Techniques; Finasteride; Hair Follicle; Humans; Insulin-Like

2004
Androgenetic alopecia and current methods of treatment.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2005, Volume: 14, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Enzyme Inhibitors; Female; Finasteride; Hair; Hair Follicle;

2005
Psychological effect, pathophysiology, and management of androgenetic alopecia in men.
    Mayo Clinic proceedings, 2005, Volume: 80, Issue:10

    Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil

2005
Rapqunzel no more. Hair loss in older women.
    Advance for nurse practitioners, 2005, Volume: 13, Issue:10

    Topics: Age Factors; Aging; Alopecia; Diagnosis, Differential; Diet; Female; Hair; Hair Preparations; Humans

2005
[The treatment of female pattern hair loss].
    Duodecim; laaketieteellinen aikakauskirja, 2006, Volume: 122, Issue:2

    Topics: Administration, Oral; Administration, Topical; Adult; Age Distribution; Alopecia; Female; Finland; F

2006
Androgenetic alopecia.
    Endocrinology and metabolism clinics of North America, 2007, Volume: 36, Issue:2

    Topics: Alopecia; Androgens; Comorbidity; Finasteride; Humans; Male; Minoxidil; Models, Biological; Prevalen

2007
Clinical practice. Hair loss in women.
    The New England journal of medicine, 2007, Oct-18, Volume: 357, Issue:16

    Topics: Alopecia; Androgen Antagonists; Female; Hair; Humans; Middle Aged; Minoxidil; Practice Guidelines as

2007
Female pattern hair loss: current treatment concepts.
    Clinical interventions in aging, 2007, Volume: 2, Issue:2

    Topics: Alopecia; Androgen Antagonists; Female; Hair Preparations; Humans; Minoxidil

2007
[Hair follicle regeneration].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:5

    Topics: Alopecia; Animals; Cell- and Tissue-Based Therapy; Dermis; Finasteride; Hair; Hair Follicle; Humans;

2008
Female androgenetic alopecia: an update.
    The Australasian journal of dermatology, 1995, Volume: 36, Issue:2

    Topics: Alopecia; Androgens; Cyproterone Acetate; Female; Humans; Minoxidil; Prognosis; Spironolactone

1995
Status of medical treatment for androgenetic alopecia.
    International journal of dermatology, 1993, Volume: 32, Issue:10

    Topics: Alopecia; Female; Humans; Male; Minoxidil

1993
Minoxidil. Update on its clinical role.
    Dermatologic clinics, 1993, Volume: 11, Issue:1

    Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil

1993
[The therapy of androgenetic alopecia with minoxidil].
    Deutsche medizinische Wochenschrift (1946), 1993, May-28, Volume: 118, Issue:21

    Topics: Alopecia; Drug Evaluation; Female; Humans; Male; Minoxidil

1993
[Current treatment of androgenetic male and female alopecia (with the exception of hormone treatment)].
    Praxis, 1997, Jun-04, Volume: 86, Issue:23

    Topics: Alopecia; Androgen Antagonists; Androgens; Female; Hair; Humans; Male; Minoxidil; Prognosis; Vitamin

1997
[Male alopecia: etiopathogenic concepts and current therapies].
    Revue medicale de Liege, 1997, Volume: 52, Issue:8

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Female; Finasteride; Humans; Inflammation; Male; Minoxidil;

1997
Hair regrowth. Therapeutic agents.
    Dermatologic clinics, 1998, Volume: 16, Issue:2

    Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Androgen Antagon

1998
[Androgenetic alopecia].
    Annales de dermatologie et de venereologie, 1997, Volume: 124, Issue:1

    Topics: Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Minoxidil; Treatment Outcome; Vasodilator Ag

1997
Male pattern androgenetic alopecia.
    BMJ (Clinical research ed.), 1998, Sep-26, Volume: 317, Issue:7162

    Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Alopecia; Androgens; Antihypertens

1998
Understanding and managing common baldness.
    Australian family physician, 1999, Volume: 28, Issue:3

    Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Female; Finasteride; Hair; Humans; Incidence; M

1999
Medical treatments for balding in men.
    American family physician, 1999, Apr-15, Volume: 59, Issue:8

    Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Patient Education as Topic; Severity of Illnes

1999
Androgenetic alopecia.
    International journal of dermatology, 1999, Volume: 38 Suppl 1

    Topics: Alopecia; Female; Finasteride; Humans; Male; Minoxidil

1999
Management of androgenetic alopecia.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 1999, Volume: 12, Issue:3

    Topics: Alopecia; Androgen Antagonists; Female; Humans; Male; Minoxidil

1999
Treatment of hair loss.
    The New England journal of medicine, 1999, Sep-23, Volume: 341, Issue:13

    Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Alopecia Areata; Anthralin; Anti-In

1999
The psychosocial consequences of androgenetic alopecia: a review of the research literature.
    The British journal of dermatology, 1999, Volume: 141, Issue:3

    Topics: Alopecia; Body Image; Culture; Enzyme Inhibitors; Female; Finasteride; Humans; Interpersonal Relatio

1999
Current management of androgenetic alopecia in men.
    European journal of dermatology : EJD, 1999, Volume: 9, Issue:8

    Topics: Alopecia; Androgen Antagonists; Humans; Male; Minoxidil

1999
Finasteride revisited: Proscar for the prostate and Propecia for the pate.
    Harvard men's health watch, 2000, Volume: 4, Issue:12

    Topics: Adrenergic alpha-Antagonists; Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Minoxidil; Pro

2000
[Drug treatment of androgenetic alopecia in men].
    Pharmazie in unserer Zeit, 2000, Volume: 29, Issue:3

    Topics: Adult; Alopecia; Finasteride; Humans; Male; Minoxidil

2000
Male pattern baldness.
    Southern medical journal, 2000, Volume: 93, Issue:7

    Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Age of Onset; Alopecia; Coronary Disease; E

2000
Medical management of male pattern hair loss.
    International journal of dermatology, 2000, Volume: 39, Issue:8

    Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hair Follicle; Humans; Minoxidil

2000
Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.
    Drugs, 2001, Volume: 61, Issue:1

    Topics: Adrenal Cortex Hormones; Alopecia; Animals; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fi

2001
Hair loss.
    Indian journal of medical sciences, 2000, Volume: 54, Issue:3

    Topics: Adult; Alopecia; Child; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Finasteride; Hu

2000
Management of male pattern hair loss.
    Cutis, 2001, Volume: 68, Issue:1

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Alopecia; Enzyme Inhibitors; Finasteride; H

2001
Baldness. Medical solutions for men and women.
    Mayo Clinic health letter (English ed.), 2001, Volume: 19, Issue:11

    Topics: Alopecia; Enzyme Inhibitors; Female; Finasteride; Hair; Humans; Male; Minoxidil; Scalp; Sex Factors;

2001
Androgenetic alopecia: overview.
    Journal of cutaneous medicine and surgery, 1999, Volume: 3 Suppl 3

    Topics: Alopecia; Androgens; Enzyme Inhibitors; Female; Finasteride; Humans; Male; Minoxidil; Nonprescriptio

1999
[Loss of hair].
    Duodecim; laaketieteellinen aikakauskirja, 2000, Volume: 116, Issue:7

    Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Enzyme Inhibitors; Female; Finasteride; Hair; H

2000
Quantitative models for the study of hair growth in vivo.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Aging; Alopecia; Animals; Diazoxide; DNA Replication; Hair; Humans; Macaca; Minoxidil; Models, Biolo

1991
Cosmetic modalities for aging skin: what to tell patients.
    Geriatrics, 1990, Volume: 45, Issue:9

    Topics: Aged; Alopecia; Collagen; Cryosurgery; Dermabrasion; Humans; Minoxidil; Skin Aging; Skin Diseases; T

1990
Topical minoxidil does little for baldness.
    Drug and therapeutics bulletin, 1989, Sep-18, Volume: 27, Issue:19

    Topics: Administration, Topical; Alopecia; Humans; Minoxidil

1989
Topical minoxidil: review of efficacy and safety.
    Cutis, 1989, Volume: 43, Issue:1

    Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Consumer Produ

1989
Hair loss. What causes it and what can be done about it.
    Postgraduate medicine, 1989, May-01, Volume: 85, Issue:6

    Topics: Adult; Age Factors; Alopecia; Contraceptives, Oral; Dihydrotestosterone; Female; Hair; Humans; Male;

1989
[Minoxidil. Objectivity and criticism].
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 1989, Volume: 124, Issue:9

    Topics: Alopecia; Cell Differentiation; Cells, Cultured; Hair; Humans; Keratinocytes; Minoxidil; Skin; Vasod

1989
[New therapeutic aspects in non-cicatricial alopecias].
    Zeitschrift fur Hautkrankheiten, 1988, Aug-15, Volume: 63, Issue:8

    Topics: Alopecia; Alopecia Areata; Androgen Antagonists; Autoimmune Diseases; Humans; Minoxidil

1988
[The tractiophototrichogram, an objective method for evaluating hair loss].
    Annales de dermatologie et de venereologie, 1988, Volume: 115, Issue:6-7

    Topics: Alopecia; Hair; Humans; Male; Minoxidil; Photography

1988
[Topical minoxidil in the treatment of alopecia].
    Harefuah, 1988, Volume: 115, Issue:3-4

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil

1988
Topical minoxidil therapy for hair regrowth.
    Clinical pharmacy, 1987, Volume: 6, Issue:5

    Topics: Administration, Cutaneous; Alopecia; Animals; Clinical Trials as Topic; Humans; Male; Minoxidil; Ski

1987
Hair follicle biology and topical minoxidil: possible mechanisms of action.
    Dermatologica, 1987, Volume: 175 Suppl 2

    Topics: Administration, Cutaneous; Alopecia; Female; Hair; Humans; Male; Minoxidil

1987
Topical minoxidil in the treatment of male pattern alopecia.
    Pharmacotherapy, 1987, Volume: 7, Issue:6

    Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil

1987
Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.
    Drugs, 1987, Volume: 33, Issue:2

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil

1987
Topically applied minoxidil in baldness.
    International journal of dermatology, 1985, Volume: 24, Issue:2

    Topics: Administration, Topical; Alopecia; Animals; Biopsy; Double-Blind Method; Drug Evaluation; Drug Evalu

1985

Trials

125 trials available for minoxidil and Alopecia

ArticleYear
A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.
    Dermatologic therapy, 2021, Volume: 34, Issue:6

    Topics: Administration, Topical; Alopecia; Double-Blind Method; Female; Hair; Humans; Minoxidil; Tablets

2021
Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:9

    Topics: Alopecia; Fibroblast Growth Factor 2; Finasteride; Humans; Male; Minoxidil; Treatment Outcome

2022
Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:2

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Treatment Outcome

2022
Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:10

    Topics: Administration, Topical; Alopecia; Finasteride; Flutamide; Humans; Minoxidil; Treatment Outcome

2022
Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:10

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Capsaicin; Curcumin; Humans; Minoxidil

2022
Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:10

    Topics: Administration, Topical; Alopecia; Double-Blind Method; Dutasteride; Finasteride; Humans; Minoxidil;

2022
A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Alopecia; Botulinum Toxins, Type A; Finasteride; Humans; Minoxidil; Treatment Outcome

2022
Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata.
    Dermatologic therapy, 2022, Volume: 35, Issue:9

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Gels; Humans; Methotrexate; Minoxidil; Treatment

2022
Topical cetirizine for treating androgenetic alopecia: A systematic review.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil; Treatment Outcome

2022
Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:12

    Topics: Administration, Topical; Alopecia; East Asian People; Female; Hair; Humans; Minoxidil; Treatment Out

2022
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
    Dermatologic therapy, 2022, Volume: 35, Issue:12

    Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Betamethasone; Double-Blind Method; Femal

2022
Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study.
    Archives of dermatological research, 2023, Volume: 315, Issue:5

    Topics: Administration, Topical; Alopecia; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Fema

2023
EVALUATION OF THE EFFECT OF TOPICALLY APPLIED METHYLSULFONYLMETHANE AND THEIR COMBINATION WITH MINOXIDIL SOLUTION FOR IMPROVEMENT OF HAIR GROWTH IN MALE MICE.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2022, Volume: 75, Issue:11 pt 2

    Topics: Alopecia; Animals; Male; Mice; Minoxidil; Vascular Endothelial Growth Factor A

2022
Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial.
    The Journal of dermatological treatment, 2023, Volume: 34, Issue:1

    Topics: Alopecia; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma; Treatment Outcome

2023
Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:7

    Topics: Alopecia; Fibroblast Growth Factor 2; Humans; Minoxidil; Platelet-Rich Plasma; Prospective Studies;

2023
Injections of platelet-rich plasma prepared by automatic blood cell separator combined with topical 5% minoxidil in the treatment of male androgenetic alopecia.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:7

    Topics: Alopecia; Blood Cells; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma; Treatment Outcome

2023
Topical 5% minoxidil versus combined erbium YAG laser and topical 5% minoxidil in androgenetic alopecia: A randomized controlled trial.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:10

    Topics: Administration, Cutaneous; Administration, Topical; Alopecia; Humans; Lasers, Solid-State; Male; Min

2023
Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial.
    Stem cell research & therapy, 2023, 08-21, Volume: 14, Issue:1

    Topics: Adipocytes; Alopecia; Culture Media, Conditioned; Drug-Related Side Effects and Adverse Reactions; H

2023
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia.
    Journal of drugs in dermatology : JDD, 2023, 09-01, Volume: 22, Issue:9

    Topics: Alopecia; Hair; Humans; Male; Minoxidil; Platelet-Rich Plasma

2023
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.
    The Journal of dermatological treatment, 2021, Volume: 32, Issue:2

    Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Minoxidil; Patien

2021
Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.
    Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:1

    Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alopecia; Dermatologic Age

2020
A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2020, Volume: 46, Issue:6

    Topics: Administration, Topical; Adult; Aerosols; Alopecia; Cross-Over Studies; Double-Blind Method; Female;

2020
Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2020, Volume: 26, Issue:4

    Topics: Administration, Topical; Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outc

2020
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
    The Journal of dermatological treatment, 2022, Volume: 33, Issue:1

    Topics: Administration, Topical; Alopecia; China; Hair; Humans; Male; Minoxidil; Treatment Outcome; Wnt Sign

2022
Propylene glycol free 5% minoxidil lotion formulation: cosmetic acceptability, local tolerability, clinical efficacy and in-vitro skin absorption evaluations.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2020, Volume: 155, Issue:3

    Topics: Administration, Topical; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Propylene Glycol; P

2020
Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata.
    The Journal of dermatological treatment, 2022, Volume: 33, Issue:2

    Topics: Alopecia; Alopecia Areata; Humans; Injections, Intradermal; Minoxidil; Prospective Studies; Triamcin

2022
Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia.
    International journal of molecular sciences, 2020, Sep-06, Volume: 21, Issue:18

    Topics: Adult; Alopecia; Biopsy; Cell Count; Cell Proliferation; Combined Modality Therapy; Hair; Hair Folli

2020
Efficacy and safety of a novel herbal solution for the treatment of androgenetic alopecia and comparison with 5% minoxidil: A double-blind, randomized controlled trial study.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Herbal Medicine; Humans; Iran; Male;

2020
Combination therapy with topical minoxidil and nano-microneedle-assisted fibroblast growth factor for male androgenetic alopecia: a randomized controlled trial in Chinese patients.
    Chinese medical journal, 2020, Nov-05, Volume: 134, Issue:7

    Topics: Administration, Topical; Alopecia; China; Double-Blind Method; Fibroblast Growth Factors; Hair; Huma

2020
Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: A randomized, placebo-controlled trial.
    Dermatologic therapy, 2021, Volume: 34, Issue:1

    Topics: Administration, Topical; Alopecia; Double-Blind Method; Female; Hair; Humans; Injections, Intraderma

2021
A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.
    Dermatologic therapy, 2021, Volume: 34, Issue:1

    Topics: Administration, Topical; Alopecia; Drug Therapy, Combination; Hair; Humans; Minoxidil; Scalp; Spiron

2021
Pumpkin seed oil vs. minoxidil 5% topical foam for the treatment of female pattern hair loss: A randomized comparative trial.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:9

    Topics: Alopecia; Cucurbita; Female; Hair; Humans; Minoxidil; Plant Oils

2021
Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2021, Volume: 24

    Topics: Administration, Topical; Adult; Alopecia; Cetirizine; Histamine Antagonists; Humans; Male; Minoxidil

2021
Efficacy of Minoxidil Combined With Photobiomodulation for the Treatment of Male Androgenetic Alopecia. A Double-Blind Half-Head Controlled Trial.
    Lasers in surgery and medicine, 2021, Volume: 53, Issue:9

    Topics: Alopecia; Double-Blind Method; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outcome

2021
SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:1

    Topics: Administration, Topical; Alopecia; Arylsulfotransferase; Hair; Humans; Male; Minoxidil; Sulfotransfe

2022
Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:1

    Topics: Alopecia; Double-Blind Method; Female; Hair; Humans; Male; Minoxidil; Treatment Outcome

2022
Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: A randomized controlled study.
    Lasers in surgery and medicine, 2017, Volume: 49, Issue:9

    Topics: Adult; Alopecia; Combined Modality Therapy; Female; Humans; Low-Level Light Therapy; Microscopy, Aco

2017
Platelet-Rich Plasma in Combination With 5% Minoxidil Topical Solution and 1 mg Oral Finasteride for the Treatment of Androgenetic Alopecia: A Randomized Placebo-Controlled, Double-Blind, Half-Head Study.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2018, Volume: 44, Issue:1

    Topics: Administration, Topical; Alopecia; Angiogenesis Inducing Agents; Double-Blind Method; Drug Therapy,

2018
An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.
    Skin pharmacology and physiology, 2017, Volume: 30, Issue:6

    Topics: Administration, Topical; Adult; Alopecia; Caffeine; Humans; Male; Middle Aged; Minoxidil; Treatment

2017
The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study.
    Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2018, Volume: 20, Issue:1

    Topics: Administration, Cutaneous; Adult; Alopecia; Drug Delivery Systems; Hair; Humans; Male; Middle Aged;

2018
A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2017, Volume: 100, Issue:1

    Topics: Administration, Topical; Adult; Aged; Alopecia; Butylene Glycols; Emollients; Humans; Male; Middle A

2017
A pilot split-scalp study of combined fractional radiofrequency microneedling and 5% topical minoxidil in treating male pattern hair loss.
    Clinical and experimental dermatology, 2018, Volume: 43, Issue:7

    Topics: Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Cosmetic Techniques; Humans; Ma

2018
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:12

    Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adult; Alopecia; Dihydrotestosterone; Doubl

2018
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study.
    American journal of clinical dermatology, 2019, Volume: 20, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Aged; Alopecia; Dihydro

2019
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
    Lasers in medical science, 2019, Volume: 34, Issue:9

    Topics: Administration, Cutaneous; Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Glas

2019
Comparing the Efficacy of Mesotherapy to Topical Minoxidil in the Treatment of Female Pattern Hair Loss Using Ultrasound Biomicroscopy: A Randomized Controlled Trial.
    Acta dermatovenerologica Croatica : ADC, 2019, Volume: 27, Issue:1

    Topics: Administration, Topical; Adult; Alopecia; Female; Humans; Mesotherapy; Microscopy, Acoustic; Middle

2019
Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Adolescent; Adult; Alopecia; Antihypertensive Agents; Double-Blind Method; Drug Stability; Emulsions

2013
Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions on male androgenetic alopecia and measuring patient satisfaction rate.
    Acta dermatovenerologica Croatica : ADC, 2013, Volume: 21, Issue:3

    Topics: Adenosine; Alopecia; Humans; Minoxidil; Patient Satisfaction; Prospective Studies; Vasodilator Agent

2013
Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with androgenetic alopecia: a microarray analysis.
    The British journal of dermatology, 2015, Volume: 172, Issue:6

    Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Controlled Before-After Studies; Dermatologi

2015
A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men.
    Skin pharmacology and physiology, 2015, Volume: 28, Issue:5

    Topics: Administration, Cutaneous; Adult; Aged; Alopecia; Double-Blind Method; Hair; Humans; Male; Middle Ag

2015
Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:7

    Topics: Administration, Topical; Alopecia; Double-Blind Method; Humans; Male; Minoxidil; Placebos

2016
Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2016, Volume: 25, Issue:3

    Topics: Administration, Topical; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Patient Satisfaction

2016
Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.
    The Journal of dermatology, 2009, Volume: 36, Issue:8

    Topics: Adult; Alopecia; Asian People; Double-Blind Method; Hair; Humans; Japan; Male; Middle Aged; Minoxidi

2009
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:6

    Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Middle Aged; Minoxidil; Pharmac

2011
Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study.
    The Journal of dermatological treatment, 2012, Volume: 23, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Curcuma; Double-Blind Method; Drug Therapy, Combinati

2012
[Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study].
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2011, Volume: 146, Issue:6 Suppl 1

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Alopecia; Dermatologic Agents; Dermoscopy; Drug

2011
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:10

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas

2012
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:10

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas

2012
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:10

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas

2012
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:10

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Double-Blind Method; Drug Therapy, Combination; Finas

2012
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
    Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:3

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Drug Tolerance; Humans; M

2002
Comparative efficacy of various treatment regimens for androgenetic alopecia in men.
    The Journal of dermatology, 2002, Volume: 29, Issue:8

    Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Adolescent; Adult; Alop

2002
[Effect of minoxidil on hair growth in androgenic alopecia in women].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002, Volume: 13, Issue:75

    Topics: Administration, Cutaneous; Adult; Alopecia; Female; Hair; Humans; Middle Aged; Minoxidil; Time Facto

2002
The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial.
    The British journal of dermatology, 2003, Volume: 149, Issue:2

    Topics: Adolescent; Adult; Alopecia; Analysis of Variance; Drug Therapy, Combination; Fiber Optic Technology

2003
A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
    Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Female; Hair; Humans; Mid

2004
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
    Dermatology (Basel, Switzerland), 2004, Volume: 209, Issue:2

    Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Alopecia; Analysis of Variance; Do

2004
Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:5

    Topics: Administration, Topical; Alopecia; Drug Eruptions; Estradiol; Female; Germany; Hair; Humans; Middle

2007
[Effectiveness of the treatment plan for androgenetic alopecia].
    Georgian medical news, 2007, Issue:145

    Topics: Adolescent; Adult; Alopecia; Antifungal Agents; Chronic Disease; Enzyme Inhibitors; Female; Finaster

2007
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
    Journal of the American Academy of Dermatology, 2007, Volume: 57, Issue:5

    Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Middle Aged; Mino

2007
Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial.
    American journal of clinical dermatology, 2007, Volume: 8, Issue:5

    Topics: Administration, Topical; Adult; Alopecia; Dermatologic Agents; Double-Blind Method; Drug Therapy, Co

2007
Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice?
    The Journal of dermatological treatment, 2007, Volume: 18, Issue:5

    Topics: Administration, Topical; Adult; Alopecia; Dermatologic Agents; Humans; Male; Minoxidil; Patient Drop

2007
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
    The British journal of dermatology, 2008, Volume: 158, Issue:1

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Estradiol; Estrogen Antagonists; Female;

2008
Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography.
    The Journal of investigative dermatology, 1984, Volume: 82, Issue:5

    Topics: Administration, Topical; Adult; Aged; Alopecia; Blood Flow Velocity; Clinical Trials as Topic; Doubl

1984
Topical minoxidil for hair regrowth.
    Journal of the American Academy of Dermatology, 1984, Volume: 11, Issue:3

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Alopecia Areata; Androgens; Clinical Trials as

1984
Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:8

    Topics: Adult; Aged; Alopecia; Double-Blind Method; Doxorubicin; Female; Humans; Middle Aged; Minoxidil; Neo

1994
Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation.
    Journal of the American Academy of Dermatology, 1993, Volume: 29, Issue:5 Pt 1

    Topics: Administration, Cutaneous; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antigens, CD; CD4 Antigens

1993
Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
    Archives of dermatology, 1994, Volume: 130, Issue:3

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Female; Humans; Middle Ag

1994
Use of topical minoxidil therapy for androgenetic alopecia in women.
    International journal of dermatology, 1993, Volume: 32, Issue:10

    Topics: Administration, Cutaneous; Adolescent; Adult; Age Factors; Alopecia; Dermatitis, Contact; Double-Bli

1993
Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group.
    International journal of dermatology, 1993, Volume: 32, Issue:10

    Topics: Administration, Cutaneous; Adult; Age Factors; Alopecia; Hair; Humans; Male; Middle Aged; Middle Eas

1993
A randomized trial of minoxidil in chemotherapy-induced alopecia.
    Journal of the American Academy of Dermatology, 1996, Volume: 35, Issue:1

    Topics: Administration, Cutaneous; Adult; Alopecia; Antibiotics, Antineoplastic; Antimetabolites, Antineopla

1996
Propecia and Rogaine Extra Strength for alopecia.
    The Medical letter on drugs and therapeutics, 1998, Feb-27, Volume: 40, Issue:1021

    Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Alopecia; Clinical Trials as Topic; Drug Costs; Enz

1998
Ketoconazole shampoo: effect of long-term use in androgenic alopecia.
    Dermatology (Basel, Switzerland), 1998, Volume: 196, Issue:4

    Topics: Adult; Alopecia; Analysis of Variance; Antifungal Agents; Drug Therapy, Combination; Hair; Hair Prep

1998
Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment.
    Journal of the American Academy of Dermatology, 1999, Volume: 41, Issue:5 Pt 1

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Double-Blind Method; Hair; Humans; Male; Minox

1999
Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
    The British journal of dermatology, 2002, Volume: 146, Issue:6

    Topics: Administration, Topical; Adult; Alopecia; Androgen Antagonists; Body Mass Index; Contraceptives, Ora

2002
Treatment of female androgenetic alopecia with minoxidil 2%.
    International journal of dermatology, 1992, Volume: 31, Issue:11

    Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Female; Humans; Minoxidil; Scalp

1992
Contact dermatitis in reaction to 2% topical minoxidil solution.
    Journal of the American Academy of Dermatology, 1991, Volume: 24, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Contact; Double-Blind Method; Drug Eruptions;

1991
Psychologic characteristics of men with alopecia androgenetica and their modification.
    International journal of dermatology, 1991, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Alopecia; Attitude; Humans; Interpersonal Relations; Male; Middle Aged; Minoxidil

1991
Australian trial of topical minoxidil and placebo in early male pattern baldness.
    The Australasian journal of dermatology, 1990, Volume: 31, Issue:1

    Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Australia; Double-Blind Method; Humans; Male

1990
[Efficacy and cardiovascular tolerability of minotricon in the treatment of seborrheic alopecia].
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 1990, Volume: 125, Issue:10

    Topics: Adolescent; Adult; Alopecia; Dermatitis, Seborrheic; Drug Tolerance; Female; Humans; Male; Middle Ag

1990
Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil.
    Journal of the American Academy of Dermatology, 1990, Volume: 22, Issue:4

    Topics: Administration, Cutaneous; Adult; Alopecia; Drug Administration Schedule; Follow-Up Studies; Humans;

1990
[A critical review of the results of clinical experimentation with topical minoxidil 2%].
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 1990, Volume: 125, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Double-Blind Method; Humans; Male; Middle Aged; Minoxidil;

1990
Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil.
    The Journal of investigative dermatology, 1990, Volume: 95, Issue:6

    Topics: Adolescent; Adult; Alopecia; Double-Blind Method; Female; Hair; Humans; Middle Aged; Minoxidil

1990
Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution.
    Journal of pharmaceutical sciences, 1990, Volume: 79, Issue:6

    Topics: Administration, Topical; Adult; Alopecia; Chromatography, High Pressure Liquid; Humans; Male; Middle

1990
[It is difficult to predict the effect of minoxidil liniment on hair loss in men].
    Lakartidningen, 1990, Jan-10, Volume: 87, Issue:1-2

    Topics: Alopecia; Drug Evaluation; Humans; Liniments; Male; Minoxidil; Randomized Controlled Trials as Topic

1990
Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study.
    Acta dermato-venereologica, 1988, Volume: 68, Issue:3

    Topics: Administration, Cutaneous; Adult; Alopecia; Female; Humans; Lasers; Male; Middle Aged; Minoxidil; Re

1988
Topical minoxidil: review of efficacy and safety.
    Cutis, 1989, Volume: 43, Issue:1

    Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Consumer Produ

1989
Why men with hair loss go to the doctor.
    Psychological reports, 1989, Volume: 65, Issue:1

    Topics: Alopecia; Clinical Trials as Topic; Humans; Male; Minoxidil; Referral and Consultation

1989
[Minoxidil: no hope for bald people].
    Nederlands tijdschrift voor geneeskunde, 1989, Jul-22, Volume: 133, Issue:29

    Topics: Alopecia; Double-Blind Method; Humans; Minoxidil; Multicenter Studies as Topic

1989
Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness.
    Clinical and experimental dermatology, 1989, Volume: 14, Issue:1

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1989
Topical minoxidil sensitization in androgenic alopecia.
    Contact dermatitis, 1987, Volume: 17, Issue:1

    Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Drug Eruptions; Hu

1987
[Minoxidil--a hope for patients with androgen alopecia?].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1988, Oct-10, Volume: 108, Issue:28

    Topics: Adolescent; Adult; Alopecia; Androgens; Clinical Trials as Topic; Humans; Male; Middle Aged; Minoxid

1988
Topical minoxidil: cardiac effects in bald man.
    British journal of clinical pharmacology, 1988, Volume: 26, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Blood Pressure; Double-Blind Method; Heart; He

1988
Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:5 Pt 1

    Topics: Adult; Alopecia; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male;

1987
Topical minoxidil in male pattern baldness: effects of discontinuation of treatment.
    Journal of the American Academy of Dermatology, 1987, Volume: 17, Issue:1

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Dose-Response Relationship, Drug

1987
Topical minoxidil for baldness.
    The Medical letter on drugs and therapeutics, 1987, Sep-25, Volume: 29, Issue:749

    Topics: Administration, Cutaneous; Alopecia; Alopecia Areata; Clinical Trials as Topic; Humans; Male; Minoxi

1987
Topical minoxidil therapy for hair regrowth.
    Clinical pharmacy, 1987, Volume: 6, Issue:5

    Topics: Administration, Cutaneous; Alopecia; Animals; Clinical Trials as Topic; Humans; Male; Minoxidil; Ski

1987
Topical minoxidil therapy for androgenetic alopecia. A 30-month study.
    Archives of dermatology, 1987, Volume: 123, Issue:11

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Hair; Human

1987
2% topical minoxidil solution in male-pattern baldness: preliminary European results.
    Dermatologica, 1987, Volume: 175 Suppl 2

    Topics: Administration, Cutaneous; Adult; Alopecia; Clinical Trials as Topic; Dermatitis, Contact; Double-Bl

1987
Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia.
    Journal of the American Academy of Dermatology, 1988, Volume: 18, Issue:5 Pt 1

    Topics: Adolescent; Adult; Alopecia; Double-Blind Method; Drug Administration Schedule; Gels; Humans; Male;

1988
Topical minoxidil for male pattern baldness.
    The American journal of the medical sciences, 1986, Volume: 291, Issue:5

    Topics: Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Female; Hair; Humans; Male; Middle A

1986
Androgenetic alopecia treated with topical minoxidil.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mino

1987
Dose-response study of topical minoxidil in male pattern alopecia.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Dose-Response Relationship, Drug

1987
Safety and efficacy of topical minoxidil in the management of androgenetic alopecia.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Blood Pressure; Clinical Trials as Topic; Double-Blind Met

1987
Long-term follow-up of men with male pattern baldness treated with topical minoxidil.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Drug Administration Schedule; Fo

1987
Androgenetic alopecia: treatment results with topical minoxidil.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1987
Use of topical minoxidil in the treatment of male pattern baldness.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1987
Long-term efficacy of topical minoxidil in male pattern baldness.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1987
Topical minoxidil in early androgenetic alopecia.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1987
Deaths occurring during clinical studies of topical minoxidil.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Aged; Alopecia; Clinical Trials as Topic; Female; Humans; Male; Midd

1987
Topical minoxidil therapy for hereditary male pattern alopecia.
    Cutis, 1987, Volume: 39, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Clinical Trials as Topic; Follow-Up Stud

1987
Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection.
    Dermatologica, 1987, Volume: 175 Suppl 2

    Topics: Administration, Cutaneous; Alopecia; Double-Blind Method; Humans; Male; Minoxidil

1987
Topical minoxidil in the treatment of alopecia areata and male-pattern alopecia.
    Archives of dermatology, 1986, Volume: 122, Issue:5

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Female; Humans;

1986
Dose-response study of topical minoxidil in male pattern baldness.
    Journal of the American Academy of Dermatology, 1986, Volume: 15, Issue:1

    Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Humans;

1986
Topical tretinoin for hair growth promotion.
    Journal of the American Academy of Dermatology, 1986, Volume: 15, Issue:4 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Drug Combinations; Female; Hair; Humans; Male; Middle Aged

1986
Topical minoxidil therapy in hereditary androgenetic alopecia.
    Archives of dermatology, 1985, Volume: 121, Issue:2

    Topics: Administration, Topical; Alopecia; Clinical Trials as Topic; Double-Blind Method; Hair; Humans; Male

1985
Topical minoxidil in early male pattern baldness.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:2 Pt 1

    Topics: Administration, Topical; Adult; Alopecia; Clinical Trials as Topic; Double-Blind Method; Humans; Mal

1985
The effect of topical minoxidil on blood pressure.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Blood Pressure; Clinical Trials as Topic; Double-Blind Met

1985
Topical minoxidil dose-response effect in alopecia areata.
    Archives of dermatology, 1986, Volume: 122, Issue:2

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Child; Dose-Response Relationship, Drug; Femal

1986

Other Studies

357 other studies available for minoxidil and Alopecia

ArticleYear
Thyroid receptor agonists for the treatment of androgenetic alopecia.
    Bioorganic & medicinal chemistry letters, 2010, Jan-01, Volume: 20, Issue:1

    Topics: Administration, Topical; Alopecia; Animals; BALB 3T3 Cells; Hair; Humans; Macaca; Mice; Neutral Red;

2010
Low-dose oral minoxidil increases hair density and thickness in androgenetic alopecia: a retrospective analysis of 60 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:3

    Topics: Alopecia; Hair; Humans; Minoxidil; Retrospective Studies; Treatment Outcome

2022
Minoxidil-induced hypertrichosis in a breastfed infant.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:3

    Topics: Alopecia; Breast Feeding; Female; Humans; Hypertension; Hypertrichosis; Infant; Minoxidil

2022
Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:2

    Topics: Administration, Topical; Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Re

2022
Systemic minoxidil as maintenance treatment in alopecia areata: a retrospective case series of 24 patients.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:4

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Hair; Humans; Immunotherapy; Minoxidil; Retrospe

2022
Frontal edema due to mesotherapy for androgenetic alopecia: A case series.
    Dermatologic therapy, 2022, Volume: 35, Issue:2

    Topics: Alopecia; Edema; Female; Finasteride; Humans; Male; Mesotherapy; Minoxidil; Retrospective Studies; T

2022
Effect of minoxidil formulations on human scalp skin xenotransplants on SCID mice: A novel pre-clinical in vivo assay for androgenetic alopecia research.
    Experimental dermatology, 2022, Volume: 31, Issue:6

    Topics: Administration, Topical; Alopecia; Animals; Hair; Humans; Mice; Mice, SCID; Minoxidil; Scalp; Treatm

2022
Treatment with oral vitamin D alone, topical minoxidil, or combination of both in patients with female pattern hair loss: A comparative clinical and dermoscopic study.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:9

    Topics: Alopecia; Female; Hair; Humans; Minoxidil; Treatment Outcome; Vitamin D

2022
Comparative histological and immunohistochemical study on the effect of platelet rich plasma/minoxidil, alone or in combination, on hair growth in a rat model of androgenic alopecia.
    Tissue & cell, 2022, Volume: 75

    Topics: Alopecia; Animals; Hair Follicle; Humans; Male; Minoxidil; Platelet-Rich Plasma; Rats; Treatment Out

2022
Preparation of topical bimatoprost with enhanced skin infiltration and
    Drug delivery, 2022, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Animals; Antioxidants; Bimatoprost; Cell Proliferation; Dose-Resp

2022
Topical minoxidil-induced paresthesia.
    Dermatologic therapy, 2022, Volume: 35, Issue:4

    Topics: Administration, Topical; Alopecia; Double-Blind Method; Hair; Humans; Minoxidil; Paresthesia

2022
Hair Are the Rankings-5-α Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia.
    JAMA dermatology, 2022, 03-01, Volume: 158, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Hair; Humans; Male; Minoxidil

2022
Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2022, Volume: 172

    Topics: Administration, Topical; Alopecia; Animals; Drug Delivery Systems; Hair Follicle; Humans; Latanopros

2022
Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model.
    Acta biomaterialia, 2022, 04-15, Volume: 143

    Topics: Alopecia; Animals; Antineoplastic Agents; Disease Models, Animal; Hyaluronic Acid; Mice; Minoxidil

2022
Oral minoxidil use in androgenetic alopecia and telogen effluvium.
    Archives of dermatological research, 2023, Volume: 315, Issue:2

    Topics: Adult; Aged; Alopecia; Alopecia Areata; Female; Humans; Male; Middle Aged; Minoxidil; Retrospective

2023
Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:7

    Topics: Alopecia; Dutasteride; Humans; Male; Microinjections; Minoxidil; Retrospective Studies; Treatment Ou

2022
Reply to: "Comment on: Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:1

    Topics: Administration, Topical; Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Re

2022
Comment on "Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:1

    Topics: Alopecia; Anilides; Female; Humans; Hypertrichosis; Minoxidil; Nitriles; Retrospective Studies; Tosy

2022
Unusual clinical presentation of allergic contact dermatitis to topical minoxidil.
    Contact dermatitis, 2022, Volume: 87, Issue:2

    Topics: Administration, Topical; Alopecia; Dermatitis, Allergic Contact; Humans; Minoxidil; Patch Tests

2022
Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:3

    Topics: Alopecia; Alopecia Areata; Child; Humans; Minoxidil

2022
Morning Periorbital Edema Related to Low-Dose Oral Minoxidil.
    Actas dermo-sifiliograficas, 2023, Volume: 114, Issue:5

    Topics: Alopecia; Angioedema; Edema; Humans; Minoxidil

2023
Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:2

    Topics: Administration, Topical; Alopecia; Blood Pressure Monitoring, Ambulatory; Humans; Male; Minoxidil; P

2023
Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia: A retrospective chart review.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Retrospective Studies; Treatment Outcome; Vaso

2022
Treatment of hereditary hypotrichosis simplex of the scalp with oral minoxidil and growth factors.
    Dermatologic therapy, 2022, Volume: 35, Issue:9

    Topics: Alopecia; Humans; Hypotrichosis; Intercellular Signaling Peptides and Proteins; Minoxidil; Scalp

2022
Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:2

    Topics: Administration, Oral; Adolescent; Alopecia; Humans; Minoxidil; Retrospective Studies

2023
A Drug-Free, Hair Follicle Cycling Regulatable, Separable, Antibacterial Microneedle Patch for Hair Regeneration Therapy.
    Advanced healthcare materials, 2022, Volume: 11, Issue:19

    Topics: Alopecia; Animals; Anti-Bacterial Agents; Cells, Cultured; Chitosan; Hair; Hair Follicle; Hyaluronic

2022
Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Combined Modality Therapy; Hair; Humans; Minoxidil; Retrospective

2022
Conditioned media-integrated microneedles for hair regeneration through perifollicular angiogenesis.
    Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 350

    Topics: Alopecia; Animals; Culture Media, Conditioned; Hair; Hair Follicle; Mice; Minoxidil; Neovascularizat

2022
Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.
    International journal of dermatology, 2023, Volume: 62, Issue:2

    Topics: Administration, Topical; Adult; Alopecia; Child; Child, Preschool; Hair; Humans; Infant; Infant, New

2023
Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:6

    Topics: Administration, Topical; Alopecia; Blood Pressure Monitoring, Ambulatory; Controlled Before-After St

2022
Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:1

    Topics: Alopecia; Female; Humans; Lichen Planus; Minoxidil

2023
Active Antialopecia Chemical Identification of
    TheScientificWorldJournal, 2022, Volume: 2022

    Topics: Alopecia; Animals; Convolvulaceae; Humans; Minoxidil; Molecular Docking Simulation; Molecular Dynami

2022
Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Mal

2022
Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp.
    The American Journal of dermatopathology, 2022, Nov-01, Volume: 44, Issue:11

    Topics: Alopecia; Alopecia Areata; Glycyrrhizic Acid; Humans; Lipedema; Minoxidil; Scalp; Vitamin D

2022
Evaluation of efficacy of derma roller sizes vs topical application for administration of QR678 Neo® hair regrowth formulation in the treatment of androgenetic alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11

    Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Treatment Outcome

2022
What's New in Therapy for Male Androgenetic Alopecia?
    American journal of clinical dermatology, 2023, Volume: 24, Issue:1

    Topics: Alopecia; Dutasteride; Finasteride; Humans; Male; Minoxidil; Retrospective Studies; Treatment Outcom

2023
In Vitro and In Vivo Scalp Retention and Penetration of 99mTc-Minoxidil Solution.
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:1

    Topics: Administration, Topical; Alopecia; Excipients; Humans; Minoxidil; Propylene Glycol; Scalp; Skin; Ski

2023
A Survey of Patient Attitudes Towards Topical Minoxidil in the Treatment of Hair Loss.
    Journal of drugs in dermatology : JDD, 2022, Oct-01, Volume: 21, Issue:10

    Topics: Alopecia; Attitude; Dihydrotestosterone; Female; Humans; Male; Minoxidil; Scalp; Treatment Outcome

2022
Digital health platforms expand access and improve care for male androgenetic alopecia.
    International journal of dermatology, 2023, Volume: 62, Issue:2

    Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; Treatment Outcome

2023
Machine Learning Guided Discovery of Superoxide Dismutase Nanozymes for Androgenetic Alopecia.
    Nano letters, 2022, 11-09, Volume: 22, Issue:21

    Topics: Alopecia; Hair; Humans; Machine Learning; Minoxidil; Superoxide Dismutase

2022
Evaluating the Efficacy of Platelet Rich Plasma and 1550 nm Fractional Laser in Combination and Alone for the Management of Androgenetic Alopecia.
    Journal of drugs in dermatology : JDD, 2022, Nov-01, Volume: 21, Issue:11

    Topics: Alopecia; Female; Finasteride; Humans; Lasers, Solid-State; Male; Minoxidil; Platelet-Rich Plasma; T

2022
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Gene detection in a family with monilethrix and treatment with 5% topical minoxidil.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:1

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Monilethrix; Mothers; Mutation

2023
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:5

    Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect

2023
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:5

    Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect

2023
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:5

    Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect

2023
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study.
    Journal of the American Academy of Dermatology, 2023, Volume: 88, Issue:5

    Topics: Administration, Topical; Alopecia; Breast Neoplasms; Female; Humans; Minoxidil; Patients; Retrospect

2023
PROTAC Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration.
    Small methods, 2023, Volume: 7, Issue:1

    Topics: Administration, Topical; Adolescent; Alopecia; Androgens; Humans; Minoxidil; Proteolysis Targeting C

2023
In Brief: Oral minoxidil for hair loss.
    The Medical letter on drugs and therapeutics, 2022, 12-26, Volume: 64, Issue:1666

    Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome

2022
Allergic Contact Dermatitis Due to Minoxidil in a Patient with Alopecia Areata.
    Actas dermo-sifiliograficas, 2022, Volume: 113 Suppl 1

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Dermatitis, Allergic Contact; Humans; Minoxidil;

2022
Regrowth of hair in congenital triangular alopecia induced by sublingual minoxidil.
    The Australasian journal of dermatology, 2023, Volume: 64, Issue:1

    Topics: Administration, Topical; Alopecia; Genetic Diseases, X-Linked; Hair; Humans; Minoxidil

2023
Effects of oral minoxidil on nails: a cross-sectional analysis.
    International journal of dermatology, 2023, Volume: 62, Issue:9

    Topics: Alopecia; Cross-Sectional Studies; Humans; Minoxidil; Nails

2023
Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging.
    International journal of pharmaceutics, 2023, Mar-05, Volume: 634

    Topics: Alopecia; Hair; Humans; Microscopy, Confocal; Minoxidil; Skin

2023
Low-dose oral minoxidil improves hair density in traction alopecia.
    Journal of the American Academy of Dermatology, 2023, Volume: 89, Issue:1

    Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Traction; Treatment Outcome

2023
Topical Minoxidil Adherence in Patients With Alopecia.
    Journal of drugs in dermatology : JDD, 2023, Mar-01, Volume: 22, Issue:3

    Topics: Alopecia; Humans; Minoxidil; Patient Compliance; Social Group

2023
A case of aromatase inhibitor-induced alopecia successfully treated with low-dose oral minoxidil.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:8

    Topics: Administration, Topical; Alopecia; Aromatase Inhibitors; Humans; Minoxidil; Treatment Outcome

2023
Dissolving Microneedle Patch Integrated with Microspheres for Long-Acting Hair Regrowth Therapy.
    ACS applied materials & interfaces, 2023, Apr-12, Volume: 15, Issue:14

    Topics: Administration, Topical; Alopecia; Animals; Female; Hair; Mice; Microspheres; Minoxidil; Treatment O

2023
Could oral minoxidil be superior to its topical variant for treatment of female pattern hair loss?
    Italian journal of dermatology and venereology, 2023, Volume: 158, Issue:3

    Topics: Alopecia; Female; Humans; Minoxidil; Vasodilator Agents

2023
Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model.
    International journal of pharmaceutics, 2023, May-25, Volume: 639

    Topics: Alopecia; Animals; Antioxidants; Chitosan; Dextrans; Emulsions; Hair; Lecithins; Melatonin; Minoxidi

2023
Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss.
    JAMA network open, 2023, 05-01, Volume: 6, Issue:5

    Topics: Administration, Oral; Alopecia; Humans; Minoxidil

2023
The medicinal activity of lyophilized aqueous seed extract of Lepidium sativum L. in an androgenic alopecia model.
    Scientific reports, 2023, 05-11, Volume: 13, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Animals; Chromatography, Liquid; Hair; Lepidium sativum; Min

2023
Minoxidil and vitamin E therapy for nail growth disorders: A retrospective study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:10

    Topics: Alopecia; Distance Counseling; Humans; Minoxidil; Nail Diseases; Nails; Retrospective Studies; Vitam

2023
Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia.
    Journal of drugs in dermatology : JDD, 2023, Jun-01, Volume: 22, Issue:6

    Topics: Alopecia; Drug Administration Schedule; Female; Finasteride; Humans; Male; Minoxidil; Treatment Outc

2023
RF - Bicalutamide: An Emergent Treatment Option in Trichology.
    Actas dermo-sifiliograficas, 2023, Volume: 114, Issue:9

    Topics: Administration, Topical; Alopecia; Humans; Minoxidil; Treatment Outcome

2023
Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2023, 09-01, Volume: 49, Issue:9

    Topics: Alopecia; Drug-Related Side Effects and Adverse Reactions; Dutasteride; Humans; Mesotherapy; Minoxid

2023
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:12

    Topics: Alopecia; Alopecia Areata; Hair; Humans; Minoxidil; Quality of Life

2023
Retrospective review of oral and topical minoxidil for cancer treatment-induced hair loss.
    Archives of dermatological research, 2023, Volume: 315, Issue:9

    Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Neoplasms; Retrospective Studies; Treatm

2023
Sensitive Quantitative In Vivo Assay for Evaluating the Effects of Biomolecules on Hair Growth and Coloring Using Direct Microinjections into Mouse Whisker Follicles.
    Biomolecules, 2023, 07-05, Volume: 13, Issue:7

    Topics: Alopecia; Animals; Hair; Mice; Microinjections; Minoxidil; Vibrissae

2023
Fabrication of carboxymethyl cellulose/hyaluronic acid/polyvinylpyrrolidone composite pastes incorporation of minoxidil-loaded ferulic acid-derived lignin nanoparticles and valproic acid for treatment of androgenetic alopecia.
    International journal of biological macromolecules, 2023, Sep-30, Volume: 249

    Topics: Alopecia; Animals; Carboxymethylcellulose Sodium; Hyaluronic Acid; Lignin; Mice; Minoxidil; Nanopart

2023
Investigation of oral finasteride enhanced occipital hair diameter index in different types of male androgenetic alopecia.
    Journal of the American Academy of Dermatology, 2023, Volume: 89, Issue:6

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Finasteride; Hair; Humans; Male; Minoxidil

2023
New Target for Minoxidil in the Treatment of Androgenetic Alopecia.
    Drug design, development and therapy, 2023, Volume: 17

    Topics: Alopecia; Dietary Supplements; Estradiol; Humans; Minoxidil; Molecular Docking Simulation

2023
Co-delivery of minoxidil and tocopherol acetate ethosomes to reshape the hair Follicular Microenvironment and promote hair regeneration in androgenetic alopecia.
    International journal of pharmaceutics, 2023, Nov-05, Volume: 646

    Topics: Alopecia; alpha-Tocopherol; Animals; Hair; Mice; Minoxidil; Regeneration; Treatment Outcome

2023
Vellus-to-terminal Hair Follicle Reconversion Occurs in Male Pattern Balding and is Promoted by Minoxidil and Platelet-rich Plasma: In Vivo Evidence from a New Humanized Mouse Model of Androgenetic Alopecia.
    Acta dermato-venereologica, 2023, 10-18, Volume: 103

    Topics: Alopecia; Animals; Hair; Hair Follicle; Male; Mice; Minoxidil; Platelet-Rich Plasma; Treatment Outco

2023
Inverse androgenic alopecia.
    BMJ case reports, 2023, Oct-31, Volume: 16, Issue:10

    Topics: Alopecia; Androgen Antagonists; Finasteride; Humans; Male; Minoxidil; Treatment Outcome

2023
Low dose oral minoxidil and the conundrum of cardiovascular complications.
    Dermatology online journal, 2023, Aug-15, Volume: 29, Issue:4

    Topics: Administration, Topical; Alopecia; Antihypertensive Agents; Hair; Humans; Hypertrichosis; Minoxidil

2023
Increased prescriptions of oral minoxidil after a high-profile newspaper article about its benefits for hair loss.
    Dermatology online journal, 2023, 08-15, Volume: 29, Issue:4

    Topics: Administration, Topical; Alopecia; Hair; Humans; Minoxidil; Treatment Outcome

2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Nov-22, Volume: 31, Issue:12

    Topics: Administration, Cutaneous; Alopecia; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Mi

2023
Successful use of topical minoxidil in the treatment of hypotrichosis associated with desmoplakin mutations.
    Pediatric dermatology, 2019, Volume: 36, Issue:6

    Topics: Administration, Topical; Alopecia; Child; Dermatologic Agents; Desmoplakins; Genetic Diseases, X-Lin

2019
Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:1

    Topics: Administration, Oral; Alopecia; Female; Hair Follicle; Humans; Minoxidil; Sulfotransferases

2020
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:3

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines

2021
Reply to: "Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation".
    Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:1

    Topics: Alopecia; Documentation; Finasteride; Humans; Male; Minoxidil

2020
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation.
    Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:1

    Topics: Alopecia; Documentation; Finasteride; Humans; Male; Minoxidil

2020
Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6-year-old girl.
    International journal of dermatology, 2020, Volume: 59, Issue:4

    Topics: Alopecia; Child; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Humans;

2020
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia.
    Cutaneous and ocular toxicology, 2020, Volume: 39, Issue:1

    Topics: Administration, Topical; Alopecia; Animals; Biological Transport; Drug Therapy, Combination; Hydroge

2020
Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients.
    Dermatologic therapy, 2020, Volume: 33, Issue:1

    Topics: Administration, Topical; Adult; Aged; Alopecia; Brazil; Female; Hair Follicle; Humans; Middle Aged;

2020
Efficacy and Influence Factors of 308-nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata.
    Lasers in surgery and medicine, 2020, Volume: 52, Issue:8

    Topics: Alopecia; Alopecia Areata; Female; Hair; Humans; Lasers, Excimer; Male; Minoxidil; Prospective Studi

2020
[XANTHOTRICHIA (YELLOWING OF THE HAIR) DUE TO MINOXIDIL TREATMENT].
    Harefuah, 2020, Volume: 159, Issue:1

    Topics: Administration, Topical; Alopecia; Color; Hair; Humans; Minoxidil

2020
Severity of androgenetic alopecia associated with poor sleeping habits and carnivorous eating and junk food consumption-A web-based investigation of male pattern hair loss in China.
    Dermatologic therapy, 2020, Volume: 33, Issue:2

    Topics: Alopecia; China; Humans; Internet; Male; Minoxidil; Sleep

2020
Colored Polymeric Nanofiber Loaded with Minoxidil Sulphate as Beauty Coverage and Restoring Hair Loss.
    Scientific reports, 2020, 03-05, Volume: 10, Issue:1

    Topics: Alopecia; Drug Carriers; Drug Liberation; Humans; Minoxidil; Nanofibers; Polymers

2020
Effective combination therapy with high concentration of Minoxidil and Carboxygas in resistant Androgenetic alopecia: Report of nine cases.
    Journal of cosmetic dermatology, 2020, Volume: 19, Issue:11

    Topics: Adult; Alopecia; Female; Hair; Hair Follicle; Humans; Male; Middle Aged; Minoxidil

2020
Rapid response of topical minoxidil in congenital triangular alopecia.
    Dermatologic therapy, 2020, Volume: 33, Issue:3

    Topics: Administration, Topical; Alopecia; Ectodermal Dysplasia; Genetic Diseases, X-Linked; Humans; Minoxid

2020
How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?
    Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:2

    Topics: Administration, Topical; Alopecia; Humans; Hypersensitivity; Minoxidil

2022
Oral minoxidil improves background hair thickness in lichen planopilaris.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adult; Aged; Alopecia; Female; Hair; Humans; Hypertrichosis; Hypotension, Orth

2021
The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia.
    Pharmacology research & perspectives, 2020, Volume: 8, Issue:3

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Topical; Alopecia; Animals; Blood Pressure; Elect

2020
Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:12

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil; Research; Retrospective St

2020
Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:12

    Topics: Administration, Topical; Alopecia; Hair Follicle; Humans; Minoxidil; Sulfotransferases

2020
Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases.
    European journal of clinical pharmacology, 2020, Volume: 76, Issue:8

    Topics: Administration, Oral; Alopecia; Anticoagulants; Dabigatran; Data Mining; Databases, Factual; Humans;

2020
Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia.
    Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Treatment O

2020
The Utilization of YouTube as a Resource on Hair Loss Treatments.
    Aesthetic plastic surgery, 2020, Volume: 44, Issue:5

    Topics: Alopecia; Female; Humans; Male; Minoxidil; Pharmaceutical Preparations; Social Media; Video Recordin

2020
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:2

    Topics: Aged; Alopecia; Erythema; Hair; Humans; Male; Minoxidil; Scalp; Treatment Outcome

2021
Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
    BMC ophthalmology, 2020, Jun-05, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Alopecia; Central Serous Chorioretinopathy; Coloring Agents; Eplerenone

2020
Usefulness of home-use microneedle devices in the treatment of pattern hair loss.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:2

    Topics: Administration, Topical; Alopecia; Analysis of Variance; Hair; Humans; Minoxidil; Needles

2021
Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2021, Volume: 35, Issue:1

    Topics: Administration, Oral; Alopecia; Arylsulfotransferase; Female; Humans; Minoxidil; Sulfotransferases;

2021
Contact dermatitis to minoxidil.
    Contact dermatitis, 2021, Volume: 84, Issue:1

    Topics: Adult; Alopecia; Dermatitis, Allergic Contact; Dermatologic Agents; Humans; Male; Minoxidil; Patch T

2021
Frontal Fibrosing Alopecia Presenting as Androgenetic Alopecia in an African American Woman.
    Journal of drugs in dermatology : JDD, 2020, Jul-01, Volume: 19, Issue:7

    Topics: Administration, Cutaneous; Alopecia; Diagnosis, Differential; Female; Forehead; Humans; Lichen Planu

2020
Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
    JAMA dermatology, 2020, 09-01, Volume: 156, Issue:9

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Central Nervous System Neoplasms; Child;

2020
Microneedling and Platelet-Rich Plasma versus Microneedling and 5% Topical Minoxidil Therapy in Male Pattern Hair Loss.
    Skinmed, 2020, Volume: 18, Issue:3

    Topics: Administration, Topical; Adult; Alopecia; Combined Modality Therapy; Cosmetic Techniques; Humans; Ma

2020
Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Administration, Cutaneous; Administration, Topical; Alopecia; Humans; Hypertrichosis; Infant; Minoxi

2020
Novel "After Minoxidil" spray improves topical minoxidil compliance and hair style manageability.
    Journal of cosmetic dermatology, 2020, Volume: 19, Issue:10

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Minoxidil; Patient Compliance

2020
Efficacy and safety of oral minoxidil in female androgenetic alopecia.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Aged; Alopecia; Double-Blind Method; Female; Hair; Humans; Middle Aged; Minoxidil

2020
Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Alopecia; Hair; Humans; Middle Aged; Minoxidil; Young Adult

2021
Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:1

    Topics: Adolescent; Adult; Aged; Alopecia; Antihypertensive Agents; Female; Hair Removal; Humans; Hypertrich

2021
Evaluation of the effect of autologous platelet-rich plasma on androgenic alopecia.
    Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2020, Jul-03, Volume: 22, Issue:4-5

    Topics: Adolescent; Adult; Alopecia; Finasteride; Hair; Humans; Minoxidil; Platelet-Rich Plasma; Treatment O

2020
Comparison of low-level light therapy and combination therapy of 5% minoxidil in the treatment of female pattern hair loss.
    Lasers in medical science, 2021, Volume: 36, Issue:5

    Topics: Adult; Alopecia; Combined Modality Therapy; Female; Humans; Low-Level Light Therapy; Male; Middle Ag

2021
[Central serous chorioretinopathy associated with minoxidil 2].
    Journal francais d'ophtalmologie, 2020, Volume: 43, Issue:10

    Topics: Adult; Alopecia; Central Serous Chorioretinopathy; Humans; Male; Minoxidil; Retinal Detachment; With

2020
Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:6

    Topics: Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines; Pyrroles

2021
Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:3

    Topics: Administration, Oral; Adult; Alopecia; Canada; Dose-Response Relationship, Drug; Female; Follow-Up S

2021
Low-Level Laser Therapy for Androgenetic Alopecia.
    Actas dermo-sifiliograficas, 2021, Volume: 112, Issue:2

    Topics: Alopecia; Humans; Low-Level Light Therapy; Minoxidil

2021
Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:4

    Topics: Adult; Alopecia; Body Weight; Dermatologic Agents; Headache; Humans; Hypertrichosis; Male; Minoxidil

2021
HIF-1α Stimulators Function Equally to Leading Hair Loss Agents in Enhancing Dermal Papilla Growth.
    Skin pharmacology and physiology, 2020, Volume: 33, Issue:6

    Topics: Alopecia; Cells, Cultured; Deferiprone; Deferoxamine; Dermis; Hair Follicle; Humans; Hypoxia-Inducib

2020
Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adolescent; Alopecia; Dermoscopy; Drug Therapy, Combination; Female; Hair Foll

2021
Side effects of low-dose oral minoxidil for treating alopecia.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:5

    Topics: Administration, Oral; Alopecia; Drug-Related Side Effects and Adverse Reactions; Humans; Minoxidil

2021
Comment on "Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series": Adding further evidence about side effects.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:5

    Topics: Alopecia; Humans; Minoxidil; North America; Retrospective Studies; Treatment Outcome

2021
Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study.
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Cetirizine; Hair; Humans; Male; Middle Aged; Minoxidil; Yo

2021
Coming full circle (almost): Low dose oral minoxidil for alopecia.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:3

    Topics: Alopecia; Humans; Minoxidil

2021
[A new treatment for androgenetic alopecia : platelet-rich plasma injections].
    Revue medicale de Liege, 2021, Volume: 76, Issue:2

    Topics: Alopecia; Female; Humans; Male; Minoxidil; Platelet-Rich Plasma; Scalp; Treatment Outcome

2021
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema;

2021
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema;

2021
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema;

2021
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Child; Dizziness; Edema;

2021
The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia.
    Journal of cosmetic dermatology, 2022, Volume: 21, Issue:2

    Topics: Alopecia; Humans; Hyperbaric Oxygenation; Minoxidil

2022
"Comparison of QR 678
    Journal of cosmetic dermatology, 2021, Volume: 20, Issue:6

    Topics: Alopecia; Combined Modality Therapy; Finasteride; Hair; Humans; Male; Minoxidil

2021
Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity.
    Lasers in surgery and medicine, 2021, Volume: 53, Issue:9

    Topics: Alopecia; Biomarkers; Humans; Low-Level Light Therapy; Male; MicroRNAs; Minoxidil; Scalp; Treatment

2021
Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:1

    Topics: Adult; Alopecia; Anilides; Female; Hair; Humans; Minoxidil; Nitriles; Remission Induction; Tosyl Com

2022
Ceria Nanozyme-Integrated Microneedles Reshape the Perifollicular Microenvironment for Androgenetic Alopecia Treatment.
    ACS nano, 2021, 08-24, Volume: 15, Issue:8

    Topics: Alopecia; Animals; Hair; Hair Follicle; Mice; Minoxidil; Reactive Oxygen Species

2021
Bitemporal hair loss related to traction alopecia.
    Dermatology online journal, 2016, Sep-15, Volume: 22, Issue:9

    Topics: Alopecia; Female; Humans; Minoxidil; Traction; Vasodilator Agents; Young Adult

2016
Reversible Alopecia with Localized Scalp Necrosis After Accidental Embolization of the Parietal Artery with Hyaluronic Acid.
    Aesthetic plastic surgery, 2017, Volume: 41, Issue:3

    Topics: Adult; Alopecia; Arterial Occlusive Diseases; Arteries; Biopsy, Needle; Cosmetic Techniques; Dermal

2017
Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.
    Scientific reports, 2017, 03-28, Volume: 7

    Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Calcium; Cell Line, Tumor; Disease Models, Ani

2017
A Retrospective Review of Treatment Results for Patients With Central Centrifugal Cicatrical Alopecia.
    Journal of drugs in dermatology : JDD, 2017, Apr-01, Volume: 16, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Biopsy; Black or African American; Black People; Cicatrix;

2017
Association Between Gender and Drug Cost for Over-the-Counter Minoxidil.
    JAMA dermatology, 2017, 08-01, Volume: 153, Issue:8

    Topics: Alopecia; Drug Costs; Female; Humans; Male; Minoxidil; Nonprescription Drugs; Retrospective Studies;

2017
An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia.
    Cell cycle (Georgetown, Tex.), 2017, Volume: 16, Issue:17

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Gene Expression Profiling; Gene Expression Reg

2017
Androgenic alopecia: an entity to consider in adolescence.
    BMJ case reports, 2017, Jul-27, Volume: 2017

    Topics: Adolescent; Alopecia; Contraceptives, Oral, Hormonal; Female; Humans; Mineralocorticoid Receptor Ant

2017
Preparation and in vivo evaluation of lecithin-based microparticles for topical delivery of minoxidil.
    Archives of pharmacal research, 2017, Volume: 40, Issue:8

    Topics: Administration, Cutaneous; Alopecia; Animals; Drug Carriers; Drug Delivery Systems; Female; Hair; Hu

2017
Topical cetirizine 1% for treatment of androgenetic alopecia.
    Dermatologic therapy, 2017, Volume: 30, Issue:6

    Topics: Administration, Topical; Alopecia; Cetirizine; Hair; Humans; Minoxidil

2017
Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction.
    Archives of dermatological research, 2017, Volume: 309, Issue:9

    Topics: Administration, Topical; Alopecia; Animals; Hair; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Mi

2017
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Drug Therapy, Combination; Dutasteride; Evidence-Based Medic

2018
Alginate-Based Hydrogel Containing Minoxidil/Hydroxypropyl-β-Cyclodextrin Inclusion Complex for Topical Alopecia Treatment.
    Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:4

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Cutaneous; Administration, Topical; Alginates; Al

2018
Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
    International journal of dermatology, 2018, Volume: 57, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Diuretics; Drug Combinat

2018
Minoxidil-encapsulated poly(L-lactide-co-glycolide) nanoparticles with hair follicle delivery properties prepared using W/O/W solvent evaporation and sonication.
    Bio-medical materials and engineering, 2018, Volume: 29, Issue:2

    Topics: Administration, Cutaneous; Alopecia; Animals; Drug Carriers; Drug Delivery Systems; Drug Liberation;

2018
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
    JAMA dermatology, 2018, 06-01, Volume: 154, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre

2018
Minoxidil for Endocrine Therapy-Induced Alopecia in Women With Breast Cancer-Saint Agatha's Blessing?
    JAMA dermatology, 2018, 06-01, Volume: 154, Issue:6

    Topics: Alopecia; Breast; Breast Neoplasms; Female; Humans; Minoxidil

2018
Bibbidi bobbidi bald: Two "hairowing" tales of Princess Package hairstyles.
    Pediatric dermatology, 2018, Volume: 35, Issue:3

    Topics: Alopecia; Child, Preschool; Cicatrix; Female; Glucaric Acid; Hair; Humans; Minoxidil; Scalp; United

2018
Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version.
    The Journal of dermatology, 2018, Volume: 45, Issue:9

    Topics: Adenosine; Administration, Oral; Administration, Topical; Alopecia; Dutasteride; Female; Finasteride

2018
Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up.
    Journal of the American Academy of Dermatology, 2018, Volume: 79, Issue:5

    Topics: Adrenal Cortex Hormones; Alopecia; Anti-Bacterial Agents; Cicatrix; Cohort Studies; Combined Modalit

2018
Platelet rich plasma for the management of hair loss: Better alone or in combination?
    Journal of cosmetic dermatology, 2019, Volume: 18, Issue:2

    Topics: Alopecia; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Finasteride; Hair Follicle; Hum

2019
Female pattern hair loss.
    Australian journal of general practice, 2018, Volume: 47, Issue:7

    Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Androgen Receptor Antagonists; Female; Humans; Minoxi

2018
Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Administration, Cutaneous; Adult; Alopecia; Aspirin; Drug Interactions; Enzyme Inhibitors; Hair Foll

2018
Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Administration, Oral; Adult; Aged; Alopecia; Cost Savings; Drug Costs; Drug Therapy, Combination; Fe

2018
Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Dermatologic therapy, 2019, Volume: 32, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Administration, Topical; Alopecia; Finasteride;

2019
Anterior, frontal congenital triangular alopecia, redundancy in therapy without improvement.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Administration, Cutaneous; Alopecia; Biopsy; Drug Administration Schedule; Female; Genetic Diseases,

2018
Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent.
    Dermatologic therapy, 2018, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Alopecia; Biomarkers; Cross-Sectional Studies; Female; Hair; Humans; India; Male;

2018
Over-the-Counter Hair Loss Treatments: Help or Hype?
    Journal of drugs in dermatology : JDD, 2018, 12-01, Volume: 17, Issue:12

    Topics: Alopecia; Consumer Behavior; Humans; Minoxidil; Nonprescription Drugs; Phytotherapy; United States;

2018
Immune checkpoint inhibitor-related alopecia: Insight into the pathophysiology utilizing non-invasive diagnostic techniques.
    The Journal of dermatology, 2019, Volume: 46, Issue:5

    Topics: Administration, Topical; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2019
Severe Bitemporal Alopecia As a Complication of the Thread Lift Procedure.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2019, Volume: 45, Issue:7

    Topics: Alopecia; Female; Humans; Middle Aged; Minoxidil; Postoperative Complications; Rhytidoplasty; Vasodi

2019
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2019, Feb-28, Volume: 46, Issue:272

    Topics: Administration, Topical; Adult; Alopecia; Female; Humans; Male; Middle Aged; Minoxidil; Vasodilator

2019
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
    JAMA dermatology, 2019, 06-01, Volume: 155, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents

2019
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil.
    Dermatology online journal, 2019, Feb-15, Volume: 25, Issue:2

    Topics: Administration, Cutaneous; Alopecia; Bimatoprost; Combined Modality Therapy; Drug Delivery Systems;

2019
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.
    Dermatologic therapy, 2019, Volume: 32, Issue:3

    Topics: Administration, Topical; Adult; Alopecia; Female; Gene Expression Regulation, Enzymologic; Humans; M

2019
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia.
    Journal of the American Academy of Dermatology, 2019, Volume: 81, Issue:2

    Topics: Administration, Oral; Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil; Retrospective Studies;

2019
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia.
    Journal of cosmetic dermatology, 2020, Volume: 19, Issue:1

    Topics: Administration, Oral; Administration, Topical; Alopecia; Combined Modality Therapy; Finasteride; Hum

2020
RF - Oral Minoxidil for Female Pattern Hair Loss and Other Alopecias.
    Actas dermo-sifiliograficas, 2019, Volume: 110, Issue:10

    Topics: Administration, Oral; Alopecia; Humans; Minoxidil

2019
Filler-induced alopecia.
    The Journal of dermatology, 2019, Volume: 46, Issue:11

    Topics: Administration, Topical; Alopecia; Cosmetic Techniques; Dermal Fillers; Drug Therapy, Combination; F

2019
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.
    Journal of cosmetic dermatology, 2019, Volume: 18, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Child; Combined Modality Therapy; Female;

2019
Iontophoresis-targeted, follicular delivery of minoxidil sulfate for the treatment of alopecia.
    Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:5

    Topics: Administration, Cutaneous; Alopecia; Animals; Drug Delivery Systems; Hair Follicle; Iontophoresis; M

2013
Topical minoxidil treatment for congenital alopecia in hypohidrotic ectodermal dysplasia.
    Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:4

    Topics: Administration, Topical; Alopecia; Child, Preschool; Ectodermal Dysplasia 1, Anhidrotic; Genetic Dis

2013
Hair loss: it's not just for men. With most hair-loss therapies targeted to men, where can women turn for help?
    Harvard women's health watch, 2013, Volume: 20, Issue:5

    Topics: Alopecia; Depression; Female; Hair; Health Knowledge, Attitudes, Practice; Humans; Male; Minoxidil;

2013
The efficacy of 3% minoxidil vs. combined 3% minoxidil and Korean red ginseng in treating female pattern alopecia.
    International journal of dermatology, 2014, Volume: 53, Issue:6

    Topics: Administration, Oral; Administration, Topical; Alopecia; Cohort Studies; Drug Therapy, Combination;

2014
Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies.
    International journal of nanomedicine, 2014, Volume: 9

    Topics: Administration, Topical; Alopecia; Animals; Delayed-Action Preparations; Dermatologic Agents; Drug D

2014
New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-β-cyclodextrin complex as promising tools for alopecia treatment.
    Drug development and industrial pharmacy, 2015, Volume: 41, Issue:5

    Topics: Alopecia; Animals; beta-Cyclodextrins; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical

2015
Male frontal fibrosing alopecia with generalised hair loss.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:2

    Topics: Aged; Alopecia; Anti-Inflammatory Agents; Axilla; Dermatologic Agents; Extremities; Eyebrows; Fibros

2014
Medicolegal aspects of prescribing dermatological medications in pregnancy.
    Seminars in cutaneous medicine and surgery, 2013, Volume: 32, Issue:4

    Topics: Acne Vulgaris; Alopecia; Dermatitis, Atopic; Dermatologic Agents; Dermatology; Female; Fetal Disease

2013
Minoxidil induced hypertrichosis in children.
    The Pan African medical journal, 2014, Volume: 18

    Topics: Administration, Topical; Alopecia; Child, Preschool; Female; Humans; Hypertrichosis; Minoxidil

2014
In vivo hair growth promotion effects of ultra-high molecular weight poly-γ-glutamic acid from Bacillus subtilis (Chungkookjang).
    Journal of microbiology and biotechnology, 2015, Volume: 25, Issue:3

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Alopecia; Animals; Bacillus sub

2015
Generalized Hypertrichosis Due to Topical Minoxidil.
    Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:7

    Topics: Administration, Cutaneous; Adult; Alopecia; Clobetasol; Drug Combinations; Female; Humans; Hypertric

2015
Potential synergistic effects of human placental extract and minoxidil on hair growth-promoting activity in C57BL/6J mice.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:6

    Topics: Alopecia; Analysis of Variance; Animals; beta Catenin; Cell Proliferation; Dermis; Drug Synergism; F

2015
Anti-PDGF receptor β antibody-conjugated squarticles loaded with minoxidil for alopecia treatment by targeting hair follicles and dermal papilla cells.
    Nanomedicine : nanotechnology, biology, and medicine, 2015, Volume: 11, Issue:6

    Topics: Alopecia; Animals; Antibodies; Calorimetry, Differential Scanning; Hair Follicle; Mice; Mice, Nude;

2015
Increasing utility of finasteride for frontal fibrosing alopecia.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:6

    Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia; Dose-Response Relationship, Drug; Drug A

2015
A hairy fall: syncope resulting from topical application of minoxidil.
    BMJ case reports, 2015, Sep-07, Volume: 2015

    Topics: Administration, Topical; Adult; Alopecia; Antihypertensive Agents; Hair; Humans; Male; Minoxidil; Sy

2015
[Drug treatment of alopecia].
    Der Internist, 2015, Volume: 56, Issue:10

    Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia; Anti-Bacterial Agents; Cyclopropanes; Ev

2015
Hair regrowth in male and female pattern hair loss does not involve the conversion of vellus hair to terminal hair.
    Experimental dermatology, 2016, Volume: 25, Issue:6

    Topics: Adult; Alopecia; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Retrospective Studies

2016
Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia.
    Journal of drugs in dermatology : JDD, 2016, Volume: 15, Issue:4

    Topics: Adult; Alopecia; Drug Compounding; Drug Therapy, Combination; Female; Hair Preparations; Humans; Mid

2016
Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia.
    Journal of drugs in dermatology : JDD, 2016, Volume: 15, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Drug Compounding; Drug Therapy, Combination; Hair Preparat

2016
I'm a 62-year-old woman, and the part in my hair seems to be widening. Am I going bald?
    Health after 50 with Scientific American Consumer Health, 2016, Volume: 27, Issue:12

    Topics: Alopecia; Female; Hair; Hair Follicle; Humans; Middle Aged; Minoxidil; Women's Health

2016
Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhance Hair Growth.
    Theranostics, 2016, Volume: 6, Issue:6

    Topics: Albumins; Alopecia; Animals; Chitosan; Disease Models, Animal; Drug Delivery Systems; Hair; Mice, In

2016
Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation.
    The Australasian journal of dermatology, 2017, Volume: 58, Issue:3

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Female; Fibrosis; Folliculitis; Forehead; Human

2017
[Minoxidil : From side effects to therapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2016, Volume: 67, Issue:7

    Topics: Alopecia; Dermatology; Evidence-Based Medicine; Humans; Hypertrichosis; Minoxidil; Treatment Outcome

2016
Clinical and trichoscopic characteristics of temporal triangular alopecia: A multicenter study.
    Journal of the American Academy of Dermatology, 2016, Volume: 75, Issue:3

    Topics: Administration, Topical; Adolescent; Age Factors; Alopecia; Child; Child, Preschool; Cohort Studies;

2016
Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

    Topics: 5-alpha Reductase Inhibitors; Adverse Drug Reaction Reporting Systems; Alopecia; Drug-Related Side E

2016
Interventions for Female Pattern Hair Loss.
    JAMA dermatology, 2017, 03-01, Volume: 153, Issue:3

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Minoxidil

2017
Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin.
    International journal of dermatology, 2009, Volume: 48, Issue:2

    Topics: Administration, Topical; Alopecia; Child; Dermatologic Agents; Drug Therapy, Combination; Ectodermal

2009
Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help.
    Harvard women's health watch, 2009, Volume: 16, Issue:10

    Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Androgen Antagonists; Female; Hair; Healt

2009
Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients.
    The British journal of dermatology, 2010, Volume: 163, Issue:2

    Topics: Adolescent; Adult; Age of Onset; Alopecia; Biopsy; Diagnosis, Differential; Enzyme Inhibitors; Femal

2010
Alopecia and ocular alterations: a role for Minoxidil?
    Journal of receptor and signal transduction research, 2010, Volume: 30, Issue:3

    Topics: Adult; Alopecia; Antihypertensive Agents; Aquaporin 4; Cell Line, Tumor; Eye; Eye Diseases; Female;

2010
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
    Dermatologic clinics, 2010, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Alopecia; Androgen Antagonists; Female; Humans; Male; Middle Aged; Minoxidil; Off

2010
Mayo Clinic office visit. Female-pattern hair loss. An interview with Rochelle Torgerson, M.D., Ph.D.
    Mayo Clinic women's healthsource, 2010, Volume: 14, Issue:10

    Topics: Alopecia; Androgen Antagonists; Female; Hair; Health Education; Health Knowledge, Attitudes, Practic

2010
Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect.
    Journal of dermatological science, 2011, Volume: 62, Issue:3

    Topics: Alopecia; Animals; beta Catenin; Biopsy; Cyclic AMP-Dependent Protein Kinases; Female; Hair Follicle

2011
Treatment of female pattern hair loss with the androgen receptor antagonist flutamide.
    The Australasian journal of dermatology, 2011, Volume: 52, Issue:2

    Topics: Adult; Alopecia; Androgen Receptor Antagonists; Drug Therapy, Combination; Female; Flutamide; Hair;

2011
Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil.
    Organic & biomolecular chemistry, 2011, Oct-26, Volume: 9, Issue:22

    Topics: Alopecia; Animals; Antihypertensive Agents; Chromatography, Liquid; Dimethylnitrosamine; Drug-Relate

2011
[Frontal fibrosing alopecia: dermoscopic features].
    Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:2

    Topics: Adrenal Cortex Hormones; Alopecia; Dermoscopy; Drug Resistance; Eyebrows; Female; Fibrosis; Forehead

2012
Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness.
    Cutaneous and ocular toxicology, 2012, Volume: 31, Issue:2

    Topics: Administration, Topical; Adult; Alopecia; Choroid Diseases; Fluorescein Angiography; Humans; Male; M

2012
Erosive pustular dermatosis of the scalp from topical minoxidil 5% solution.
    International journal of dermatology, 2013, Volume: 52, Issue:4

    Topics: Aged; Alopecia; Dermatologic Agents; Drug Eruptions; Female; Humans; Minoxidil; Scalp; Scalp Dermato

2013
Adolescent androgenic alopecia.
    Cutis, 2011, Volume: 88, Issue:4

    Topics: 5-alpha Reductase Inhibitors; Adolescent; Alopecia; Diagnosis, Differential; Female; Finasteride; Hu

2011
Guidelines for the management of androgenetic alopecia (2010).
    The Journal of dermatology, 2012, Volume: 39, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil; Randomiz

2012
Relation between treatment efficacy and cumulative dose of 3% topical minoxidil in male pattern baldness.
    Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:1

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Hair; Humans; Male; Medication Adherence; Midd

2012
A case of alopecia universalis with agminated lentiginosis and multiple café-au-lait macules: a synchronous coincidence?
    International journal of dermatology, 2012, Volume: 51, Issue:1

    Topics: Alopecia; Cafe-au-Lait Spots; Child; Drug Therapy, Combination; Female; Humans; Lentigo; Minoxidil;

2012
What's new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:1

    Topics: Alopecia; Azasteroids; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Dutasteride;

2011
Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Alkaline Phosphatase; Alopecia; Animals; beta Catenin; Cell Differentiation; Cells, Cultured; Dermis

2012
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast

2012
Diffuse pattern essential syphilitic alopecia: an unusual form of secondary syphilis.
    International journal of dermatology, 2012, Volume: 51, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Alopecia; Anti-Bacterial Agents; Humans; Male; Minoxidil; Penicillin

2012
Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:3

    Topics: Administration, Cutaneous; Adult; Alopecia; Drug Therapy, Combination; Estradiol; Estrogens; Humans;

2012
Visible-to-near IR quantum dot-based hypermulticolor high-content screening of herbal medicines for the efficacy monitoring of hair growth promotion and hair loss inhibition.
    Journal of biomolecular screening, 2013, Volume: 18, Issue:4

    Topics: Alopecia; Blotting, Western; Down-Regulation; Flow Cytometry; Hair; Hair Follicle; High-Throughput S

2013
The hydraulic influence in androgen-related hair growth: implications in autoimmune disease.
    Medical hypotheses, 2002, Volume: 59, Issue:5

    Topics: Alopecia; Animals; Autoimmune Diseases; Dihydrotestosterone; Disease Susceptibility; Female; Hair; H

2002
Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia.
    The Australasian journal of dermatology, 2002, Volume: 43, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Allergic Contact; Female; Humans; Minoxidil; P

2002
[TrichoScan. A new instrument for digital hair analysis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2002, Volume: 53, Issue:12

    Topics: Adult; Alopecia; Female; Finasteride; Follow-Up Studies; Hair; Hair Diseases; Humans; Image Processi

2002
Information from your family doctor. What should I know about hair loss?
    American family physician, 2003, Jul-01, Volume: 68, Issue:1

    Topics: Alopecia; Hair; Humans; Minoxidil; Vasodilator Agents

2003
By the way, doctor. I don't hear nearly as much about hair loss in women as in men. But I'm 65 and have watched my hair thin considerably over the past five or six years. Is there anything I can do about it? What about Rogaine?
    Harvard women's health watch, 2003, Volume: 10, Issue:11

    Topics: Alopecia; Dermatologic Agents; Female; Hair; Humans; Minoxidil; Sex Factors

2003
Minoxidil vs finasteride in the treatment of men with androgenetic alopecia.
    Archives of dermatology, 2003, Volume: 139, Issue:9

    Topics: Adolescent; Adult; Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Minoxidil; R

2003
Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal.
    Archives of dermatology, 2003, Volume: 139, Issue:9

    Topics: Administration, Oral; Administration, Topical; Adult; Alopecia; Drug Therapy, Combination; Enzyme In

2003
[Hair loss].
    Praxis, 2003, Sep-03, Volume: 92, Issue:36

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Biopsy; Child; Clinical Tria

2003
Androgenetic alopecia: combining medical and surgical treatments.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2003, Volume: 29, Issue:11

    Topics: Alopecia; Combined Modality Therapy; Enzyme Inhibitors; Female; Finasteride; Hair Follicle; Humans;

2003
Topical minoxidil counteracts stress-induced hair growth inhibition in mice.
    Experimental dermatology, 2003, Volume: 12, Issue:5

    Topics: Alopecia; Animals; Apoptosis; Cell Degranulation; Cell Division; Female; Hair Follicle; Mast Cells;

2003
Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle.
    Journal of dermatological science, 2004, Volume: 34, Issue:2

    Topics: Adult; Alopecia; Apoptosis; bcl-2-Associated X Protein; Cell Culture Techniques; Cell Division; Gene

2004
[Hair loss-what can one do?].
    Medizinische Monatsschrift fur Pharmazeuten, 2004, Volume: 27, Issue:10

    Topics: Adult; Alopecia; Female; Hair; Humans; Male; Minoxidil

2004
Evaluation and treatment of male and female pattern hair loss.
    Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:2

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Topical; Adoles

2005
Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution.
    Contact dermatitis, 2005, Volume: 53, Issue:1

    Topics: Administration, Topical; Aged; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Female; Human

2005
Telling the bald truth.
    Newsweek, 2003, Jun-16, Volume: 141, Issue:24

    Topics: Alopecia; Finasteride; Hair; Humans; Male; Minoxidil; United States

2003
Simultaneous effects of tocopheryl polyethylene glycol succinate (TPGS) on local hair growth promotion and systemic absorption of topically applied minoxidil in a mouse model.
    International journal of pharmaceutics, 2005, Dec-08, Volume: 306, Issue:1-2

    Topics: Administration, Topical; Alopecia; Animals; Disease Models, Animal; Drug Carriers; Hair; Male; Mice;

2005
Frontal fibrosing alopecia: a survey in 16 patients.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2005, Volume: 19, Issue:6

    Topics: Aged; Alopecia; Diagnosis, Differential; Disease Progression; Enzyme Inhibitors; Eyebrows; Female; F

2005
Finasteride and minoxidil for alopecia revisited.
    The Medical letter on drugs and therapeutics, 2005, Nov-21, Volume: 47, Issue:1222

    Topics: Adult; Alopecia; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Enzyme Inhi

2005
Recent findings with computerized methods for scalp hair growth measurements.
    The journal of investigative dermatology. Symposium proceedings, 2005, Volume: 10, Issue:3

    Topics: Adult; Alopecia; Computing Methodologies; Dermoscopy; Female; Hair; Hair Follicle; Humans; Male; Mid

2005
Alopecia areata masquerading as frontal fibrosing alopecia.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:1

    Topics: Administration, Topical; Alopecia; Alopecia Areata; Biopsy, Needle; Dermatologic Agents; Diagnosis,

2006
Managing hair loss. Treatments may help.
    Mayo Clinic health letter (English ed.), 2006, Volume: 24, Issue:6

    Topics: Alopecia; Dermatologic Agents; Female; Finasteride; Humans; Male; Minoxidil

2006
The additive effects of minoxidil and retinol on human hair growth in vitro.
    Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:1

    Topics: Adult; Alopecia; Apoptosis; bcl-2-Associated X Protein; Cell Line; Cell Proliferation; Dose-Response

2007
Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
    The Australasian journal of dermatology, 2007, Volume: 48, Issue:1

    Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Drug Therapy, Combination; Female; Humans

2007
Evolution of techniques in hair transplantation: a 12-year perspective.
    Facial plastic surgery : FPS, 2007, Volume: 23, Issue:1

    Topics: Adult; Alopecia; Cosmetic Techniques; Disease Progression; Enzyme Inhibitors; Female; Finasteride; F

2007
Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate.
    Acta dermato-venereologica, 1983, Volume: 63, Issue:3

    Topics: Adult; Alopecia; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination;

1983
Topical minoxidil in the treatment of alopecia areata.
    British medical journal (Clinical research ed.), 1983, Nov-05, Volume: 287, Issue:6402

    Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Child, Preschool

1983
Unusual hair changes with minoxidil therapy.
    International journal of dermatology, 1983, Volume: 22, Issue:2

    Topics: Adult; Alopecia; Hair; Hair Color; Humans; Male; Minoxidil; Pyrimidines

1983
Reversal of male pattern baldness by minoxidil. A case report.
    Cutis, 1981, Volume: 28, Issue:5

    Topics: Adult; Alopecia; Humans; Hypertension; Male; Minoxidil; Pyrimidines

1981
Reversal of baldness in patient receiving minoxidil for hypertension.
    The New England journal of medicine, 1980, Dec-18, Volume: 303, Issue:25

    Topics: Adult; Alopecia; Humans; Hypertension; Male; Minoxidil; Pyrimidines

1980
Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride.
    Archives of dermatology, 1995, Volume: 131, Issue:12

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Alopecia; Cholestenone 5 alpha-Reductase; En

1995
Minoxidil induced hair growth after leukaemia treatment?
    Archives of disease in childhood, 1995, Volume: 73, Issue:2

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Humans; Male; Minoxidil;

1995
Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model.
    International journal of dermatology, 1995, Volume: 34, Issue:7

    Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Disease Mo

1995
Allergic contact dermatitis from minoxidil.
    Contact dermatitis, 1995, Volume: 32, Issue:5

    Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Humans; Male

1995
Minoxidil over the counter.
    BMJ (Clinical research ed.), 1995, Aug-26, Volume: 311, Issue:7004

    Topics: Alopecia; Drug Costs; Humans; Minoxidil; Nonprescription Drugs

1995
Alopecia: diagnosis and management.
    American family physician, 1995, May-01, Volume: 51, Issue:6

    Topics: Alopecia; Dermatomycoses; Female; Humans; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemi

1995
[Increase of aminotransferase levels during percutaneous minoxidil therapy].
    Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:12

    Topics: Administration, Cutaneous; Alanine Transaminase; Alopecia; Aspartate Aminotransferases; gamma-Glutam

1994
Concerns about medical treatment for androgenetic alopecia.
    International journal of dermatology, 1994, Volume: 33, Issue:8

    Topics: Alopecia; Drug Monitoring; Humans; Male; Middle Aged; Minoxidil

1994
Male pattern baldness.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1994, Volume: 146, Issue:1

    Topics: Alopecia; Hair; Humans; Male; Minoxidil; Scalp; Surgical Flaps

1994
Chemotherapy-induced alopecia.
    Southern medical journal, 1993, Volume: 86, Issue:12

    Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents; Antineoplastic Combined Chemother

1993
Topical minoxidil for baldness: a reappraisal.
    The Medical letter on drugs and therapeutics, 1994, Jan-21, Volume: 36, Issue:914

    Topics: Administration, Cutaneous; Alopecia; Female; Humans; Male; Minoxidil; Multicenter Studies as Topic

1994
[Treatment of androgenic alopecia with minoxidil].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1993, Volume: 44, Issue:2

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil

1993
Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
    Journal of the American Academy of Dermatology, 1993, Volume: 28, Issue:5 Pt 1

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Alopecia; Biopsy; Collagen; Female; Fibrosis; Fo

1993
The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque.
    Skin pharmacology : the official journal of the Skin Pharmacology Society, 1995, Volume: 8, Issue:5

    Topics: Administration, Topical; Alopecia; Animals; Drug Delivery Systems; Female; Hair; Macaca mulatta; Min

1995
Hair growth therapy(ies) for androgenetic alopecia.
    Archives of dermatology, 1996, Volume: 132, Issue:6

    Topics: Alopecia; Finasteride; Hair; Humans; Minoxidil; Tretinoin

1996
Diffuse hypertrichosis during treatment with 5% topical minoxidil.
    The British journal of dermatology, 1997, Volume: 136, Issue:1

    Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia; Female; Humans; Hypertrichosis; Middle Aged;

1997
Chronic telogen effluvium: potential complication for clinical trials in female androgenetic alopecia?
    Journal of the American Academy of Dermatology, 1997, Volume: 37, Issue:6

    Topics: Adult; Alopecia; Clinical Trials as Topic; Dermatologic Agents; Diagnosis, Differential; Female; Hai

1997
Human genetics. Hair apparent.
    Nature, 1998, Feb-05, Volume: 391, Issue:6667

    Topics: Alopecia; Animals; Enzyme Inhibitors; Female; Finasteride; Humans; Male; Mice; Minoxidil; Mutation;

1998
Application of solid-phase extraction in the method development for determination of SEPA, an acronym for soft enhancement of percutaneous absorption, in human, rat, and rabbit serum using GC-FID method.
    Journal of pharmaceutical and biomedical analysis, 1998, Volume: 16, Issue:7

    Topics: Absorption; Adjuvants, Pharmaceutic; Administration, Topical; Alopecia; Animals; Chromatography, Gas

1998
Pustular allergic contact dermatitis from minoxidil.
    Contact dermatitis, 1998, Volume: 38, Issue:5

    Topics: Adult; Alopecia; Dermatitis, Allergic Contact; Facial Dermatoses; Female; Humans; Minoxidil; Skin

1998
Retinoids and hair growth.
    Journal of the American Academy of Dermatology, 1998, Volume: 39, Issue:2 Pt 3

    Topics: Alopecia; Animals; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finasteride; Hair; Humans;

1998
[Maxilène and alopecia].
    Annales de dermatologie et de venereologie, 1998, Volume: 125, Issue:4

    Topics: Alopecia; Hair; Hair Preparations; Humans; Minoxidil; Organic Chemicals; Treatment Outcome

1998
A 45-year-old man with dizziness.
    Journal of emergency nursing, 1999, Volume: 25, Issue:1

    Topics: Alopecia; Dizziness; Emergency Nursing; Humans; Male; Middle Aged; Minoxidil; Nursing Assessment; Tr

1999
Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp.
    Journal of dermatological science, 1999, Volume: 19, Issue:2

    Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adolescent; Adult; Aged; Al

1999
Hair loss: does anything really help?
    Consumer reports, 1996, Volume: 61, Issue:8

    Topics: Alopecia; Female; Hair Follicle; Hair Preparations; Humans; Male; Minoxidil; Scalp; Surgical Flaps

1996
Authors' conflicts of interest: a disclosure and editors' reply.
    The New England journal of medicine, 1999, Nov-18, Volume: 341, Issue:21

    Topics: Alopecia; Conflict of Interest; Drug Industry; Financial Support; Finasteride; Humans; Minoxidil; Pu

1999
Where's the hair?
    Health news (Waltham, Mass.), 1999, Oct-25, Volume: 5, Issue:13

    Topics: Alopecia; Female; Finasteride; Hair; Humans; Male; Minoxidil

1999
Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects?
    Medical hypotheses, 1999, Volume: 53, Issue:5

    Topics: Alopecia; Endothelin-1; Estrogens; Humans; Male; Minoxidil; Models, Theoretical; Sebum; Testosterone

1999
[21-year old patient with a pituitary microadenoma and gynecomastia of recent onset].
    Der Internist, 1999, Volume: 40, Issue:12

    Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Alopecia; Diagnosis, Differential; Estradiol Congeners; Eth

1999
Should men still go bald gracefully?
    Lancet (London, England), 2000, Jan-15, Volume: 355, Issue:9199

    Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hair Follicle; Humans; Male; Minoxidil

2000
Short and curly.
    The Medical journal of Australia, 2000, Jan-03, Volume: 172, Issue:1

    Topics: Administration, Cutaneous; Alopecia; Diagnosis, Differential; Drug Hypersensitivity; Edema; Humans;

2000
Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients.
    Contact dermatitis, 2000, Volume: 42, Issue:4

    Topics: Administration, Topical; Alopecia; Chemistry, Pharmaceutical; Dermatitis, Allergic Contact; Dose-Res

2000
Permanent alopecia following chemotherapy and bone marrow transplantation.
    The Australasian journal of dermatology, 2000, Volume: 41, Issue:2

    Topics: Adult; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols;

2000
[Treatment for hair loss].
    Medizinische Monatsschrift fur Pharmazeuten, 2000, Volume: 23, Issue:6

    Topics: Alopecia; Alopecia Areata; Female; Finasteride; Humans; Male; Minoxidil

2000
[Toward an effective treatment of androgenetic alopecia?].
    Annales de dermatologie et de venereologie, 2000, Volume: 127 Suppl 1

    Topics: Alopecia; Androgens; Female; Finasteride; Humans; Male; Minoxidil; Treatment Outcome

2000
[Androgenetic alopecia: drug treatment].
    Annales de dermatologie et de venereologie, 2000, Volume: 127 Suppl 1

    Topics: Administration, Oral; Alopecia; Androgens; Animals; Clinical Trials as Topic; Female; Finasteride; H

2000
A case of acute myocardial infarction associated with topical use of minoxidil (RiUP) for treatment of baldness.
    Japanese heart journal, 2000, Volume: 41, Issue:4

    Topics: Administration, Topical; Alopecia; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle Ag

2000
[Minoxidil: more than an antihypertensive].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2001, Volume: 52, Issue:1

    Topics: Adult; Alopecia; Antihypertensive Agents; Female; Humans; Male; Minoxidil; Sex Factors; Solutions; V

2001
KF19418, a new compound for hair growth promotion in vitro and in vivo mouse models.
    Journal of dermatological science, 2001, Volume: 25, Issue:3

    Topics: Alopecia; Animals; Cells, Cultured; Culture Techniques; Dermatologic Agents; Disease Models, Animal;

2001
[Status of scalp hair and therapy of alopecia in men in Switzerland].
    Praxis, 2001, Feb-15, Volume: 90, Issue:7

    Topics: Adolescent; Adult; Aged; Alopecia; Cross-Sectional Studies; Cyclic N-Oxides; Finasteride; Humans; In

2001
[Hereditary hair loss. A tincture against expanding alopecia].
    MMW Fortschritte der Medizin, 2001, Feb-15, Volume: 143, Issue:7

    Topics: Administration, Topical; Alopecia; Dose-Response Relationship, Drug; Female; Humans; Male; Minoxidil

2001
Topical application of cyclosporin A induces rapid-remodeling of damaged anagen hair follicles produced in cyclophosphamide administered mice.
    Journal of dermatological science, 2001, Volume: 27, Issue:1

    Topics: Administration, Topical; Alopecia; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cyc

2001
[When hair is thinning. Preventing baldness].
    MMW Fortschritte der Medizin, 2001, Sep-27, Volume: 143, Issue:39

    Topics: Adult; Alopecia; Child; Estrogens; Family Practice; Female; Hair; Humans; Male; Minoxidil; Oxidoredu

2001
Allergic contact dermatitis to topical minoxidil solution: etiology and treatment.
    Journal of the American Academy of Dermatology, 2002, Volume: 46, Issue:2

    Topics: Administration, Topical; Aged; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Female; Follo

2002
My hair is thinning on the top of my head. What treatments are available for hair loss in women?
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:3

    Topics: Alopecia; Diuretics; Enzyme Inhibitors; Female; Finasteride; Humans; Minoxidil; Spironolactone; Unit

2002
Prevention of temporal alopecia following rhytidectomy: the prophylactic use of minoxidil. A study of 60 patients.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2002, Volume: 28, Issue:1

    Topics: Administration, Topical; Aged; Aged, 80 and over; Alopecia; Female; Humans; Middle Aged; Minoxidil;

2002
Pigmented contact dermatitis from topical minoxidil 5%.
    Contact dermatitis, 2002, Volume: 46, Issue:4

    Topics: Administration, Topical; Alopecia; Dermatitis, Allergic Contact; Humans; Hyperpigmentation; Male; Mi

2002
[Androgenetic alopecia in the man].
    Therapeutische Umschau. Revue therapeutique, 2002, Volume: 59, Issue:5

    Topics: Adult; Age Factors; Aged; Alopecia; Androgens; Finasteride; Hair; Hair Follicle; Humans; Male; Middl

2002
[Diffuse hair loss in women].
    Therapeutische Umschau. Revue therapeutique, 2002, Volume: 59, Issue:5

    Topics: Adult; Aged; Alopecia; Androgen Antagonists; Diagnosis, Differential; Estradiol Congeners; Female; H

2002
Hair loss with minoxidil withdrawal.
    Lancet (London, England), 1992, Sep-05, Volume: 340, Issue:8819

    Topics: Alopecia; Female; Hirsutism; Humans; Male; Middle Aged; Minoxidil; Substance Withdrawal Syndrome

1992
Topical treatment with minoxidil 2% and smoking intolerance.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:2

    Topics: Administration, Topical; Adult; Alopecia; Humans; Male; Minoxidil; Smoking

1992
Advertising baldly to the public.
    The New England journal of medicine, 1992, Jan-30, Volume: 326, Issue:5

    Topics: Advertising; Alopecia; Drug Industry; Humans; Minoxidil; United States

1992
[Treatment of androgenic alopecia with topical minoxidil].
    Harefuah, 1991, Nov-01, Volume: 121, Issue:9

    Topics: Administration, Topical; Adult; Alopecia; Follow-Up Studies; Humans; Male; Minoxidil

1991
The hair growing effect of minoxidil.
    Annals of the New York Academy of Sciences, 1991, Dec-26, Volume: 642

    Topics: Alopecia; Animals; Hair; Hair Color; Male; Mice; Mice, Inbred C3H; Minoxidil; Skin; Time Factors

1991
Minoxidil stimulates mouse vibrissae follicles in organ culture.
    The Journal of investigative dermatology, 1991, Volume: 96, Issue:2

    Topics: Alopecia; Animals; DNA; Flow Cytometry; Hair; Humans; Male; Mice; Minoxidil; Organ Culture Technique

1991
Cosmetics and drugs. Is there a need for a third group: cosmeceutics?
    The British journal of dermatology, 1991, Volume: 124, Issue:5

    Topics: Alopecia; Cosmetics; Dermatologic Agents; Humans; Minoxidil; Nonprescription Drugs; Photosensitivity

1991
Topical minoxidil for male pattern baldness.
    Irish medical journal, 1991, Volume: 84, Issue:1

    Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil

1991
The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies.
    European journal of gynaecological oncology, 1991, Volume: 12, Issue:2

    Topics: Administration, Topical; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug

1991
Hair replacement surgery.
    The Medical journal of Australia, 1990, Oct-01, Volume: 153, Issue:7

    Topics: Alopecia; Hair; Humans; Minoxidil

1990
Safety and efficacy of 2% topical minoxidil in the management of male pattern baldness in Chinese.
    Changgeng yi xue za zhi, 1990, Jun-20, Volume: 13, Issue:2

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Humans; Middle Aged; Minoxidil

1990
Minoxidil with tretinoin in baldness.
    DICP : the annals of pharmacotherapy, 1990, Volume: 24, Issue:1

    Topics: Alopecia; Humans; Male; Minoxidil; Tretinoin

1990
Dermatology days.
    Cutis, 1990, Volume: 45, Issue:3

    Topics: Aging; Alopecia; Androgens; Dermatitis, Contact; Dermatology; Fibrosis; Graft vs Host Disease; Human

1990
Baldness and minoxidil advertising.
    Lancet (London, England), 1989, Feb-25, Volume: 1, Issue:8635

    Topics: Advertising; Alopecia; Attitude; Humans; Male; Minoxidil

1989
Baldness and minoxidil.
    Lancet (London, England), 1989, Apr-22, Volume: 1, Issue:8643

    Topics: Advertising; Alopecia; Anxiety; Humans; Male; Minoxidil

1989
Telogen effluvium and minoxidil.
    Journal of the American Academy of Dermatology, 1989, Volume: 21, Issue:3 Pt 1

    Topics: Adult; Alopecia; Humans; Male; Middle Aged; Minoxidil

1989
[The peculiar magic of minoxidil].
    Medicina cutanea ibero-latino-americana, 1989, Volume: 17, Issue:3

    Topics: Adult; Alopecia; Humans; Male; Minoxidil; Physician-Patient Relations

1989
Dermatology.
    JAMA, 1989, May-19, Volume: 261, Issue:19

    Topics: Alopecia; Dermatology; Female; Humans; Male; Minoxidil; Skin; Syphilis; Tretinoin

1989
[Minoxidil: no hope for bald people].
    Nederlands tijdschrift voor geneeskunde, 1989, Apr-29, Volume: 133, Issue:17

    Topics: Alopecia; Evaluation Studies as Topic; Male; Minoxidil

1989
Approach to hair loss reduction.
    Journal of the National Medical Association, 1989, Volume: 81, Issue:7

    Topics: Adult; Alopecia; Ethinyl Estradiol; Hair; Humans; Minoxidil; Progesterone

1989
Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness.
    Archives of dermatological research, 1989, Volume: 281, Issue:4

    Topics: Alopecia; Androgens; Animals; Antihypertensive Agents; Disease Models, Animal; Female; Male; Mice; M

1989
Explosive eruption of pyogenic granuloma on the scalp due to topical combination therapy of minoxidil and retinoic acid.
    Dermatologica, 1989, Volume: 179, Issue:2

    Topics: Alopecia; Drug Combinations; Hemangioma; Humans; Male; Middle Aged; Minoxidil; Scalp; Skin Neoplasms

1989
[Stop giving discounts for Regaine].
    Lakartidningen, 1989, Oct-04, Volume: 86, Issue:40

    Topics: Alopecia; Costs and Cost Analysis; Drug Therapy; Humans; Male; Minoxidil

1989
Cosmetics by prescription.
    The Journal of family practice, 1989, Volume: 29, Issue:5

    Topics: Alopecia; Cosmetics; Drug Prescriptions; Humans; Minoxidil; Physicians, Family; Self Concept; Tretin

1989
Minoxidil: hope for the bald?
    Lancet (London, England), 1987, May-02, Volume: 1, Issue:8540

    Topics: Administration, Topical; Adult; Alopecia; Drug Evaluation; Humans; Male; Minoxidil; Skin Absorption

1987
Topical minoxidil, scalp hair, and vasodilatation.
    Lancet (London, England), 1987, May-30, Volume: 1, Issue:8544

    Topics: Administration, Topical; Alopecia; Ethics, Medical; Humans; Male; Minoxidil; Rheology; Scalp; Vasodi

1987
Minoxidil for male-pattern baldness.
    Lancet (London, England), 1987, Jun-20, Volume: 1, Issue:8547

    Topics: Alopecia; Humans; Male; Minoxidil

1987
Minoxidil for male-pattern baldness.
    Lancet (London, England), 1987, Sep-05, Volume: 2, Issue:8558

    Topics: Alopecia; Esthetics; Humans; Male; Minoxidil; Sex Factors

1987
Topical minoxidil used before and after hair transplantation.
    The Journal of dermatologic surgery and oncology, 1989, Volume: 15, Issue:1

    Topics: Administration, Topical; Adult; Alopecia; Hair; Humans; Male; Middle Aged; Minoxidil; Postoperative

1989
Bald scalps and wrinkles.
    Journal of the American Academy of Dermatology, 1989, Volume: 20, Issue:1

    Topics: Aging; Alopecia; Humans; Minoxidil; Skin; Tretinoin

1989
Is minoxidil (Rogaine) clinically effective?
    Archives of dermatology, 1989, Volume: 125, Issue:4

    Topics: Advertising; Alopecia; Humans; Male; Minoxidil

1989
Allergic contact dermatitis to minoxidil.
    Contact dermatitis, 1985, Volume: 13, Issue:3

    Topics: Adult; Alopecia; Drug Eruptions; Female; Humans; Minoxidil; Patch Tests; Scalp Dermatoses

1985
Scalp comedones after topical minoxidil.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:6

    Topics: Acne Vulgaris; Alopecia; Humans; Male; Minoxidil; Scalp Dermatoses

1985
Allergic contact dermatitis from minoxidil.
    Contact dermatitis, 1987, Volume: 17, Issue:1

    Topics: Adult; Alopecia; Drug Eruptions; Facial Dermatoses; Humans; Male; Minoxidil; Patch Tests; Scalp Derm

1987
Alopecia: common and uncommon.
    Hospital practice (Office ed.), 1986, May-30, Volume: 21, Issue:5A

    Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Min

1986
Topical minoxidil for common baldness.
    British medical journal (Clinical research ed.), 1986, Jul-19, Volume: 293, Issue:6540

    Topics: Administration, Topical; Alopecia; Female; Humans; Minoxidil; Substance-Related Disorders

1986
Minoxidil. A few of the questions you're likely to hear.
    American pharmacy, 1988, Volume: NS28, Issue:11

    Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil

1988
[Toxic effects of 2% minoxidil].
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 1988, Volume: 123, Issue:11

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Heart Rate; Humans; Male; Middle Aged; Minoxid

1988
Topical minoxidil therapy for androgenetic alopecia.
    Archives of dermatology, 1988, Volume: 124, Issue:3

    Topics: Administration, Topical; Alopecia; Humans; Male; Minoxidil

1988
Allergic contact dermatitis from minoxidil.
    Contact dermatitis, 1988, Volume: 18, Issue:1

    Topics: Alopecia; Dermatitis, Contact; Humans; Male; Minoxidil

1988
[Sensitization for external treatment with minoxidil].
    Nederlands tijdschrift voor geneeskunde, 1988, Jun-18, Volume: 132, Issue:25

    Topics: Administration, Topical; Alopecia; Dermatitis, Contact; Humans; Minoxidil

1988
Duration of minoxidil therapy to yield maximum benefit.
    Archives of dermatology, 1988, Volume: 124, Issue:10

    Topics: Alopecia; Drug Evaluation; Female; Humans; Male; Minoxidil; Time Factors

1988
Rogaine (topical minoxidil, 2%) in the management of male pattern baldness and alopecia areata. Proceedings of a symposium. Palm Beach, FL, May 17, 1986.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Alopecia; Alopecia Areata; Humans; Male; Minoxidil

1987
Action of topical minoxidil in the bald stump-tailed macaque.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Alopecia; Animals; Female; Hair; Macaca; Male; Minoxidil; Scalp

1987
Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:3 Pt 2

    Topics: Administration, Topical; Adult; Alopecia; Hair; Humans; Male; Middle Aged; Minoxidil; Pilot Projects

1987
[Minoxidil in the local treatment of alopecia areata and of androgenous alopecia].
    Annales de dermatologie et de venereologie, 1986, Volume: 113, Issue:5

    Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Drug Evaluation; Humans; Male; Minoxidil

1986
Topical minoxidil for male pattern alopecia in two sets of twins.
    Cutis, 1987, Volume: 39, Issue:4

    Topics: Administration, Topical; Adult; Alopecia; Diseases in Twins; Humans; Male; Minoxidil

1987
[Minoxidil: hope for bald people?].
    Nederlands tijdschrift voor geneeskunde, 1987, May-23, Volume: 131, Issue:21

    Topics: Alopecia; Humans; Minoxidil; Solutions

1987
[Minoxidil: hope for bald people?].
    Nederlands tijdschrift voor geneeskunde, 1987, Jul-18, Volume: 131, Issue:29

    Topics: Alopecia; Female; Humans; Male; Minoxidil

1987
[Minoxidil: hope for bald people?].
    Nederlands tijdschrift voor geneeskunde, 1987, Aug-15, Volume: 131, Issue:33

    Topics: Adult; Alopecia; Humans; Male; Minoxidil; Statistics as Topic

1987
Topical minoxidil for hair loss.
    Rational drug therapy, 1987, Volume: 21, Issue:5

    Topics: Administration, Topical; Alopecia; Female; Hair; Humans; Male; Minoxidil

1987
Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia.
    The British journal of dermatology, 1987, Volume: 117, Issue:5

    Topics: Adult; Alopecia; Humans; Male; Minoxidil; Nicotinic Acids; Regional Blood Flow; Scalp

1987
Topical minoxidil: experimental and clinical results. Proceedings of a session of the 17th World Congress of Dermatology. Berlin, May 27, 1987.
    Dermatologica, 1987, Volume: 175 Suppl 2

    Topics: Alopecia; Humans; Minoxidil

1987
Topical minoxidil, experimental and clinical results.
    Dermatologica, 1987, Volume: 175 Suppl 2

    Topics: Administration, Cutaneous; Alopecia; Humans; Minoxidil

1987
Evaluation technics for male pattern baldness.
    Journal of the American Academy of Dermatology, 1986, Volume: 14, Issue:5 Pt 1

    Topics: Alopecia; Humans; Male; Minoxidil

1986
Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases.
    Dermatologica, 1986, Volume: 173, Issue:3

    Topics: Administration, Topical; Adolescent; Adult; Alopecia; Androgens; Blood Pressure; Humans; Male; Middl

1986
Promotion of hair growth.
    Cutis, 1986, Volume: 38, Issue:4

    Topics: Alopecia; Hair; Hair Preparations; Humans; Minoxidil

1986
Topical minoxidil. A survey of use and complications.
    Archives of dermatology, 1987, Volume: 123, Issue:1

    Topics: Administration, Topical; Alopecia; Blood Pressure; Costs and Cost Analysis; Drug Utilization; Humans

1987
A falling out following minoxidil: telogen effluvium.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:1 Pt 1

    Topics: Alopecia; Humans; Male; Middle Aged; Minoxidil; Substance Withdrawal Syndrome

1987
Effect of time on male pattern baldness.
    Journal of the American Academy of Dermatology, 1987, Volume: 16, Issue:2 Pt 1

    Topics: Alopecia; Humans; Male; Methods; Minoxidil; Time Factors

1987
Topical minoxidil therapy and hair regrowth.
    Archives of dermatology, 1985, Volume: 121, Issue:2

    Topics: Adult; Alopecia; Animals; Hair; Humans; Macaca; Mice; Middle Aged; Minoxidil; Pyrimidines

1985
Unravelling the pathophysiology of male pattern baldness.
    Journal of the National Medical Association, 1985, Volume: 77, Issue:2

    Topics: Aged; Alopecia; Humans; Male; Minoxidil; Regional Blood Flow; Scalp; Vascular Resistance

1985
Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques.
    The American Journal of dermatopathology, 1985, Volume: 7, Issue:3

    Topics: Administration, Topical; Age Factors; Alopecia; Animals; Female; Hair; Humans; Macaca; Male; Minoxid

1985
Contact dermatitis to minoxidil.
    Contact dermatitis, 1985, Volume: 13, Issue:4

    Topics: Adult; Alopecia; Dermatitis, Contact; Facial Dermatoses; Humans; Male; Minoxidil; Scalp Dermatoses

1985
Unapproved use of minoxidil.
    FDA drug bulletin, 1985, Volume: 15, Issue:4

    Topics: Alopecia; Humans; Minoxidil; United States; United States Food and Drug Administration

1985